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 1 
CHAPTER I 
 
INTRODUCTION 
 
Glucose Metabolism and Homeostasis 
Carbohydrates, fat, and proteins are required to make energy available to 
the various cells and tissues of the body. Three major sources of carbohydrates 
exist in the normal human diet (Chinachoti, 1995). They are sucrose, which is the 
disaccharide known popularly as cane sugar; lactose, which is a disaccharide 
found in milk; and starches, which are large polysaccharides present in almost all 
nonanimal foods, particularly in potatoes and the different types of grains 
(Chinachoti, 1995). Other carbohydrates ingested to a slight extent are amylose, 
glycogen, alcohol, lactic acid, pyruvic acid, pectins, dextrins, and minor quantities 
of carbohydrate derivatives in meats (Chinachoti, 1995). The final products of 
carbohydrate digestion in the alimentary tract are almost entirely glucose, 
fructose, and galactose—with glucose representing, on average, ~80% of these 
(Ivy, 1999). After absorption from the intestinal tract, much of the fructose and 
almost all the galactose are rapidly converted into glucose in the liver. Glucose 
thus becomes the final common molecule for the transport of almost all 
carbohydrates to cells. Glucose can be supplied by the liver as a result of release 
from stored glycogen (glycogenolysis) and the de novo hepatic synthesis of 
glucose through the conversion of non-carbohydrate precursors to glucose 
(gluconeogenesis) (Cherrington, 1999). 
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It is critical to maintain body glucose homeostasis. Glucose is the only 
nutrient that normally can be used by the brain, retina, and germinal epithelium of 
the gonads in sufficient quantities to supply them optimally with their required 
energy. Therefore, it is important to maintain the blood glucose concentration at a 
sufficiently high level to provide this necessary nutrition. Indeed, it is important 
that the pancreas secrete little insulin during fasting; otherwise, the scant 
supplies of glucose that are available would all go into the muscles and other 
peripheral tissues, leaving the central nervous system without a nutritive source. 
It is also important that the blood glucose concentration not rise too high: Firstly, 
glucose can exert a large amount of osmotic pressure in the extracellular fluid, so 
if the glucose concentration rises to excessive values, this can cause 
considerable cellular dehydration. Secondly, an excessively high level of blood 
glucose causes loss of glucose in the urine (glycosuria), which is in turn results in 
osmotic diuresis by the kidney, depleting fluids and electrolytes from body. 
Thirdly, long-term hyperglycemia can cause tissue damage, especially to blood 
vessels, nerves and kidney. For example, vascular injury, associated with 
uncontrolled diabetes mellitus, leads to increased risk for heart attack, stroke, 
end-stage renal disease, and blindness (Brownlee, 2005).  
In a normal state, the blood glucose concentration is tightly controlled, 
usually between 80 and 90 mg/dl of blood in the over night fasted humans. This 
concentration increases to 120 to 140 mg/dl during the first hour or so after a 
meal, but the feedback systems for control of blood glucose return the glucose 
concentration rapidly back to the basal level, usually within 2 hours after the 
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absorption of carbohydrates (1969). In starvation, the glycogenolytic and 
gluconeogenic functions of the liver allow it to provide the glucose that is required 
to sustain glucose requiring tissues.  
The liver functions as a pivotal blood glucose buffer system. That is, when 
the blood glucose rises to a high concentration after a meal and the rate of 
insulin secretion also increases, as much as one third of the glucose absorbed 
from the gut is quickly stored in the liver in the form of glycogen (Cherrington, 
1999). Then, during the succeeding hours, when both the blood glucose 
concentration and the rate of insulin secretion fall, the liver releases the glucose 
back into the blood. In this way, the liver decreases the fluctuations in blood 
glucose concentration to about one third of what they would otherwise be. In fact, 
in patients with severe liver disease, it becomes almost impossible to maintain a 
narrow range of blood glucose concentration (Del Vecchio Blanco et al., 1990). 
Both insulin and glucagon function as important feedback control systems 
for maintaining a normal blood glucose concentration. When the glucose 
concentration rises, insulin is secreted; the insulin in turn causes the blood 
glucose concentration to decrease toward normal. Conversely, a decrease in 
blood glucose stimulates glucagon secretion; the glucagon then functions to 
cause an increase in glucose toward normal.  
In severe hypoglycemia, a direct effect of low blood glucose on the 
hypothalamus stimulates the sympathetic nervous system (Matsuhisa et al., 
1997). In turn, the epinephrine secreted by the adrenal glands causes still further 
release of glucose from the liver. This, too, helps protect against severe 
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hypoglycemia. Over a period of hours and days, growth hormone and cortisol are 
secreted in response to prolonged hypoglycemia, and they both decrease the 
rate of glucose utilization by most cells of the body, converting them instead to 
greater amounts of fat utilization (Schwartz et al., 1987). This, too, helps return 
the blood glucose concentration toward normal. 
In summary, the normal human body is able to carefully maintain plasma 
glucose homeostasis by matching glucose utilization with endogenous glucose 
production and dietary glucose delivery. Liver, muscle, fat, brain and the 
endocrine organs work together to achieve this precise matching. 
 
Hepatic Glucose Uptake 
The liver can both provide glucose, to and remove glucose from, the 
circulation. A number of studies in dogs and humans have shown that the liver is 
responsible for ~30% of glucose disposal following glucose ingestion 
(Pagliassotti et al. 1994) (Meyer et al., 2002), clearly demonstrating the 
importance of the liver under this physiological condition.  
Glucose ingestion results in significant hyperglycemia, as well as marked 
hyperinsulinemia, with the change of glucagon being minimal. As reported by 
Abumrad et al. (Abumrad et al., 1982), when normal conscious dogs received an 
intragastric glucose load of 1.6 g/kg, the arterial blood glucose concentration 
almost doubled within 30 minutes, the arterial plasma insulin level increased 
approximately 4-5 fold, and the plasma glucagon level remained unchanged. As 
a consequence of these signals, the liver rapidly switched from a state of net 
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hepatic glucose production during the basal period (~2 mg/kg/min) to a state of 
net hepatic glucose uptake after oral glucose administration (peak rate  at ~4.5 
mg/kg/min). In a study performed by Hamilton et al. (Hamilton et al., 1996), 
conscious dogs  received glucose infused into the duodenum at 8 mg/kg/min for 
150 min. In response to intraduodenal glucose infusion, arterial plasma glucose 
rapidly rose ~30%, the arterial plasma insulin increased approximately 3-4 fold, 
and the arterial plasma glucagon was unchanged, and this resulted in the rate of 
net hepatic glucose uptake ~ 2.3 mg/kg/min. 
There are three main factors which impact the rate of net hepatic glucose 
uptake (uptake in excess of production) in response to an oral/intraduodenal 
glucose load: the insulin concentration in the liver, the glucose concentration (the 
glucose load to the liver), and a glucose gradient between the hepatic artery and 
portal vein. A series of studies by Cherrington et al. and others have been 
performed to show how these three factors work individually, or in concert with 
one another, to bring about the resulting net hepatic glucose uptake. 
 
Effect of Hyperglycemia on Hepatic Glucose Uptake 
It has been shown that hyperglycemia within the physiologic range 
(plasma glucose ~230 mg/dl) when brought about acutely by glucose infusion 
into a peripheral vein, in the presence of basal levels of insulin and glucagon, 
causes a suppression of net hepatic glucose output, but little net glucose uptake 
by the liver. Studies in humans have demonstrated that a plasma glucose 
increment of 125 mg/dl, in the presence of basal insulin levels, leads to a 
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decrease in net splanchnic glucose output from ~2.5 to 0.6 mg/kg/min but no net 
glucose uptake (DeFronzo et al., 1987; DeFronzo et al., 1983). It has been 
shown that nonhepatic net splanchnic (gut) glucose uptake makes only a small 
contribution (~10%) to overall net splanchnic glucose uptake, so net splanchnic 
glucose uptake rates in humans are very similar to net  hepatic glucose uptake 
(Cherrington et al., 1991). Similarly, doubling the blood glucose level/hepatic 
glucose load in the dog by infusing exogenous glucose into a peripheral vein, in 
the presence of basal insulin and glucagon caused a reduction in net hepatic 
glucose output from 2.2 to 0.9 mg/kg/min, but no evidence of net hepatic glucose 
uptake was observed (Cherrington et al., 1987; Cherrington et al., 1982). 
Selective hyperglycemia can result in slight net hepatic glucose uptake (up to 0.6 
mg/kg/min) if hyperglycemia lasts for more than 2 hours (Pagliassotti et al., 
1996b). A recent study in dogs showed that the rate of net hepatic glucose could 
reach ~1.5 mg/kg/min after 6 hours of hyperglycemic clamp in the presence of 
basal levels of insulin and glucagon (Winnick et al., 2009).  
On the mechanistic level, an increase in blood glucose concentration per 
se has been shown to regulate net hepatic glucose balance by suppressing 
hepatic glucose production and by stimulating glucose uptake (Pagliassotti et al., 
1996b; Rossetti et al., 1993). Transport of glucose into hepatocytes is through 
the GLUT2 transporter, which maintains the intracellular to extracellular glucose 
concentrations in equilibrium. Elevated blood glucose has been shown to 
increase glucose influx into hepatocytes and to activate glucokinase, resulting in 
an increase in the concentration of glucose 6-phosphate (G-6-P), which 
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modulates the phosphorylation state of downstream enzymes synergistically with 
glucose (Agius et al., 1997). In the fasted state, glucokinase is in part 
sequestered in the nucleus in an inactive form, complexed to the glucokinase 
regulatory protein (GKRP). Glucokinase is mobilized to the cytoplasm during the 
postprandial state in response to elevated glucose by rapid mechanisms that 
involve glucose-induced dissociation from GKRP (Agius et al., 1996). The 
elevated G-6-P concentration, consequent to glucokinase activation, has a 
synergistic effect with glucose, by stimulating phosphatase, to promote 
dephosphorylation (inactivation) of glycogen phosphorylase and induce 
dephosphorylation (activation) of glycogen synthase, resulting in glycogen 
deposition and increased hepatic glucose uptake (Ferrer et al., 2003). Further, 
this reciprocal change of synthase and phosphorylase activities lead to an 
inhibition of net glycogenolysis and an suppression of hepatic glucose production 
(Rossetti et al., 1993). 
Thus, acute hyperglycemia resulting from a peripheral glucose infusion is 
able to reduce net hepatic glucose output, but cannot independently switch the 
liver, in a net sense, from glucose output to uptake in the short term. 
 
Effect of Insulin on Hepatic Glucose Uptake 
In humans, in the presence of euglycemia and arterial plasma insulin 
levels which were maintained at about 100 µU/ml (8-10 times basal levels) using 
the pancreatic clamp technique, net splanchnic glucose uptake was only 0.7 
mg/kg/min (DeFronzo et al., 1987). In dogs, NHGU was 0.6 mg/kg/min in the 
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presence of euglycemia and physiologic hyperinsulinemia (120 µU/ml), and even 
pharmacological levels of insulin (2044 µU/ml) were only able to achieve rates of 
2.9 mg/kg/min (McGuinness et al., 1990). Thus high physiologic levels of insulin 
alone are only able to trigger hepatic glucose uptake to a very limited extent. 
Thus, hyperinsulinemia, without elevated glucose, is not very effective means of 
causing glycogen storage in the liver.  
It has been shown that the augmentation of NHGU in response to 
elevated insulin occurs through both an increase in hepatic glucose uptake and 
suppression of hepatic glucose production (Pagliassotti et al., 1996b). These 
changes were due to an increase in glycogen synthesis and an inhibition in 
glycogen breakdown (Cherrington, 1999), which was mediated by promoting 
dephosphorylation of glycogen phosphorylase (inactivation) and glycogen 
synthase (activation). The change of phosphorylation state of these two enzymes 
is regulated by activation of protein phosphatase-1 and inhibition of GSK-3, 
resulting from activation of PKB/Akt in response to elevated insulin (Cheatham et 
al., 1995; Taniguchi et al., 2006).  
Selective glucagon deficiency (i.e. usually kept basal), which was brought 
about using the pancreatic clamp in the presence of euglycemia, reduced hepatic 
glucose output but failed to cause net glucose uptake by the liver in dogs and 
humans (Liljenquist et al., 1977; Shulman et al., 1978). Further, 
hypoglucagonemia, even when brought about in the presence of hyperglycemia 
and hyperinsulinemia did not result in any measurable enhancement of NHGU 
(Holste et al., 1997).  
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Therefore, physiologic changes in glucose, insulin or glucagon individually 
cannot explain the significant net hepatic glucose uptake evident following oral 
glucose intake. 
 
Effect of Combined Hyperglycemia and Hyperinsulinemia  
on Hepatic Glucose Uptake 
Elevated insulin, when brought about in the presence of basal glucagon, 
and hyperglycemia resulting from the infusion of glucose into a peripheral vein 
can result in significant net hepatic glucose uptake. In humans, the combination 
of hyperglycemia (arterial plasma levels of 175-225 mg/dl) and hyperinsulinemia 
(arterial blood levels of 40-55 µU/ml) caused rates of net splanchnic glucose 
uptake of 1.0 to 1.6 mg/kg/min (DeFronzo et al., 1987; DeFronzo et al., 1983; 
Sacca et al., 1982). In dogs, arterial plasma glucose levels of 160-290 mg/dl and 
insulin levels of 35-384 µU/ml caused rates of NHGU of 1.0 to 2.9 mg/kg/min 
(Adkins-Marshall et al., 1990; Barrett et al., 1985; Cherrington et al., 1987; Ishida 
et al., 1983; Myers et al., 1991a; Myers et al., 1991b). Despite the increase in 
NHGU in response to combined hyperglycemia and hyperinsulinemia, it is clear 
that these two factors at physiological levels (arterial plasma glucose levels <225 
mg/dl and arterial blood insulin levels <100 µU/ml) cannot result in the peak rates 
of NHGU that are seen following a moderate oral glucose load. Thus, one can 
postulate that there must be other factors, in addition to increased insulin and 
glucose, which are involved in the regulation of NHGU, to ensure normal glucose 
uptake by the liver after a carbohydrate meal. 
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The “Portal Glucose Signal” Theory 
In contrast to the hyperglycemic hyperinsulinemic data above, it has been 
shown that in conscious dogs receiving an intragastric glucose load of 1.6 g/kg, 
that by 75 min after feeding, when the plasma glucose concentrations in the 
artery, hepatic portal vein, and hepatic vein were 190, 230, and 220 mg/dl, 
respectively, with elevated plasma insulin at ~5X basal, and the plasma glucagon 
level at basal, net hepatic glucose uptake peaked at ~4.5 mg/kg/min (Abumrad et 
al., 1982). In line with this work in dogs, a human study conducted by DeFronzo 
(DeFronzo et al., 1978) demonstrated that the route of glucose administration 
could be another signal in regulating hepatic glucose uptake. They showed that 
infusion of glucose through an antecubital vein resulted in hyperglycemia (arterial 
plasma glucose ~220 mg/dl) and hyperinsulinemia, but there was little net 
splanchnic glucose uptake in response to this treatment (~1.0 mg/kg/min). When 
glucose was given orally (1.2 g/kg), and the intravenous glucose infusion rate 
was decreased to achieve a similar arterial glucose level (plasma glucose ~220 
mg/dl) to that seen during peripheral glucose infusion, net splanchnic glucose 
uptake increased almost 6 fold (5.9 mg/kg/min). As expected, insulin levels 
following the oral glucose ingestion were higher than those as observed during 
the peripheral glucose administration even though the arterial glucose levels 
were equivalent. However, it is unlikely that this explains the difference in net 
splanchnic glucose uptake, since the rate of net splanchnic glucose uptake was 
only ~1.1 mg/kg/min when the insulin levels went even higher than those seen 
following the oral glucose ingestion and arterial plasma glucose levels were 
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similar (~220 mg/dl) in the presence of intravenous insulin and glucose infusion. 
It also needs to be noted that in these experiments, although the arterial plasma 
glucose levels (~220 mg/dl) were matched, there was an increase in glucose 
load to the splanchnic bed in the group giving oral glucose load. This increase of 
the glucose load was probably not large enough to account for the increase in 
splanchnic glucose uptake. The discrepancy between NHGU during oral glucose 
delivery and peripheral glucose delivery was initially attributed to effects of 
incretins associated with oral glucose delivery (DeFronzo et al., 1978; Lickley et 
al., 1975). Several laboratories have since shown in conscious dogs, however, 
that intraportal administration of glucose can bring about the same response of 
net hepatic glucose uptake as oral glucose delivery  (Bergman et al., 1982; 
Ishida et al., 1983; Ogihara et al., 2003). In a key study, Adkins et al. determined 
that when plasma insulin and glucagon were clamped at basal levels in 
conscious dogs, and glucose was infused into either a peripheral vein or the 
hepatic portal vein such that the hepatic glucose load (the mass of glucose 
reaching the liver per unit of time) was doubled, the liver showed a trivial glucose 
output (~0.1 mg/kg/min) during peripheral glucose delivery, but significant 
glucose uptake (~1.4 mg/kg/min) during portal glucose delivery (Adkins et al., 
1987). This enhancement of NHGU by portal versus peripheral glucose delivery 
has been attributed to the “portal glucose signal”. 
In another work performed by Adkins et al. in 18h and 36h fasted dogs, 
glucose was given either via a peripheral vein or the hepatic portal vein to double 
the hepatic glucose load in the presence of four fold elevated insulin and basal 
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glucagon. Despite a similar hormonal milieu and hepatic glucose loads, NHGU 
was 1.4±0.7 mg/kg/min in response to peripheral glucose infusion but 3.5±0.8 
mg/kg/min in response to portal glucose infusion in 18h fasted dogs (Adkins-
Marshall et al., 1990).  Similar to these data, NHGU was 1.6±0.4 mg/kg/min and 
4.0±0.4 mg/kg/min during the peripheral and intraportal glucose infusions, 
respectively, in the presence of hyperinsulinemia and hyperglycemia in 36h 
fasted dogs (Adkins-Marshall et al., 1990). 
Further exploration of the effects of the portal signal in the conscious dog 
revealed that when hormone concentrations and the hepatic glucose load were 
fixed and equivalent, delivery of a portion of the glucose into the hepatic portal 
vein enhanced NHGU ~2-3 fold, compared with the rate when all of the glucose 
was infused through a peripheral vein (Myers et al., 1991a; Myers et al., 1991b; 
Pagliassotti et al., 1996b).  
 
The Relationships between the Portal Glucose Signal, Hepatic Glucose Load, 
Insulin and NHGU 
 
Myers et al. (Myers et al., 1991b) examined the relationship between the 
insulin level and NHGU, and the effects of portal glucose delivery on that 
relationship. A pancreatic clamp was used in 42h fasted conscious dogs and the 
arterial plasma insulin level was increased by intraportal insulin infusion at two-, 
four-, or eight-fold basal (each rate lasted for 90 min) in two sets of experiments 
(with or without portal glucose delivery) in the presence of basal glucagon. In one 
set of experiments, the arterial blood glucose concentration was clamped at ~175 
mg/kg/min by glucose infusion exclusively through a peripheral vein, and NHGU 
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was 0.6±0.3, 1.5±0.4 and 3.0±0.8 mg/kg/min, respectively, in response to the 
three different levels of insulin. In the second set of experiments, glucose was 
infused intraportally (4-5 mg/kg/min) throughout the study and peripheral glucose 
infusion was used to match the hepatic glucose loads to those observed in the 
first protocol. NHGU was 2.0±0.5, 3.7±0.7, and 5.5±0.9 mg/kg/min, respectively, 
in the three different insulin infusion periods. One can calculate that when arterial 
plasma insulin levels were 4X basal in the presence of hyperglycemia (2X basal), 
insulin could account for approximately half of the increase in NHGU with the rest 
being attributable to the portal glucose signal. These results suggested that 
NHGU is dependent on both insulin levels and the route of glucose delivery, and 
under physiological conditions the "portal" signal is at least as important as 
insulin in the regulation of postprandial NHGU. 
In another work by Myers et al (Myers et al., 1991a), similar metabolic 
clamp techniques were used in 42h fasted conscious dogs to keep plasma 
glucagon at basal, to elevate the arterial plasma insulin fourfold, and to examine 
the effect of three different hepatic glucose loads (2, 3 and 4X basal) on NHGU in 
the presence or absence of portal glucose delivery. In the absence of portal 
glucose delivery, increasing the hepatic glucose load increased NHGU by 
1.2±0.4, 2.8±0.8, and 5.1±1.2 mg/kg/min in the three periods, respectively. In the 
presence of portal glucose delivery, NHGU was 3.8±0.4, 4.8±0.6, and 9.6±1.4 
mg/kg/min in response to the three increments in the hepatic glucose load. 
These results indicated that NHGU was positively correlated with the hepatic 
glucose load regardless of the route of glucose administration and it did not 
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reach saturation even when the hepatic glucose load was elevated four times 
basal. In addition, at any given rate of hepatic glucose load in this study, NHGU 
was greater when portal glucose delivery was present than when glucose was 
exclusively infused through a peripheral vein. It was also apparent that portal 
glucose delivery lowered the threshold at which the liver switched from net 
glucose output to net glucose uptake from ~180 to ~100 mg/dl. 
As stated above, it has been well established that physiologic elevations in 
insulin or glucose do not individually lead to significant net hepatic glucose 
uptake in humans and dogs (DeFronzo et al., 1987; McGuinness et al., 1990). In 
the absence of insulin, brought about either by pancreatectomy or by 
suppression of insulin secretion by somatostatin infusion, the liver did not 
respond to portal glucose delivery, even when hyperglycemia was present. 
These results suggested that the augmentation of NHGU in response to 
intraportal glucose delivery requires the presence of insulin (Pagliassotti et al., 
1992b). On the other hand, Galassetti (Galassetti et al., 1999) showed that under 
euglycemic conditions, the portal signal is still effective in activating NHGU in the 
presence of hyperinsulinemia.  
Pagliassotti et al. (Pagliassotti et al., 1991) determined the relationship 
between the magnitude of the portal glucose signal and NHGU in the presence of 
three to four-fold elevation in insulin, basal glucagon, and a doubling of the 
hepatic glucose load in 42h fasted dogs. The magnitude of the portal signal (the 
glucose gradient between hepatic artery and hepatic vein, A-P gradient) was 
achieved by varying the portion of the glucose delivered intraportally vs. 
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peripherally. When the A-P gradient was -7 mg/dl, NHGU was ~2.1 mg/kg/min, 
whereas when the A-P gradient was increased to -15 mg/dl, NHGU was ~5.3 
mg/kg/min, and when the A-P gradient was increased to -75 mg/dl, NHGU 
increased to ~7.6 mg/kg/min. This suggests that the relationship between the A-P 
gradient and NHGU is such that NHGU does not linearly increase with the 
increase in the magnitude of the A-P gradient. These results indicated that the 
liver can sense the magnitude of the negative A-P glucose gradient under 
physiologic conditions.  
Combination of hyperinsulinemia and hyperglycemia in the presence of 
the portal glucose signal re-produces rates of NHGU that approach those 
observed after glucose ingestion. It is clear that the rate of NHGU is determined 
by dynamic interaction between the levels of pancreatic hormones, glucose, and 
the route of glucose delivery. Thus, these factors act efficiently in concert under 
physiological conditions to ensure adequate net removal of glucose by the liver, 
without requiring excessive excursions of insulin or glucose. 
A further study by Pagliassotti et al. (Pagliassotti et al., 1996b) extended 
the temporal response of the liver glucose uptake to insulin and/or portal glucose 
delivery in the dog. The experiments were carried out under hyperglycemic (2X 
basal) conditions with basal glucagon in 42-h-fasted conscious dogs, when 
insulin levels were kept at basal or elevated four fold, in the presence or absence 
of portal glucose delivery. NHGU was minimal in the presence of basal insulin 
and hyperglycemia (brought about by peripheral glucose infusion) in the absence 
of portal glucose delivery. In response to four-fold insulin and hyperglycemia 
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without portal glucose delivery, NHGU was 0.7±0.6 mg/kg/min at 15 min and 
gradually rose to the maximum rate (~2.9±1.2 mg/kg/min) until 90 min. In 
contrast, NHGU quickly reached a maximum of 2.3±0.6 mg/kg/min in only 15 min 
in response to portal glucose delivery in the presence of basal insulin and 
hyperglycemia. NHGU was 2.7±0.5 mg/kg/min at 15 min and reached a 
maximum as 4.3±0.6 mg/kg/min at 60 min in the presence of both elevated 
insulin and portal glucose delivery. Therefore, intraportal insulin could enhance 
NHGU minimally in the first 15 min after the rise in glucose, while the portal 
signal produced a rapid (15 min) and significant stimulation of NHGU. These 
results demonstrated that portal glucose delivery generates a signal that is 
associated with meal ingestion to activate NHGU rapidly and significantly. 
Interestingly, Hsieh et al. (Hsieh et al., 1998) demonstrated that in the presence 
of basal insulin and glucagon, the effect of the portal signal on NHGU was rapidly 
reversed when portal glucose delivery was stopped. Taken together, it seems 
that the ‘‘on’’ and ‘‘off’’ times of the effect are similar and both very rapid. The 
quick response of the liver to the portal signal allows the tight matching of the 
meal associated rise in plasma glucose to hepatic glucose uptake in order to 
minimize perturbations in the circulating blood glucose levels.  
 
Effects of the Portal Glucose Signal on Other Tissues 
In addition to its effects on the liver, portal glucose delivery suppresses 
glucose uptake in non-hepatic tissues, especially skeletal muscle (Galassetti et 
al., 1999; Galassetti et al., 1998). Several studies (Adkins et al., 1987; 
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Pagliassotti et al., 1996b) showed that although NHGU increases in response to 
portal glucose delivery, the change of whole body glucose clearance was 
minimal. Therefore, in response to intraportal glucose delivery, a reduction in net 
glucose uptake by non-hepatic tissues must occur in parallel with the increase in 
NHGU. 
In a study by Galassetti et al. (Galassetti et al., 1998), insulin was elevated 
three-fold while glucagon was replaced at basal levels. In one set of the 
experiments, arterial blood glucose (2-fold basal) was clamped by glucose 
infusion into a peripheral vein, and in another set, glucose was given intraportally 
at 5 mg/kg/min along with the peripheral glucose infusion to maintain similar 
blood glucose levels. Despite comparable glucose loads and insulin levels, the 
portal signal blunted the increase of glucose uptake by nonhepatic tissues in 
response to hyperglycemia and hyperinsulinemia by ~40%. Simultaneous 
measurement of net glucose balance across the hindlimb, which is primarily 
muscle, showed that virtually all nonhepatic glucose uptake could be accounted 
for by muscle glucose uptake. This study concluded that muscle and hepatic 
glucose uptake are altered reciprocally in response to portal glucose delivery, 
suggesting that the portal signal does not increase whole body glucose clearance, 
but rather directs glucose to the liver and away from the muscle to ensure a 
balanced distribution of glucose and rapid accumulation of hepatic glycogen 
reserves following glucose ingestion. Interestingly, like the temporal response of 
NHGU to portal glucose delivery, the suppression of nonhepatic glucose uptake 
in the presence of portal glucose signal can also be quickly reversed once the 
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signal is removed (Hsieh et al., 1998). 
Another study (Galassetti et al., 1999) showed that the portal signal is as 
effective in increasing NHGU under euglycemic conditions as it is during 
hyperglycemia. The inhibition of glucose uptake by nonhepatic tissues, on the 
other hand, is minimal under euglycemic as opposed to hyperglycemic conditions.  
The above results clearly show that the portal signal enhances glucose 
uptake by the liver but reduces muscle glucose uptake in the presence of fixed 
hormone concentrations and hyperglycemia. Further, even when hormones are 
free to change, Moore et al. (Moore et al., 2000) found that in the absence of 
somatostatin, when the arterial blood glucose concentrations during glucose 
infusion were at 120-125 mg/dl, the portal glucose delivery alters partitioning of 
glucose among the tissues, enhancing NHGU and reducing glucose uptake by 
peripheral tissues.  
In the study above, Moore et al. (Moore et al., 2000) also observed that 
when 42-h-fasted dogs received identical (10 mg/kg/min for 3 hours) infusions of 
glucose via the hepatic portal or a peripheral vein, arterial plasma insulin levels 
tended to be higher during the first hour, particularly at 60 min in dogs receiving 
intraportal glucose infusion (~50% greater, but not significant due to high 
variabilities). This suggests that the portal signal might also stimulate pancreatic 
insulin secretion. Dunning et al. (Dunning et al., 2002) then went on to determine 
the effects of the portal signal on insulin secretion by direct measurement of the 
pancreatic venous effluent using the superior pancreaticoduodenal vein catheter. 
In that study, hyperglycemia (arterial plasma glucose ~155 mg/dL) was 
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maintained in 2 groups of 42h-fasted conscious dogs by glucose infusion into the 
hepatic portal vein or a leg vein. Arterial plasma insulin levels increased by 28±5 
and 16±3 mU/mL, and pancreatic insulin output increased by 10±3 and 7±2 
mU/min in response to portal or peripheral glucose administration, respectively. 
Pancreatic polypeptide output and norepinephrine spillover were measured as 
indices of pancreatic parasympathetic and sympathetic neural activity, 
respectively. The pancreatic polypeptide output to norepinephrine spillover ratio 
decreased by 65% in response to peripheral glucose infusion, while the ratio did 
not change significantly in response to portal glucose infusion. Thus, the portal 
glucose signal appears to inhibit the shift toward sympathetic dominance that 
would otherwise result in stimulation of insulin secretion. 
 
The Portal Glucose Signal in Humans 
The portal signal is less well explored in the human than in animal models, 
largely due to the difficulty in accessing the hepatic and portal veins. This 
technical limitation leads investigators to use the oral/intraduodenal glucose 
delivery rather than intraportal glucose infusion, and measure splanchnic glucose 
uptake or even whole body glucose disposal rather than net hepatic glucose 
uptake. It has been shown that the extrahepatic portion of net splanchnic glucose 
uptake makes only a small contribution (~10%) to overall net splanchnic glucose 
uptake, so the net splanchnic glucose uptake rate in humans is a reasonable 
approximation of net  hepatic glucose uptake (Cherrington et al., 1991). 
As discussed previously, DeFronzo et al. (DeFronzo et al., 1978) reported 
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that the increase in net splanchnic balance of glucose was much greater in 
response to ingested glucose than in response to intravenous glucose and 
insulin, suggesting that the route of glucose delivery was an important 
determinant of  splanchnic/hepatic glucose uptake. 
In a recent study carried out by Vella et al. (Vella et al., 2002) in non-
diabetic humans under hyperglycemic hyperinsulinemic conditions, glucose was 
delivered via a peripheral vein or intraduodenal infusion. Somatostatin was used 
to inhibit pancreatic endocrine secretion, plasma insulin concentrations were 
clamped at ~75 µU/mL by infusion into a leg vein (creating a two to three fold rise 
in hepatic sinusoidal insulin), and plasma glucose concentrations were 
maintained at ~150 mg/dL with the two treatments. [3H] glucose was mixed with 
the intraduodenal infusate (i.e. saline during peripheral glucose delivery and 
glucose during intraduodenal glucose delivery). In that investigation, initial 
splanchnic glucose extraction was modestly but not significantly greater in 
response to duodenal vs. peripheral glucose delivery (16.4 vs. 12.8%). The latter 
rate was very likely an overestimate, however, considering that the systemic 
appearance of duodenally delivered [3H] glucose was probably underestimated 
due to the fact that duodenally delivered [3H] glucose was infused duodenally 
without cold glucose carrier. Furthermore, studies in dogs and pigs have showed 
that intestinal glucose extraction ranges from 4-10% (Abumrad et al., 1982; Stoll 
et al., 1999). Thus, if one corrects the data in the vella’s study for that, it 
becomes apparent that a 40-130% increase in hepatic glucose uptake occurred 
in response to intraduodenal glucose administration despite the modest A-P 
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glucose gradient and the limited hyperglycemia. Therefore, these findings 
supported the concept that hepatic glucose extraction is enhanced by duodenal 
versus peripheral glucose infusion. It should be noted that the route of glucose 
delivery did not appear to affect whole body glucose uptake. This is not 
surprising since it has been previously showed that the increase in net hepatic 
glucose uptake in response to portal glucose delivery is concomitant with a 
proportional decrease in nonhepatic glucose uptake, thus the whole body 
glucose disposal remains unchanged (Galassetti et al., 1999). 
Other investigators using tracer methods and indirect calorimetry rather 
than direct measurement, observed that when glucose was infused 
intraduodenally or intravenously at 6 mg/kg/min into healthy humans for 180 min, 
neither hepatic nor whole body glucose storage was affected by the route of 
administration (Fery et al., 2001). However, this study was limited in that it was 
not a clamp study, thus there were higher insulin levels and lower glucose levels 
following intraduodenal glucose infusion, and no direct data regarding hepatic 
glucose uptake were presented.  
Another study comparing the metabolic responses to intraduodenal and 
intravenous glucose delivery in the humans also concluded that hepatic and 
peripheral glucose disposal is not significantly influenced by the route of glucose 
delivery (Fery et al., 2004). These authors used dual-isotope techniques and 
indirect calorimetry, in the presence of a hyperinsulinemic euglycemic clamp. 
They found whole body glucose uptake, glycolysis, oxidation, and storage were 
similar whether glucose was administered enterally or via a peripheral vein. A 
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major drawback to this study is the fact that it was carried out under euglycemic 
conditions, when the role of the liver in glucose disposition is less important and 
the role of muscle is dominant (Galassetti et al., 1999). Another drawback is that 
net first-pass splanchnic uptake, which was estimated by subtracting the 
appearance of exogenous glucose from the total glucose infusion rate, did not 
coincide with the value of hepatic glucose uptake. This may be due to the 
recycling of the enteral glucose initially taken up by the liver through glucose 6-
phosphate and/or glycogen, and this estimation omits the portion of glucose 
taken up by extrahepatic splanchnic tissues. 
As mentioned previously, one of the major limitations in exploration of 
hepatic glucose uptake in response to route of glucose administration in the 
human is an ability to access the hepatic portal vein. As a consequence, 
splanchnic glucose uptake is commonly used as the index of hepatic glucose 
uptake. Tracer kinetics technique could be an alternative method to measure 
hepatic glucose uptake, but its accuracy depends heavily upon the experimental 
conditions. In addition, the effects of factors released from the gut, such as 
incretins, following an oral/enternal glucose load will make it more difficult to 
differentiate the effects of portal glucose signal on hepatic glucose uptake. 
Therefore, whereas the portal signal has been demonstrated to exist in the 
human, its relative importance in human glucose metabolism remains to be 
completely elucidated.  
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Mechanism of Portal Signaling 
The mechanism by which the portal glucose signal exerts its effects has 
been also investigated. Niijima and his coworkers (Niijima, 1982) showed the 
existence of glucose sensitive cells in the portal vein, therefore it is possible that 
portal glucose delivery somehow generates a unique signal important in 
regulating hepatic glucose uptake via portal glucose sensors.  
It has been shown that neural involvement is important in the regulation of 
glucose homeostasis. The hypothalamus is one of the key sites for sensing of the 
glucose level to regulate both energy and nutrient homeostasis (Borg et al., 1997; 
Lam et al., 2007; Lam et al., 2005; Matsuhisa et al., 1997). Furthermore,  it has 
been shown that the activation of hypothalamic adenosine triphosphate (ATP)-
sensitive potassium channels is required for hypothalamic glucose sensing (Lam 
et al., 2007). Recent research updated the hypothalamocentric model of glucose 
sensing with one emphasizing a widespread neural network involving numerous 
aspects of the central nervous system and peripheral sensory inputs. Thus, in 
addition to the hypothalamus, the area postrema, the nucleus of the solitary tract, 
and the dorsal motor nucleus have now all been shown to be important (Levin et 
al., 2004; Marty et al., 2007). Key peripheral glucose sensors have been 
identified in the oral cavity (Marty et al., 2007), carotid bodies (Koyama et al., 
2000), gastrointestinal tract (Berthoud, 2008), and portal-mesenteric vein 
(Donovan, 2002). The question then is how the portal glucose signal is generated. 
It is conceivable that when oral/portal glucose delivery is present, the portal 
glucose level is compared with the arterial glucose level at some as-yet 
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undetermined reference site to initiate the response. 
Since as noted above, the brain plays an important role in sensing glucose, 
Hsieh et al (Hsieh et al., 1999a) determined whether the comparison of the brain 
arterial glucose level with the portal glucose level initiated the stimulatory effect 
of portal signal on NHGU. The study was performed under hyperglycemic and 
hyperinsulinemic conditions with basal glucagon levels. Glucose was infused into 
the hepatic portal vein at ~4 mg/kg/min and a peripheral vein at a variable rate to 
double the hepatic glucose load. In one group, glucose was infused into both 
vertebral and carotid arteries to eliminate the glucose gradient between the 
arterial blood in the head and the portal vein, while in another group, saline was 
infused into the head. The arterial-portal glucose gradients and the hepatic 
glucose loads were similar between groups. NHGU was 4.3±0.7 and 4.5±0.8 
mg/kg/min in the glucose and saline infusion groups, respectively, in the present 
of elevated insulin and glucose. Therefore, the head arterial glucose level is not 
the reference standard used for comparison with the portal glucose level in the 
generation of the portal glucose signal.  
The carotid body had been proposed as a possible arterial glucose 
sensing site in cats (Alvarez-Buylla et al., 1988), rats (Alvarez-Buylla et al., 1994), 
and dogs (Koyama et al., 2000). However, Hsieh’s results (Hsieh et al., 1999a) 
do not support the involvement of carotid body in the initiation of the portal signal, 
since the rate of NHGU was not different when the glucose gradient between the 
arterial body and the portal vein was eliminated by giving glucose infusion into 
carotid arteries (infused glucose flowed over carotid sinus region). 
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Research using isolated perfused rat livers demonstrated that a negative 
glucose gradient between the hepatic artery and the portal vein could create a 
metabolic signal locally within the liver (Gardemann et al., 1986; Stumpel et al., 
1997). Horikawa et al (Horikawa et al., 1998) reported that both portal vein and 
hepatic arterial glucose infusion stimulated NHGU in conscious dogs. These data 
suggested that glucose sensors within the liver, rather than the portal vein, might 
be involved in the enhancement of NHGU in response to the portal glucose 
delivery.  
Hseih et al. (Hsieh et al., 2000) then went on to examine whether 
elimination of the hepatic A-P venous glucose gradient within the liver would alter 
the changes in net hepatic and peripheral glucose uptake induced by portal 
glucose delivery in the generation of the portal glucose signal. The study was 
again carried out under hyperglycemic and hyperinsulinemic conditions with 
basal glucagon levels. In two experimental groups, glucose was infused into the 
hepatic portal vein at ~4 mg/kg/min and a peripheral vein at a variable rate to 
double the hepatic glucose load, while glucose was exclusively infused into a 
peripheral vein in a control group. In one of the portal glucose infusion groups, 
saline was infused into the hepatic artery while the other portal glucose infusion 
group received a glucose infusion into the hepatic artery to eliminate the negative 
A-P glucose gradient induced by portal glucose delivery. NHGU was 2.3±0.4 
mg/kg/min in the control group, and it increased to 4.3±0.6 mg/kg/min in 
response to the portal glucose delivery, while it was 2.5±0.8 mg/kg/min when the 
hepatic A-P glucose gradient was eliminated. The authors concluded that the 
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glucose level at the hepatic artery plays an important role in generation of the 
effect of portal glucose delivery on glucose uptake by liver. 
As a corollary to these data, one could speculate that ligation of the 
hepatic artery would result in augmentation of NHGU during peripheral glucose 
delivery, since the hepatic arterial glucose level would always be lower than that 
in the portal vein. On the other hand, hepatic artery ligation would not lead to 
enhancement in NHGU in response to the portal glucose delivery, in comparison 
with peripheral glucose delivery, because the maximal effects of the negative A-P 
gradient should be present at all times. Moore et al. (Moore et al., 2003) 
performed a study in which the hepatic artery was chronically ligated in 
conscious dogs. They demonstrated that NHGU in response to hyperinsulinemia 
and glucose delivered via a peripheral vein was not significantly different in dogs 
that had undergone the hepatic artery ligation than in sham dogs. Furthermore, 
portal glucose delivery still resulted in a significant increment in NHGU in dogs 
that had undergone the ligation. These data suggest that there may be more than 
one reference site for comparison to portal vein glucose levels, and that 
redundancy exists such that when the primary sensing site is lost, control reverts 
to other sites.  
Another piece of evidence to support the notion of neural involvement in 
generation of portal glucose signal comes from the findings that when the liver 
was denervated, the hepatic response to the portal glucose delivery was blunted. 
Adkins-Marshall et al. (Adkins-Marshall et al., 1992) determined in conscious 
dogs that portal glucose delivery had no effect on NHGU, in the presence of a 
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hyperglycemic-hyperinsulinemic clamp, following a total hepatic denervation; 
thus, hepatic denervation blunted the ability of the liver to discriminate between 
portal and peripheral glucose delivery.  
Since it has been suggested that the portal signal may be neurally 
mediated, the parasympathetic and sympathetic nerves that innervate the liver 
need to be considered. Autonomic nerves innervate the liver along three routes: 
the portal vein, the hepatic artery, and the bile ducts, and the autonomic nerves 
from the hypothalamus could control glycogen metabolism (Shimazu, 1967; 
Shimazu et al., 1966). Tiniakos et al. (Tiniakos et al., 1996) showed that both 
parasympathetic and sympathetic efferent innervation is involved in hepatic 
hemodynamics, bile flow regulation, and control of carbohydrate and lipid 
metabolism. Shimazu et al. showed that stimulation of the sympathetic efferent 
resulted in an increase in hepatic glucose output by stimulating glycogen 
phosphorylase (Shimazu, 1981; Shimazu, 1987; Shimazu, 1983) and PEPCK 
activity. In contrast, stimulation of the parasympathetic efferents led to activation 
of glycogen synthase and inactivation of PEPCK in the liver (Shimazu, 1981; 
Shimazu, 1987; Shimazu, 1983). Furthermore, the hepatic vagus nerve, in which 
~90% of the fibers are afferent (Stumpel et al., 1997) has been shown to convey 
information regarding plasma glucose and other nutrients to the brain (Sakaguchi 
et al., 1982).  
DiCostanzo et al. (Dicostanzo et al., 2006) examined the importance of 
the hepatic sympathetic innervation and its role in mediating the effects of the 
portal glucose delivery in 42-h-fasted conscious dogs. They hypothesized that 
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the sympathetic nervous system exerts a restraining effect on hepatic glucose 
uptake that can be reversed by the entry of glucose into the portal vein. One 
group of dogs underwent selective sympathetic denervation. This was achieved 
by cutting the nerves at the celiac nerve bundle near the common hepatic artery. 
Control dogs underwent a sham procedure. The study was carried out under 
hyperglycemic conditions with basal arterial insulin and glucagon levels in both 
groups. In the first 90 min, glucose was infused peripherally to double the hepatic 
glucose load, then glucose was infused intraportally (~4 mg/kg/min), and the 
peripheral glucose infusion was reduced so as to maintain the hepatic glucose 
load. This was followed by a 90 min period during which glucose was not infused 
portally and peripheral glucose infusion was increased to again maintain the 
hepatic glucose load. NHGU in the sham dogs averaged 1.4±0.4, 2.9±0.3, and 
2.0±0.3 mg/kg/min while NHGU averaged 2.5±0.4, 3.2±0.2, 3.3±0.5 mg/kg/min in 
denervated dogs, in three periods, respectively. These data suggested that the 
sympathetic nerves do indeed exert an inhibitory tone on hepatic glucose uptake 
and the removal of this inhibition by hepatic sympathetic denervation enhanced 
NHGU during hyperglycemia in the absence of portal signal. Furthermore, the 
increment of NHGU in response to portal glucose delivery was significantly 
blunted. Thus, the portal signal may lead to the removal of an inhibitory tone to 
the liver, which in turn allows NHGU to increase. 
It should be noted that intrahepatic nerves containing nitric oxide (NO), 
which takes part of the nonadrenergic noncholinergic (NANC) neurotransmission 
(Rand et al., 1995), have been identified in a variety of mammalian species 
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traveling with the structures of the hepatic hilus, including rats, guinea pigs, and 
cats (Esteban et al., 2001; Esteban et al., 1998; Esteban et al., 1997; Peinado et 
al., 2002). Varicose nerve fibers immunoreactive for neuronal nitric oxide 
synthase (nNOS) form a dense plexus around the larger portal veins, hepatic 
arteries, and bile ducts (Esteban et al., 2001; Peinado et al., 2002). Therefore, it 
is conceivable that the observation by DiCostanzo et al. was influenced by the 
surgical intervention of NANC nerves, complicating the interpretation of their data. 
One study examined the role of the hepatic vagus nerve in hepatic 
glucose metabolism in rats which were subjected to hepatic vagotomy or sham 
operation (Matsuhisa et al., 2000).  They found that hepatic glucose uptake was 
markedly reduced in rats with hepatic vagotomy compared with sham rats in 
response to the portal glucose delivery in the presence of a euglycemic-
hyperinsulinemic clamp. It appears that innervation of the hepatic vagus nerve is 
important for the regulation of hepatic glucose uptake.  
Cardin et al. (Cardin et al., 2004) then showed that in the presence of 
hyperinsulinemia and hyperglycemia brought about by portal glucose infusion, 
halting electrical transmission in the vagus nerves using the vagal cooling 
technique had no effect on NHGU. It appears that this finding does not support 
the concept that the vagus nerves play a role in the transmission of the portal 
glucose signal. However, it is possible that afferent signaling via the vagus nerve 
had been maximally suppressed by portal glucose delivery, and thus vagal 
cooling would have resulted in no further reduction in vagal afferent firing nor 
effect on efferent sympathetic nerve activity to the liver. To further explore the 
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possibility, a recent study by DiCostanzo et al. (DiCostanzo et al., 2007) 
examined the role of the vagus nerve in mediating the portal signal in the 
absence of portal glucose infusion. They hypothesized that in the absence of the 
portal glucose signal, vagal blockade would simulate a rise in portal glucose 
causing decreased afferent vagal firing, which in turn enhance net hepatic 
glucose uptake. The study was performed under hyperglycemic and 
hyperinsulinemic conditions in the presence of basal glucagon, and the vagus 
nerves were cooled or sham-cooled. The result showed that net hepatic glucose 
uptake did not differ in the two groups before (2.2±0.5 vs. 2.9±0.8 mg/kg/min, 
respectively) or during the coil perfusion period (3.0±0.5 vs. 3.4±0.6 mg/kg/min, 
respectively). These data indicated that interruption of vagal signaling in the 
presence of hyperinsulinemia and hyperglycemia, without portal glucose delivery, 
had no effect on NHGU, thus it is unlikely that vagus nerve is a determinant of 
the afferent limb of NHGU. However, the role of the efferent vagus nerve in 
response to the portal glucose delivery cannot be ruled out since Shiota et al. 
(Shiota et al., 2000) showed that intraportal infusion of acetylcholine at 3 
ug/kg/min enhanced net hepatic glucose uptake by ~65% in the presence of 
hyperinsulinemia and hyperglycemia in the absence of portal glucose delivery.  
More evidence supporting neural regulation of glucose uptake by the liver 
in response to portal signal comes from studies on the effects of neural 
mediators on hepatic glucose uptake. Norepinephrine (NE), the major 
sympathetic neurotransmitter, affects glucose metabolism in hepatocytes via α1- 
adrenergic receptors (Garceau et al., 1984). Intraportal NE infusion (50 ng/kg/min, 
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which elevated the hepatic sinusoidal NE concentration to 4,100 pg/ml) markedly 
increased hepatic glucose production by selectively stimulating hepatic 
glycogenolysis (Chu et al., 1998). Besides NE, another neuro-transmitter, 
neuropeptide Y (NPY), which is released during sympathetic signaling to the liver 
(Taborsky et al., 1994), has been recently shown to stimulate net hepatic glucose 
uptake in conscious dogs during the intraportal NPY infusion (Nishizawa et al., 
2008). 
Another piece of evidence supporting neural control of the liver comes 
from the time course of the effects of the portal glucose signal on the liver. If the 
hepatic response to the portal signal involves a neural system, both the 
transmission of the signal and the hepatic response should be rapid. Pagliassotti 
et al. (Pagliassotti et al., 1996b) examined the time course of the effects of the 
portal glucose signal on the liver and showed that the speed of the response is 
consistent with neural mediation.  
In that study, when both glucagon and insulin levels were kept at basal, 
the hepatic glucose load was doubled by peripheral glucose infusion in all groups, 
they showed that in the absence of the portal signal, the liver took up a very 
small amount of glucose (~0.4 mg/kg/min). When the portal signal was generated 
under the same experimental conditions, there was a rapid increase in net 
hepatic glucose uptake, which reached a maximum (~2.7 mg/kg/min) within 15 
min and was sustained. Thus, the portal glucose signal activates the liver much 
more quickly than would otherwise be the case. It is worth noting that the 
dissipation of the effect of the portal signal on NHGU is also very rapid (~15 min), 
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indicating that uncoupling is also very efficient (Hsieh et al., 1998; Hsieh et al., 
1999b).  
It is also important to understand the intracellular mechanism by which 
hepatocytes are activated in response to the portal glucose signal and the fate of 
the extracted glucose.  When levels of insulin and glucagon were maintained at 
basal values, hyperglycemia in the absence of portal glucose was associated 
with little accumulation of glycogen. In the presence of the portal glucose signal, 
there was a significant increase in glycogen deposition (Pagliassotti et al., 1996b). 
The portal signal caused rapid glucose uptake by the liver, and a significant 
accumulation in hepatic glycogen deposition, which resulted from the activation 
of liver glycogen synthase. Thus, hyperglycemia alone was unable to activate 
glycogen synthase, but glycogen synthase was activated in a time-dependent 
manner in response to portal glucose delivery. It seems that an increase in 
glucose-6-phosphate levels and a reduction in phosphorylation of glycogen 
synthase within hepatocytes may be responsible for the metabolic responses 
induced by portal glucose delivery.  
Net hepatic glucose flux is the balance between the rate of glucose entry 
and exit. These rates are dependent on the rate of glucose phosphorylation 
catalyzed by glucokinase (GK) and the rate of dephosphorylation of glucose-6-
phosphate catalyzed by glucose-6-phosphatase. Another potential intracellular 
regulatory point is the translocation of GK within the hepatocyte. It has been 
shown that in the unstimulated state, GK is sequestered in the hepatocyte 
nucleus, where it is bound to its regulatory protein (GKRP), and it is allosterically 
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inhibited due to a decreased affinity for glucose (Agius et al., 1997; van 
Schaftingen et al., 1997). A rise in intracellular fructose-1-phosphate due to 
fructose uptake by the liver (Davies et al., 1990) or treatment with high 
concentration of glucose (Agius et al., 2000) in isolated hepatocytes led to 
dissociation of GK from GKRP, allowing GK to enter the cytosol, where it 
catalyzes the phosphorylation of glucose, thus promoting glucose entry into 
hepatocytes. Chu et al. (Chu et al., 2004) determined that in response to 
intraduodenal glucose delivery in conscious rats, GK was exported from the 
nucleus within 10 min as determined evidenced by the ratio of the nuclear to the 
cytoplasmic immunofluorescence of GK, whereas GKRP, the binding protein that 
tethers GK in the nucleus did not change its location. The results suggested that 
GK but not GKRP translocates rapidly in a manner that corresponds with 
enhancement of NHGU in response to glucose ingestion. Furthermore, the 
resulting rise in glucose-6-phosphate following GK translocation would then 
result in the activation of glycogen synthase, and these two changes would drive 
glucose uptake and glycogen storage by the liver. 
It has been established that portal signal plays a key role in the 
coordination of the metabolic response to glucose ingestion, however, more work 
still needs to be carried out to understand the mechanism of this signaling 
system. 
 
Other Mediators of Net Hepatic Glucose Uptake 
To date, it remains to be elucidated how the coordinated responses of 
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muscle and liver to portal glucose delivery come about. It has been shown that 
other regulators of NHGU may exist, such as GLP-1, nitric oxide, and serotonin 
etc.  
GLP-1 
Glucagon-like peptide-1 amide (GLP-1), is released by the L cells of the 
intestine in the postprandial period. It improves glucose tolerance by both 
stimulating insulin and decreasing glucagon secretion and slowing gastric 
emptying (Drucker, 2006). It has been reported that treatment with GLP-1 
increases glycogen sythase activity, decreases glycogen phosphorylase, and 
promotes glycogen storage in a dose-dependent manner in isolated rat 
hepatocytes (D'Alessio et al., 2004). It is interesting to note that, at the whole 
body level, not like commonly used oral hypoglycemic agents, GLP-1 exerts its 
incretin effect only when hyperglycemia is present. In addition to its incretin 
effects, evidence from animal models indicates that both high physiological and 
pharmacological doses of GLP-1 can directly stimulate NHGU, independent of its 
well-recognized effects on insulin and glucagon secretion (Dardevet et al., 2004; 
Nishizawa et al., 2003). In line with these findings, a recent study in dogs showed 
that intraportal infusion of Vildagliptin (DPP-4 inhibitor) augmented hepatic 
glucose disposal by means beyond the effects of GLP-1 on insulin and glucagon 
(Edgerton et al., 2009). On the other hand, the increase in glucose clearance in 
response to intraportal glucose delivery was ablated, when the GLP-1 receptor 
antagonist exendin-(9-39) was infused intraportally in mice (Burcelin et al., 2001). 
Conflicting data are available regarding the non-incretin effects of GLP-1 in 
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humans, probably due to the methodological differences, with most not showing 
a significant direct effect (Meneilly et al., 2001; Vella et al., 2001) or a small effect 
(Prigeon et al., 2003)of GLP-1 on hepatic glucose metabolism. Thus, the 
potential direct role of GLP-1 on hepatic glucose metabolism in the humans 
remains unclear. 
Portal infusion of GLP-1 and glucose, but not systemic glucose, can 
produce decreased peripheral glucose levels independent of insulin, indicating a 
functional relationship between portal glucose and GLP-1 actions (Ionut et al., 
2005). Consistent with this observation, Johnson et al. (Johnson et al., 2008) 
determined that a physiological elevation of GLP-1 in the hepatic portal vein does 
not increase NHGU and whole body glucose uptake when hyperglycemia is 
induced by peripheral glucose infusion, suggesting that a physiological increase 
in GLP-1 augments glucose utilization only when GLP-1 and a negative arterial-
portal glucose gradient co-exist. These data clearly showed the GLP-1 has the 
ability to regulate NHGU.  Given that there are no data supporting that GLP-1 
secretion could be changed by portal glucose delivery, and portal glucose 
delivery can promote NHGU when the secretion of endogenous GLP-1 was 
inhibited by somatostatin, it is unlikely that GLP-1 is mechanistically responsible 
for metabolic response induced by portal signal. It is possible, however, that 
GLP-1 and portal signal have interactive effects on hepatic glucose metabolism 
in the postprandial state, and that the activation of the portal glucose signal and 
GLP-1 actions might be a fundamental requirement for hepatic glucose uptake in 
response to a carbohydrate meal. 
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Nitric Oxide 
Nitric oxide (NO) is a potent biological mediator produced in a variety of 
tissues during the catabolism of L-arginine to L-citrulline catalized by nitric oxide 
synthase (NOS). The latter exists in three isoforms including endothelial (eNOS), 
neuronal (nNOS) and inducible (iNOS) forms. All three isoforms of NOS have 
been reported to be expressed in liver (McNaughton et al., 2002). Intrahepatic 
nerves containing the neuroeffector nitric oxide (NO), which comprises part of the 
nonadrenergic noncholinergic (NANC) nerve system (Rand et al., 1995), have 
been identified in a variety of mammalian species traveling within the structures 
of the hepatic hilus, including rat, guinea pig, and cat (Esteban et al., 2001; 
Esteban et al., 1998; Esteban et al., 1997). Varicose nerve fibers immunoreactive 
for neuronal nitric oxide synthase (nNOS), the enzyme that catalyzes the 
formation of NO, form a dense plexus around the larger portal veins, hepatic 
arteries, and bile ducts. These fibers diminish in numbers in the distal branches 
of these structures. In the guinea pig, nNOS colocalized with both NPY and 
CGRP, suggesting both an afferent and an efferent function (Esteban et al., 
2001). NO intralobular fibers have been found. In the guinea pig, but not in the 
other species studied, nitrergic innervation of the hepatic veins was also 
identified (Esteban et al., 2001; Peinado et al., 2002). 
Physiological levels of NO can stimulate glucose uptake and oxidation in 
skeletal muscle and adipocytes (Roy et al., 1998). Moreover, chronic 
administration of L-NAME, a NOS inhibitor in drinking water, decreased glucose 
tolerance in rats (Balon et al., 1999). eNOS knockout mice have 
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hyperinsulinemia and impaired insulin-stimulated glucose uptake relative to 
control mice (Duplain et al., 2001). These findings suggest that NO could play an 
important regulatory role in glucose metabolism. 
In vitro studies have shown that NO can have direct effects on isolated 
hepatocytes, which result in an inhibition of gluconeogenesis, a reduction in 
glycogen synthesis and an increase in glucose output (Horton et al., 1994; 
Sprangers et al., 1998). Lautt and others (Lautt, 2005) have investigated the role 
of hepatic NO in regulating whole body glucose metabolism. They hypothesized 
the existence of a novel neurohumoral mechanism by which hepatic 
parasympathetic nerves, through permissive release of a putative insulin 
sensitizing substance (HISS) from the liver, regulate peripheral glucose disposal. 
According to their theory, following a meal, insulin results in the release of HISS, 
which requires a parasympathetic permissive reflex that signals the presence of 
feeding. The parasympathetic nerves work through activation of cholinergic 
muscarinic receptors in the liver and subsequent production of NO, which then 
increases the release of HISS from the liver. This, in turn, stimulates peripheral 
glucose uptake, however, nothing is known about the direct effect of NO on 
hepatic glucose uptake in vivo. 
Our preliminary data showed that intraportal infusion of a nitric oxide 
donor, SIN-1(3-morpholynosydnonimine), in the presence of portal glucose 
delivery, was associated with hypotension and decreased NHGU during a 
hyperglycemic (2X basal) hyperinsulinemic (4X basal) clamp in 42-h-fasted 
conscious dogs. This inhibitory effect of intraportal SIN-1 infusion on NHGU was 
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rapid and significant, suggesting that a decrease in NO may be involved in 
mediation of portal glucose signal. The question then arises as to how intraportal 
SIN-1 infusion leads to decreased NHGU. Supported by our observation of 
increased heart rate and lipolysis in this study, one possibility is that an indirect 
mechanism could be involved, such that an increase in sympathetic drive to the 
liver resulting from hypotension led to a drop of NHGU. Furthermore, our recent 
finding that hepatic sympathectomy increased NHGU in response to peripheral 
glucose infusion suggests that the sympathetic nerves exert a tonic inhibition on 
NHGU (Dicostanzo et al., 2006). Another possibility is that NO had a direct effect  
on the hepatocytes since in vitro studies have clearly shown that endogenous 
and exogenous NO can alter signaling in the liver (Billiar et al., 1989).  
It is generally agreed that the most prominent NO signaling pathway 
involves activation of soluble guanylate cyclase (sGC). sGC converts guanosine 
triphosphate (GTP) to cGMP, which promotes diverse responses through several 
potential pathways, including protein kinase G (PKG), cGMP phosphodiesterase 
(PDE), and AMP-activated protein kinase (AMPK) (Lira et al., 2007; Zhang et al., 
2008). Alternatively, cGMP-independent NO reactions may occur as well, 
including interaction of NO with superoxide anion to generate peroxynitrite, or 
direct nitrosylation of cysteine thiol residues of target proteins like glutathione 
(Rockey et al., 2004). Studies showed that NO produced by hepatocytes and 
neighboring Kupffer cells can in turn stimulate sGC and increase cGMP levels in 
the liver (Billiar et al., 1989; Curran et al., 1989). Thus, these intracellular 
pathways could be responsible for the change of glucose uptake by the liver 
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seen in the preliminary study. Thus, specific aim I is to assess effects of the 
change of nitric oxide on net hepatic glucose uptake in conscious dogs, and the 
specific aims III and IV are to understand the intracellular mechanism of the 
effects of NO on net hepatic glucose uptake. 
5-HT 
Neuropeptides involved in the innervation of the liver include neuropeptide 
Y, substance P, vasoactive intestinal peptide, glucagon-like peptides, 
somatostatin, serotonin, etc, (Akiyoshi et al., 1998; el-Salhy et al., 1993; 
Stoyanova et al., 1998). Serotonin is localized within neurons in the enteric 
nervous system (Ormsbee et al., 1985), and serotonergic nerves are found 
associated with the branches of the portal vein, hepatic artery, bile duct in the 
connective tissue of portal tracts (McCuskey, 2004). 
There is growing evidence showing that selective serotonin reuptake 
inhibitors (SSRI), which prolong the action of endogenous serotonin, may 
facilitate glycemic control in patients with type 2 diabetes (Breum et al., 1995; 
Maheux et al., 1997; Potter van Loon et al., 1992). These findings suggest that 
serotonin may play a regulatory role in controlling glucose metabolism. Park and 
Choi (Park et al., 2002) demonstrated that oral treatment with the SSRI fluoxetine 
for 8 weeks increased glucose disposal during a hyperinsulinemic euglycemic 
clamp in both sham-operated and 90%-pancreatectomized rats without changing 
food intake or body weight. Serotonin (5-hydroxytryptamine; 5-HT) has been 
shown to dose dependently decrease serum glucose levels in mice (Sugimoto et 
al., 1990; Yamada et al., 1989). Interestingly, type 2 diabetes is associated with 
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reduced levels of serotonin in blood (Martin et al., 1995). Furthermore, there is 
growing body of work showing that selective serotonin reuptake inhibitors (SSRI), 
which increase the level of endogenous serotonin, may impact glycemic control 
in people with type 2 diabetes (Breum et al., 1995; Maheux et al., 1997; Potter 
van Loon et al., 1992). Taken together, these findings suggest that serotonin may 
play a regulatory role in controlling glucose metabolism. 
Splanchnic glucose uptake, which is impaired in type 2 diabetic individuals 
(Basu et al., 2001; Ludvik et al., 1997), accounts for the disposal of ~1/3 of a 
moderately sized oral glucose load, and the liver accounts for the majority of this 
disposal (Bajaj et al., 2002; Cherrington, 1999). Data support the possibility that 
hepatic serotonin levels might have an impact on net splanchnic/hepatic glucose 
uptake. For example, intraportal infusion of 5-HT (Moore et al., 2004b) or 5-
hydroxytryptophan (5-HTP) (Moore et al., 2005b), the immediate precursor of 5-
HT, enhanced net hepatic glucose uptake (NHGU) in conscious dogs during a 
hyperinsulinemic hyperglycemic clamp. Further, it has been demonstrated that 
intraportal delivery of the SSRI fluvoxamine to the liver increased NHGU with 
concomitant stimulation of hepatic glycogen storage (Moore et al., 2004a). 
However, due to the limitations of drug specificity, whether these effects were 
caused by an inhibition of serotonin reuptake, or whether some other mechanism 
was involved, remains unclear.  
Escitalopram (S-enantiomer of citalopram), another commonly prescribed 
antidepressant, has the highest selectivity for the serotonin transporter (Klein et 
al., 2006). Compared with fluvoxamine, it has little or no affinity for noradrenergic 
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or dopaminergic transporters (Owens et al., 2001). Compared to other 
antidepressants, this drug has relatively modest effects on appetite and weight 
as well as lower potential for drug interactions (Culpepper, 2002; Hyttel, 1994). 
Because of these characteristics, it serves as a useful tool for determining the 
effects of serotonin on hepatic glucose metabolism in the absence of the 
previously described confounding variables. Therefore, the purpose of specific 
aim II is to further assess the role of inhibition of serotonin level in the liver on 
NHGU by determining the effect of escitalopram on NHGU in conscious dogs.  
 
 
Specific Aims 
 
Specific Aim I: To Examine the Effect of an Intraportal Nitric Oxide (NO) Donor 
(SIN-1) on Net Hepatic Glucose Metabolism in the Presence of the Portal 
Glucose Signal 
Specific Aim 1 assessed effects of the increase in nitric oxide in the liver 
on NHGU in the 42-h-fasted conscious dog under hyperinsulinemic 
hyperglycemic conditions. Portal infusion of the NO donor SIN-1, in the presence 
of the portal glucose signal, was used to increase NO levels within the liver and 
hepatic substrate balance was calculated in the presence or absence of SIN-1, 
while in another group, SIN-1 was given intraportally at the same rate into a leg 
vein. Consequently, Aim I increased the power of the preliminary data and 
addressed the question of whether the effect of SIN-1 on NHGU in the liver was 
 42 
secondary to hypotension induced by SIN-1 infusion or a direct effect of NO on 
the liver.  
Specific Aim II: To Assess Effects of Intraportal Infusion of the SSRI 
Escitalopram (Lexapro) on NHGU 
Specific aim 2 assessed the role of inhibition of serotonin level in the liver 
on NHGU by determining the effect of intraportal infusion of a SSRI escitalopram 
on NHGU in the 42-h-fasted conscious dog under hyperinsulinemic 
hyperglycemic conditions. The hypothesis is that inhibition of serotonin level in 
the liver by intraportal infusion of a SSRI escitalopram enhances NHGU. 
Specific Aim III: To Determine the role of sGC/cGMP Pathway in the Regulation 
of Net Hepatic Glucose Uptake, and Whether the Regulation of NHGU by NO is 
sGC/cGMP Dependent 
The possibility raised by specific aim 1 is that hepatic NO, or some 
downstream signal that it generates, has an inhibitory effect on glucose uptake 
by the liver. Thus, the intracellular mechanism by which the effects of NO on 
NHGU are brought about need to be assessed. Therefore, specific aim 3 
assessed the role of sGC/cGMP in the regulation of NHGU, and whether the 
regulation of NHGU by NO is sGC/cGMP-dependent in the 42-h-fasted 
conscious dogs under hyperinsulinemic hyperglycemic conditions. In one 
experimental group, a potent and specific sGC inhibitor ODQ was infused 
intraportally in the 42-h-fasted conscious dog under hyperinsulinemic 
hyperglycemic conditions, and NHGU was quantified. In another experimental 
group, ODQ was given intraportally to inhibit sGC/cGMP pathway, and then NO 
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donor SIN-1 was given intraportally later. The hypothesis is that a sGC-
dependent mechanism has the ability to regulate NHGU, and the inhibition of 
sGC/cGMP pathway would blunt the effect of NO on NHGU.  
Specific Aim IV: To Explore the Effect of an Intraportal Infusion of a cGMP 
Analog, 8-Bromo-cGMP, on Net Hepatic Glucose Metabolism 
In Aim4, a membrane-permeable cGMP analog, 8-Bromo-cGMP, was infused 
intraportally in the 42-h-fasted conscious dog under hyperinsulinemic 
hyperglycemic conditions to determine the effect of an increase in hepatic cGMP 
on NHGU. We hypothesized that the increase in hepatic cGMP levels enhances 
NHGU. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Animals and Surgical Procedures 
 
Animal Care 
Experiments were conducted on healthy 42h fasted conscious mongrel 
dogs (20-26 kg) of either sex that had been fed once daily a diet of meat (Kal 
Kan, Vernon, CA) and chow (Purina Lab Canine Diet No. 5006; Purina Mills, St. 
Louis, MO) comprised of 34% protein, 14.5% fat, 46% carbohydrate, and 5.5% 
fiber (~ 1500 kcal/d) based on dry weight. Water was available ad libitum. A fast 
of this duration was chosen because it produces a metabolic state resembling 
that in the overnight-fasted human and results in liver glycogen levels in the dog 
that are at a stable minimum (Adkins-Marshall et al., 1990).  Each dog was only 
used for one experiment. The animals were housed in a facility that met 
American Association for Accreditation of Laboratory Animal Care guidelines, 
and the protocols were approved by the Vanderbilt University Medical Center 
Animal Care and Use Committee. 
 
Surgical Procedures 
 Approximately 16 days prior to the study, each dog underwent a 
laparotomy under general anesthesia (0.01 mg/kg buprenorphine HCl and 5 
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mg/kg proppofol presurgery and 1% isoflurane inhalation anesthetic during 
surgery) by making a midline incision 1.5 cm caudal to the xyphoid process 
through the skin, subcutaneous layers and linea alba and extending caudally 
about 10 cm. A portion of the jejunum was exposed and a branch of a jejunal 
vein was selected for cannulation. The vein was separated from surrounding 
connective tissue and ligated with 4-0 silk (Ethicon, Inc., Sommerville, NJ). A 
silicone rubber infusion catheter (0.03 in ID; Dow Corning Corp., Midland, MI) 
was inserted into the vessel through a small incision and passed anterograde 
until the catheter tip was at the next major jejunal vein junction. The catheter was 
secured in place with three ties of 4-0 silk. The jejunum was replaced in the 
abdomen and the spleen was exteriorized. One of the branches of the common 
splenic vein was cannulated in a similar manner to the jejunal vein and the 
spleen was then replaced in the abdomen. The jejunal and splenic catheters 
were used for intraportal infusion of pancreatic hormones (insulin and glucagon). 
The liver was retracted, the left lateral lobe of the liver caudally and the 
central lobe cephalically. The left common hepatic vein and the left branch of the 
portal vein were exposed. A 14 gauge Angiocath (Benton Dickinson Vascular 
Access; Sandy, UT) was inserted in the left branch of the portal vein 2 cm from 
the central liver lobe. A silicone rubber catheter (0.04 in ID) for blood sampling 
was inserted, advanced retrograde about 4 cm into the portal vein and secured 
with three ties of 4-0 silk through the adventitia of the vessel and around the 
catheter. An angiocath was inserted into the left common hepatic vein 2 cm from 
its exit from the left lateral lobe. A silicone rubber sampling catheter (0.04 in ID) 
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was inserted into the hole and passed retrograde 2 cm and secured into place 
with three ties of 4-0 silk. These catheters were used for obtaining blood samples 
from the portal vein and hepatic vein, respectively. 
 An arterial sampling catheter was inserted into the left femoral artery 
following a cut-down in the left inguinal region.  A 2 cm incision was made 
parallel to the vessel.  The femoral artery was isolated and ligated distally. The 
sampling catheter (0.04 in ID) was inserted and advanced 16 cm in order to 
place the tip of the catheter in the abdominal aorta.  Again, like all previously 
mentioned catheters, the catheter was secured, filled with heparinized saline 
(1U/ml; Abbott Laboratories, North Chicago, IL), knotted and placed in a 
subcutaneous pocket prior to closure of the skin. This catheter was used to 
obtain arterial blood.   
 Sections of the portal vein and hepatic artery were exposed by retracting 
the duodenum laterally.  A small section of the portal vein was exposed by blunt 
dissection taking care not to disturb the nerve bundle located on the vessel.  A 6 
or 8 mm ID ultrasonic flow probe (Transonic Systems Inc, Ithaca, NY) was placed 
around the vessel.  A small portion of the common hepatic artery was also 
carefully exposed and a 3 mm ID ultrasonic flow probe was secured around the 
vessel.  The flow probes were used to determine portal vein and hepatic artery 
blood flow during experiments. The gastroduodenal vein was isolated and ligated 
to prevent blood from entering the portal vein beyond the site of the flow probe.  
Blood that would normally flow through the gastroduodenal vein was shunted 
through the caudal pancreatoduodenal vein draining the tail of the pancreas. The 
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ultrasonic flow probe leads were positioned in the abdominal cavity and the ends 
of the catheters were secured to the abdominal wall.   
 The subcutaneous layer was closed with a continuous suture of 2-0 
chromic gut (Ethicon, Inc.).  The skin was closed with horizontal mattress sutures 
of 3-0 Dermalon (Ethicon, Inc.).  The dogs received penicillin G (Procaine; 
Anthony Products, Irwindale, CA) intramuscularly (106 U) immediately after 
surgery to minimize the possibility of infection.  Flunixin (Meglumine 50 mg/ml; 
Phoenix Scientific, Inc., St. Joseph, MO) was injected intramuscularly (1 mg/kg 
body weight) after wound closure for acute pain relief.  Animals awoke from 
surgery within 2 h, were active, and ate normally approximately 8 h after surgery.  
They also received 500 mg ampicillin (Principen; Bristol-Myers Squibb, Princeton, 
NJ) orally twice a day for 3 days post-operatively or as needed.  
 All dogs studied had: 1) leukocyte count <18,000/mm3, 2) a hematocrit 
>35%, 3) a good appetite, and 4) normal stools at the time of study.  On the 
morning of the study, the free ends of the catheters and the flow probe leads 
were exteriorized from their subcutaneous pockets under local anesthesia (2% 
lidocaine; Abbott Laboratories, North Chicago, IL). The contents of each catheter 
were aspirated, and they were flushed with saline. Blunt needles (18 gauge; 
Monoject, St. Louis, MO) were inserted into the catheter ends and stopcocks 
(Medex, Inc, Hilliard, OH) were attached to prevent the backflow of blood 
between sampling times. Twenty gauge Angiocaths (Deseret Medical, Becton 
Dickinson, Sandy, UT) were inserted percutaneously into the left and right 
cephalic veins and into a saphenous vein for the infusion of dye, glucose and 
 48 
drug when appropriate. A continuous infusion of heparinized saline was started 
via the femoral artery at a rate to prevent any clotting in the line.  Animals were 
allowed to stand quietly in a Pavlov harness throughout  the experiments. At the 
end of the experiment, dogs were euthanized with an intravenous injection of 
Euthansia-5 (Veterinary Laboratories, Inc., Lenexa, KS) and the position of the 
catheter tips was confirmed upon autopsy. 
 
Collection and Processing of Samples 
 
Blood Samples 
 Arterial and portal blood samples were taken simultaneously 
approximately 30 s before collection of the hepatic venous samples to 
compensate for the transit time of glucose the liver (Goresky et al., 1975). Prior 
to sampling, a catheter was cleared of saline by withdrawing 5 ml of blood into a 
syringe. The blood sample was then drawn into a separate, pre-labeled syringe 
that had been flushed with heparinized saline (1U/ml; Abbott Laboratories, North 
Chicago, IL). After sampling, the blood taken during the clearing process was re-
infused into the animal, and the catheter was then flushed with heparinized saline 
(1U/ml; Abbott Laboratories, North Chicago, IL). Before the experiment started, a 
blood sample was drawn and centrifuged. The plasma from this blood sample 
was used for the preparation of hormone infusions, various recovery standards, 
and the indocyanine green standard curve.  After onset of the experiment, 
samples were taken at various time points depending on the specific protocol. If 
 49 
a glucose clamp was performed, small arterial samples of 0.3 ml were taken 
every 5 minutes for the measurement of the plasma glucose concentration. For 
all studies, no more than 20% of the animal’s total blood volume was withdrawn 
during the study, and two volumes of saline (0.9% sodium chloride; Baxter 
Healthcare Co., Deerfield, IL) were given for each volume of blood withdrawn. 
 Immediately after each sample was obtained, the blood was processed. A 
small arterial aliquot (20 µl) was used immediately for determination of the 
hematocrit in duplicate using capillary tubes (0.4 mm ID; Drummond Scientific 
Co., Broomall, PA). 1 ml of the collected blood was placed in a tube containing 
20 ul of 0.2M glutathione (Sigma Chemical Co.) and 1.8 mg EGTA (Sigma 
Chemical Co.) for catecholamine measurement. This tube was vortexed, 
centrifuged at 3000 rpm for 6 minutes, and the supernatant was stored in a 
separate tube for later analysis. The remaining blood was placed in a tube 
containing potassium EDTA (1.6 mg EDTA/ml; Sarstedt, Newton, NC). After 
gentle mixing, 1 ml of whole blood containing EDTA was pipetted into a tube 
containing 3 ml of 3% perchloric acid (PCA; Fisher Scientific, Fair Lawn, New 
Jersey). The tube was vortexed, centrifuged, and the supernatant was stored in a 
separate tube at -70 ºC for later analysis of metabolite levels. A portion of this 
sample was used for the measurement of lactate and glycerol. In specific aim II, 
1 ml of whole blood was aliquoted and immediately transferred to -70 ºC for the 
future assay of 5-HT concentrations. The remainder of the whole blood 
containing EDTA was also centrifuged, to obtain plasma. 
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 The plasma samples were used for all other measurements. Glucose 
concentrations were immediately determined on at least four 10 µl aliquots of 
plasma using the glucose oxidase method in a glucose analyzer (Beckman 
Instruments, Inc., Fullerton CA or Analox Instruments; Lunenburg, MA).  Insulin, 
non-esterified fatty acids (NEFA), and cortisol were measured from aliquots of 
plasma (1.0, 1.0, and 0.5 ml respectively). One ml plasma for glucagon 
measurement was added to 50 µl of 10,000 KIU/ml aprotinin (Trasylol; FBA 
Pharmaceuticals, New York, NY) a protease inhibitor. Plasma for measurement 
of NEFA was frozen immediately on dry ice to inhibit lipase activity, while the 
remainder of the samples remained on ice throughout the experiment. The 
arterial and hepatic insulin samples were used for measurement of indocyanine 
green and calculation of hepatic plasma flow, as will be described later, and then 
frozen at -70 ºC until insulin was measured. All solutions were placed at -70 ºC 
after the experiment until assays were completed.  
 
Tissue Samples 
 After completion of the experiment in all of the protocols, the animal was 
euthanized with pentobarbital (390 mg/ml Fatal-Plus; Vortech Pharmaceutical 
Inc., Dearborn, MI) at 1 ml/5 kg, and the abdomen was opened so that liver 
samples could be immediately freeze clamped in situ with precooled 
Wallenburger tongs and stored at -70 ºC. Liver samples were later pulverized 
under liquid nitrogen and then stored at -70 ºC for future use. The positions of the 
catheter tips in their respective vessels were verified at the time of the necropsy. 
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Sample Analysis 
 
Plasma Glucose 
 Plasma glucose levels were determined during the experiment using the 
glucose oxidase method (Kadish et al., 1969) with a Beckman glucose analyzer 
(Beckman Instruments, Fullerton, CA). The reaction sequence was as follows: 
 
    glucose oxidase 
α-D-glucose + O2 ------------------------------------- gluconic acid and H2O2        (1) 
 
    catalase 
H2O2 + ethanol ------------------------------------- acetaldehyde + H20        (2) 
 
   molybdate 
H2O2 + 2H+ + 2I- -------------------------------------I2 +2 H20         (3) 
 
The plasma glucose concentration is proportional to the rate of oxygen (O2) 
consumption, and the glucose level in the unknown plasma samples is 
determined by comparison with the rate of oxygen consumption in a standard 
solution. The second and third reactions quickly remove all hydrogen peroxide 
(H2O2), so that there is no end-product inhibition of the process. Glucose was 
measured a minimum of 4 times at each sampling time point for each vessel and 
a minimum of 2 times for samples drawn to clamp glucose.  
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Plasma Non-esterified Fatty Acid (NEFA) 
 Plasma NEFA levels were determined spectrophotometrically using the 
Packard Multi Probe Robotic Liquid Handling System (Perkin Elmer; Shelton, CT) 
and a kit from Wako Chemicals (Richmond, VA). In essence, coenzyme A (CoA) 
is acylated by fatty acids in the presence of added acyl-CoA synthetase. The 
acyl-CoA that results is oxidized by acyl-CoA oxidase, leaving H2O2 as a 
byproduct. Subsequent addition of peroxidase, in the presence of H2O2, allows 
for oxidative condensation of 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline with 4- 
aminoantipyrine to form a purple colored adduct. The purple color adduct optical 
density is measured at 550 nm and is proportional to the NEFA concentration in 
the sample. The NEFA values are obtained from a calibration curve with known 
amounts of oleic acid. The reactions were run at 37 ºC. The specific reactions 
were as follows: 
   Acyl-CoA synthetase 
NEFA + ATP + CoA ----------------------------- Acyl-CoA + AMP + Ppi         
(4) 
 
   Acyl-CoA oxidase 
Acyl-CoA + O2  -------------------------------- 2,3-trans-enoyl-CoA + H2O2      (5) 
 
 
2 H2O2 + 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline + 4- aminoantipyrine 
     Peroxidase  
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    -------------------------- Purple color adduct         
(6) 
 
Whole Blood Metabolites: Lactate and Glycerol 
 Whole blood concentrations of lactate and glycerol were measured 
according to the method of Llyod et al (Lloyd et al., 1978) adapted to the Packard 
Multi Probe Robotic Liquid Handling System (Perkin Elmer; Shelton, CT). 
Enzymes and coenzymes for these metabolic assays were purchased from 
Sigma Chemical Co and Boehringer-Mannheim Biochemicals (Germany). The 
general reaction for the procedure involves the addition of an excess amount of 
NAD and an enzyme to the metabolite samples. NAD becomes reduced to 
NADH upon oxidation of the metabolite, and NADH has a native fluorescence 
that the oxidized form lacks. A fluorometer in the system detects changes in the 
florescence resulting from changes in NADH levels. The concentration of the 
metabolite present is proportional to the NADH produced. 
 Metabolites were measured from the PCA treated blood samples 
described under Sample Processing. A standard curve was constructed for each 
metabolite using known concentrations diluted in 3% PCA. Finally, each sample 
value was corrected for the dilution with PCA that had occurred during 
processing.  
The lactate assay involved the following reaction: 
   Lactate deyhdrogenase 
Lactate + NAD+ --------------------------------------- Pyruvate + NADH + H+    (7) 
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The enzyme buffer used was 0.24 M glycine, 0.25 M hydrazine dihydrochloride, 
and 7 mM EDTA, pH 9.6. The amount of NAD+ added was 4.6 mg and the 
amount of lactate dehydrogenase added was 0.1 U (to 10 ml of buffer). 
 The glycerol assay involved the following reaction: 
    
 
   Glycerokinase 
Glycerol + ATP -------------------------------- L-glycerol-1phosphate + ADP    (8) 
 
     Glycerol-3phosphate dehydrogenase 
L-glycerol-1 phosphate + NAD+ ----------------------------------------------------- 
    Dihydroxyacetone phosphate + NADH + H+        (9) 
 
The enzyme buffer used was 0.09 M glycine, 1 mM hydrazine, and 0.01 mM 
MgCl2, pH 9.5. The amount of ATP added was 15.4 mg, the amount of 
Glycerokinase added was 0.3U, the amount of NAD+ added was 15.4 mg, and 
the amount of glycerol-3-phosphate dehydrogenase added was 0.6U (to 10 ml 
buffer). 
 
Hormones 
 The plasma levels of insulin, glucagon, and cortisol were measured using 
radioimmunoassay (RIA) techniques (Wide, 1966). In general, a sample 
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containing an unknown amount of hormone was incubated with an antibody 
specific for that hormone. A known amount of radiolabeled hormone was added 
to the mixture to compete with the antibody binding sites. The sample was then 
treated so as to separate unbound hormone from the antibody-hormone 
complexes, generally by utilizing a double antibody procedure (single antibody 
procedure for cortisol) which caused precipitation of the bound complex. The 
radioactivity of the precipitate was measured via a Cobra II Gamma Counter 
(Packard Instrument Co, Meriden, CT). The binding of the radiolabeled hormone 
was inversely proportional to the amount of unlabeled hormone present, and a 
standard curve was constructed using known concentrations of the unlabelled 
hormone. 
Insulin 
 Immunoreactive plasma insulin was measured using a double antibody 
RIA as described previously (Morgan, 1963). Insulin antibodies and 125I tracers 
were obtained from Linco Research Inc (St. Charles, MO). A 100 µl aliquot of 
plasma was incubated for 18 h at 4 ºC with 200 µl of  125I- labeled insulin and 100 
µl of a guinea pig specific antibody to insulin. Next, the samples was incubated 
with 100 µl goat anti-guinea pig IgG (2nd antibody) and 100 µl IgG carrier for 30 
min at 4 ºC. One ml of wash buffer was added, and tubes were centrifuged at 
3000 rpm. The liquid portion of the samples was decanted and the remaining 
pellet containing the total radioactivity bound to the antibody was counted in a 
Cobra II Gamma Counter. 
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 The log of the amount of hormone in the samples was inversely 
proportional to the log of (bound label/free label). The insulin concentration in 
each samples was determined by comparison to a standard curve obtained using 
known amounts of unlabeled hormone. The samples were corrected for non-
specific binding, and the sample detection range was 1-150 µU/ml. The antibody 
is specific to porcine, canine, and human insulin, but cross-reacts with bovine 
insulin (90%), human proinsulin (38%), and the split proinsulin products Des 
31,32 (47%) and Des 64,65 (72%). Overall, less than 15% of the basal insulin 
level is due to non-insulin material. There is no cross-reactivity with glucagon, 
pancreatic polypeptide, C-peptide, or somatostatin. The recovery for the assay 
was between 90-100% (based on spiking samples with known amounts of 
insulin), and the interassay coefficient of variation (CV) was approximately 7-8% 
for the entire range of the dose response curve.  
Glucagon 
 Immunoreactive plasma glucagon was also measured using a double 
antibody RIA (Linco) (Ensick, 1983). The protocol was modified by utilizing 
primary and secondary antibodies specific for glucagon (glucagon antibodies and 
125I tracers from Linco). A 100 µl aliquot of plasma was incubated for 24 h at 4 ºC 
with 100 µl of guinea pig specific antibody to glucagon. Next, 100 µl 125I-labelled 
glucagon was added, and the solution was incubated for an additional 24 h at 4 
ºC. The samples was then incubated with 100 µl goat anti-guinea pig IgG (2nd 
antibody) and 100 µl IgG carrier for 2 h at 4 ºC. One ml of wash buffer was 
added, and the tubes were centrifuged at 3000 rpm. The samples were decanted 
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and the portion of total radioactivity bound to the antibody (pellet) was counted in 
a Cobra II Gamma Counter. 
 The log amount of hormone in the samples was inversely proportional to 
the log of (bound label/free label). The glucagon concentration in each sample 
was determined by comparison to a standard curve using known amounts of 
unlabeled hormone. The samples were corrected for non-specific binding, and 
the sample detection range was 20-400 pg/ml. The antibody is 100% specific for 
glucagon, with only slight cross reactivity with oxyntomodulin (0.01%), and no 
cross reactivity with human insulin, human proinsulin, human C-peptide, 
somatostatin, pancreatic polypeptide, or glucagon like peptide-1. A protein effect 
in the assay causes zero glucagon to read as 15-20 pg/ml. This represents a 
stable, constant background in all samples. The recovery for the assay was 
between 80-100%, and the interassay CV was approximately 6-10% for the 
entire range of the dose response curve.  
Cortisol 
 Immunoreactive plasma cortisol was measured with a single antibody 
technique (Foster et al., 1974) using a gamma coat RIA from Diagnostic 
Products Corporation (Los Angeles, CA). A 25 µl aliquot of plasma and 1 ml of 
125I-labeled cortisol were pipetted into a cortisol specific antibody-coated tube 
with the antibody immobilized on the lower inner wall of the tube. They were 
incubated for 2 hours in a 31 ºC water bath. Next, the tubes were decanted and 
rinsed with deionized water. The tubes were allowed to dry, then counted in a 
Cobra II Gamma Counter for 4 min. 
 58 
 The log of the amount of hormone in the samples was inversely 
proportional to the log of (bound label/free label). The cortisol concentration in 
each sample was determined by comparison to a standard curve using known 
amounts of unlabeled hormone. The sample detection range was 0.5-50 ug/dl. 
The antibody is 100% specific for cortisol, with only slight cross-reactivity with 11-
deoxycortisol (6%) and 17-hydroxyprogesterone (1%), and no cross reactivity 
with corticosterone, aldosterone, progesterone, deoxycorticosterone, and 
tetrahydrocortisone. The recovery for the assays was > 90%, and the interassay 
CV was approximately 8-10% for the entire range of the dose response curve. 
Catecholamines 
 A high-performance liquid chromatography (HPLC) method was used to 
determine epinephrine and norepinephrine levels as previously described by 
Goldstein et al (Goldstein et al., 1981). Four hundred microliters of the plasma 
samples were partially purified by absorption to 10 mg of acid-washed alumina 
(Bioanalytical Systems, West Lafayette, IN) in 600 µl of Tris/EDTA, pH 8.6, and 
50 µl of an internal standard (final concentration 500 pg/ml dihydroxybenzylamine 
(DHBA); Sigma Chemical Co.). Samples were shaken for 15 min, centrifuged for 
4 min, and aspirated. The alumina pellet was rinsed with 2 ml water, then the 
solution was vortexed, centrifuged, and aspirated, and the process was repeated 
twice. Next, the catecholamines were eluted with 200 µl 0.1 M perchloric acid 
(PCA) according to Anton and Sayre (Anton et al., 1962). 
 Samples were then injected onto an HR-80, reverse phase, 3 µm 
octadecylsilane column. The mobile phase was composed of 14.2 g of disodium 
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phosphate, 440 mg of sodium octyl sulfate, 37 mg of sodium EDTA, pH 3.4, and 
43 ml of methanol. The system utilized a Coulchem II Detector, Model 5021 
Conditioning Cell, and Model 5011 Analytical Cell (all obtained from ESA, 
Bedford, MA). Samples were measured against a linear calibration curve that 
was comprised of 5 standards(ranging from 50-1000 pg/ml) prepared from 
epinephrine bitartrate and (-)-arterenol bitartrate (norepinephrine) salts (Sigma 
Chemical Co.). In addition, a known amount of epinephrine and norepinephrine 
were added to the sample taken at the start of each experiment to ensure precise 
identification of the peaks, and to measure recovery. 
 Data reduction was performed with ESA 500 Chromatograph and data 
station software to identify peaks. The ratio of the peak height of the internal 
standard to the catecholamine was calculated, and the concentration of 
catecholamine was determined by comparison with the standard curve. The limit 
of detection of the assay was 20 pg/ml and 5 pg/ml for epinephrine and 
norepinephrine, respectively. Recovery was between 80-100% for both 
hormones. The interassay CVs was 3-11% and 4-6% for epinephrine and 
norepinephrine respectively for the entire range of the dose response curve. 
 To measure tissues catecholamines (liver), frozen tissue samples were 
ground into powder using mortars and pestles chilled in liquid nitrogen. Next, 5 
mM glutathione in 0.4 N perchloric acid was added to achieve 10% w:v extract. 
The solution was homogenized, the sample was centrifuged at 3000 rpm for 20 
min, and the supernatant was decanted and frozen at -70 ºC. Epinephrine and 
norepinephrine were then measured by HPLC as described for the plasma 
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catecholamine levels, and the concentrations were corrected for the dilution of 
samples. 
 
Serotonin (5-HT) 
A high-performance liquid chromatography (HPLC) method utilizing an 
Antec Decade (oxidation: 0.7) electrochemical detector was used to determine 
serotonin (5-HT) levels from liver tissue and whole blood samples. Liver tissue 
(5-10 mg) was homogenized in 500 µl of 0.1M TCA, which contained 0.01 M 
sodium acetate, 10-4 M EDTA and 10.5 % methanol (pH 3.8), using a tissue 
dismembrator (Fisher Scientific). Homogenates were spun at 10,000 g for 20 
minutes. The supernatant was removed and then analyzed for serotonin 
concentrations. The pellet was saved for protein analysis. 125 µl of the whole 
blood sample was mixed with 125 µl of the extraction solvent (0.8 M perchloric 
acid, 0.1 M ascorbic acid and 10 mM EDTA), vortexed for 15 sec and spun at 
10,000 g for 10 min, and the supernatant was then collected for the 5-HT assay. 
Samples (20 µl) were injected using a Waters 717+ autosampler onto a 
Phenomenex Nucleosil (5u, 100A) C18 HPLC column (150 x 4.60 mm).  5-HT 
eluted with a mobile phase consisting of 89.5% 0.1M TCA, 0.01 M sodium 
acetate, 10-4 M EDTA and 10.5 % methanol (pH 3.8). Solvent was delivered at 
0.7 ml/min using a Waters 515 HPLC pump. HPLC control and data acquisition 
were managed by Millennium 32 software. Daily calibration curves were 
generated by supplementing sample with stock 5-HT solutions to yield final 
concentrations of: 1, 3, 6, 12, 25, 50, 75, 100 ng/ml, using dihydroxybenzylamine 
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(DHBA) as internal standard. 5-HT was determined from the whole blood/liver 
extract by comparison with the standard curve. Additionally, recovery of 5-HT 
was estimated using equal volumes of 5-HT standards for comparison with 
sample standards. The interassay CVs was 3-11% and 4-6% for 5-HT for the 
entire range of the dose response curve. 
 
Hepatic Glycogen Content 
Liver glycogen content was determined using a modification of the method 
of Keppler and Decker (Moore et al., 1991). Frozen liver tissue was ground to 
powder using mortars and pestles, and weighed (~200 mg) while kept chilled with 
liquid nitrogen. The sample weight (mg) was multiplied by 5 to determine the 
volume (ml) of 0.6 N PCA to be used. The tissue was combined with PCA then 
thoroughly homogenized using an Ultra-Turrax homogenizer (TP18/10, Janke & 
Kunkel, IKA Werk, GmbH & Co., Staufen, Germany). A 200 µl aliquot was then 
combined with 100 µl KHCO3 to neutralize the sample. 500 µl of 
amyloglucosidase (2 mg/ml in 0.4 M sodium acetate buffer) was incubated in a 
shaker bath at 40 ºC for 2 hours. Glycogen concentration was then calculated by 
subtracting the glucose concentration in duplicate samples not treated with the 
enzyme from samples incubated with amyloglucosidase. 
 
Hepatic cGMP 
Liver cGMP levels were determined using cGMP EIA Kit (Cayman 
Chemical, Ann Arbor, MI). Frozen liver tissue was pulverized with mortars and 
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pestles, while kept chilled with liquid nitrogen. 300 mg of ground tissue were then 
placed into a regular 10 ml clean plastic tube with 1.5 ml 5% trichloroacetic acid 
(TCA). The sample was then kept on ice and homogenized using an Ultra-Turrax 
homogenizer (TP18/10, Janke & Kunkel, IKA Werk, GmbH & Co., Staufen, 
Germany). The precipitate was removed by centrifugation at 1,500 g for 10 
minutes, and 1 ml of supernatant was transferred to a 15 mL clear polypropylene 
centrifuge tubes (Corning Inc., Corning, NY). TCA was extracted from the 
supernatant sample using water-saturated ether, which was made by adding 
Ultrapure water (Cayman Chemical, Ann Arbor, MI) to ether (Sigma-Aldrich, St. 
Louis, MO) until layers formed, of which the top layer was used. 4-5 ml of ether 
was added to 1 ml of supernatant. They were mixed, and the organic and 
aqueous phases were separated. The top layer (ether) was carefully removed 
and the extraction was repeated three times. The residual ether was further 
removed from the aqueous layer by heating the sample to 70°C for ~15 min. 50 
µl of sample or cGMP standard was added to an EIA plate with 50 µl cGMP 
AChE Tracer and 50 µl cGMP Antiserum. The plate was then covered with 
plastic film and incubated 18 hours at room temperature. The next day, the plate 
was emptied and rinsed carefully 4-5 times using Wash Buffer (Cayman 
Chemical, Ann Arbor, MI),  and 200 µl of Ellman’s Reagent was added to each 
well. The plate was then covered with plastic film and aluminum film, and 
incubated on an orbital shaker (Stovall Life Science Inc., Greensboro, NC) at 
room temperature for 120 min. Light absorbance of the sample was measure by 
reading the plate on a Packard Multi Probe Robotic Liquid Handling System 
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(Perkin Elmer; Shelton, CT) using a filter with a wavelength of 425 nm and 
bandwidth of 35 nm. The log of the amount of cGMP in the samples was 
inversely proportional to the log of (sample bound/maximum bound). The 
concentration of cGMP in the liver sample (pmol/ml) was determined by 
comparison to the standard curve. The sample detection range was 0.2-20 
pmol/ml. 
 
Hepatic Phosphodiesterase 3 
Phosphodiesterase 3 (PDE3) has a low Km, and is a membrane-
associated enzyme which mainly hydrolyzes cAMP (Maurice et al., 2003; Muller 
et al., 1992). Liver PDE3 activity was determined using a modification of  the 
phosphodiesterase assay described by Loten et al. (Loten et al., 1980). To 
prepare liver particulate and soluble phosphodiesterases, frozen liver tissue was 
ground to powder, and weighed (~200 mg) while kept chilled with liquid nitrogen. 
The sample weight (mg) was multiplied by 10 to determine the volume (ml) of 
isotonic sucrose (250 mM sucrose, 10 mM Tris-HC1, 1 mM EDTA, pH 7.5) to be 
used. The tissue was combined with isotonic sucrose then thoroughly 
homogenized using an Ultra-Turrax homogenizer (TP18/10, Janke & Kunkel, IKA 
Werk, GmbH & Co., Staufen, Germany). The homogenate was filtered through 
Dacron wool and centrifuged in 15-ml polycarbonate tubes (Beckman Coulter, 
Inc., Fullerton, CA) at 20,000 rpm for 45 min. The supernatant, which contains 
most of the soluble high Km phosphodiesterases, was discarded. The tube was 
carefully rinsed with buffered isotonic sucrose, without disturbing the pellet, and 
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allowed to drain. The pellet, which contains most of the low Km 
phosphodiesterase, was taken up in 4 ml of dilute Tris buffer (10 mM Tris HCI, 1 
mM EDTA, pH 7.5) and rehomogenized with 4 strokes of the A pestle in a 7-ml 
with buffered isotonic sucrose. PDE3 measurements were performed in a final 
volume of 40 µl containing 50 mM Tris/HCl, pH 7.5, 25 mM MgCl, 0.33 mg/ml of 
bovine serum albumin, cyclic 3H AMP (37.7 Ci/mmol; about 160,000 dpm) and 
sufficient unlabeled cyclic AMP to produce the desired substrate concentration. 
Tubes were incubated for 5 min at 30 ºC and the reaction was terminated by stop 
mix. 5 µl of snake venom was added to each tube (Crotalus atrox, 0.5 mg/ml), 
and incubated for 45 min at 30 ºC. 1 ml of water was added to each tube and 
mixed, and 1 ml of reaction mixture was loaded onto a column (0.7 x 2.5 cm) of 
quaternary aminoethyl (QAE)-Sephadex (A-25) in the formate form to separate 
adenosine from unreacted cyclic AMP. The column was then eluted with 3 ml of 
20 mM ammonium formate, pH 7.4, and 4 ml of effluent was collected and 
counted in a Triton-based scintillation mixture. The phosphodiesterase assay 
was performed at a substrate concentration of 0.1 µmol/l, because at this 
concentration of cyclic AMP mainly low Km phosphodiesterase is measured. 
PDE3 activity (pmol 3H cAMP hydrolyzed) was calculated by radioactivity counts 
(cpm) times 0.0000326 pmol/cpm, and normalized by protein dry weight (mg). 
 
Western blotting    
Frozen liver tissue (~50 mg) was ground to powder using mortars and 
pestles, while kept chilled with liquid nitrogen. The tissue was then combined with 
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1 ml of homogenizing buffer (50 mM Tris-HCl pH 7.0, 100 mM sucrose, 10% v:v 
glycerol, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, 10 µL/mL buffer of phosphatase 
inhibitor cocktail 1 and 2, and protease inhibitor cocktail [Sigma; St. Louis, MO]) 
and thoroughly homogenized using an Ultra-Turrax homogenizer (TP18/10, 
Janke & Kunkel,. IKA Werk, GmbH & Co., Staufen, Germany). Homogenates 
were centrifuged at 2,500 g for 30 min, supernatants were removed and soluble 
protein concentration was determined using the Biorad protein assay (BioRad; 
Hercules, CA). Aliquots of supernatant were mixed 1:1 v:v with freshly prepared 
2X SDS-PAGE loading buffer (100 mM Tris-HCl, pH. 6.8, 4% w:v SDS, 20% v:v 
glycerol, 0.2% w:v bromophenol blue, 10% v:v 2-mercaptoethanol), and boiled 
for 5 min. Samples were subjected to SDS-PAGE (12% resolving gel) followed 
by transfer to nitrocellulose membranes. Blocking was performed with 5% (wt/v) 
bovine serum albumin in Tris-buffered saline containing Tween-20 (TBST: 10 
mM Tris-base, pH 7.0, 150 mM NaCl, 0.2% v:v Tween 20) for 1h at room 
temperature, and then incubated overnight with the appropriate primary antibody 
at 4 ºC. After 3x5 min washes with TBST, membranes were incubated with HRP-
conjugated secondary antibody (Promega, Madison, WI) for 1h at room 
temperature, followed by 3 x 5 min washes in TBST. Proteins were visualized 
using ECL Plus Western detection reagents (GE Healthcare, Piscataway, NJ) 
and the ECL signals were detected after brief (5-60s) exposure to X-ray film. 
Bands were quantified using ImageJ software (http://rsb.info.nih.gov/ij/) and the 
intensity of the protein signal was normalized to total protein signal. β-actin was 
used as a loading control. 
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Blood Flow 
 Blood flow was determined directly in the hepatic artery and portal vein 
with the use of ultrasonic flow probes implanted during surgery. Total hepatic 
blood flow was also assessed using the indocyanine green (ICG) dye extraction 
method, according to Leevy et al (Leevy et al., 1962). The results presented in 
this thesis were calculated using ultrasonic-determined flow, as this flow does not 
require an assumption about the distribution of arterial versus portal flow. ICG-
determined flow was used as a backup measurement. However, the same 
conclusions would be drawn if the ICG flows were used to calculate the data.  
 Ultrasonic flow probes allowed for instantaneous measurement of 
variation in velocity and provided blood flow in individual vessels. Each probe 
worked by determining the mean transit time of an ultrasonic signal passed back 
and forth between two transducers within the probe that were located upstream 
and downstream of the direction of blood flow in the vessel. The two transducers 
were piezoelectric, a material which is capable of both receiving and transmitting 
the ultrasonic signal. The downstream transducer first emitted an ultrasonic pulse 
into the blood vessel that was received upstream by a second transducer. After 
the upstream transducer received the ultrasonic signal, it re-emitted the 
ultrasonic pulse signal back to the downstream transducer. The transit time of 
each ultrasonic beam as measured by the upstream and downstream 
transducers (∆Tup and ∆Tdown, respectively) was defined by the following 
relationships: 
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∆Tup = D / (vo – vx)        (10) 
 
∆Tdown  = D / (vo + vx)       (11) 
 
where D was the distance traveled by the ultrasonic beam within the acoustic 
window of the probe, vo was the phase velocity, or the speed of sound, in blood, 
and vx was the component of fluid velocity that was parallel or antiparallel to the 
phase velocity. The parallel component augmented the phase velocity when the 
signal was traveling in the same direction of blood flow, while the antiparallel 
component subtracted from phase velocity if the ultrasonic signal was moving 
against the flow of blood in the vessel. Combining the two expressions for transit 
time yielded the following equation: 
 
∆Tup - ∆Tdown  = (D / (vo – vx))-( D / (vo + vx))    (12) 
 
Since the transit times measured by both transducers, the distance traveled by 
the beam, and the speed of sound in blood were all known quantities, this 
equation was used to calculate vx. Once vx was attained, the transit velocity (V) 
of blood traveling through the vessel could be found according to the following 
equation: 
 
V cos θ = vx         (13) 
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where θ was the angle between the centerline of the vessel and the ultrasonic 
beam axis. Finally, blood flow was determined as the product of the transit 
velocity and the cross-sectional area of the vessel. The cross-sectional area of 
the vessel was pre-determined by the size of the acoustic window according to 
the probe model. Since transit time was sampled at all points across the diameter 
of the vessel, volume flow was independent of the flow velocity profile. If a flow 
probe failed during the experiment, the missing values were estimated by one of 
two methods: either the mean blood flow for that vessel in a given protocol was 
used, or the values from the functional flow probes were subtracted from the 
corresponding ICG values (for example, values from the arterial flow probe were 
subtracted from the ICG vales to yield estimates of the portal vein flow). 
 The ICG method is based on the Fick principle, according to which the net 
balance of a substrate across an organ is equal to the concentration difference of 
the substrate across the organ multiplied by the blood flow through the organ. 
The equation can be rearranged to calculate hepatic blood flow from the ratio of 
hepatic ICG balance divided by the arteriovenous difference of ICG across the 
liver. Because the liver is assumed to be the only site of ICG clearance, hepatic 
ICG uptake is equal to the ICG infusion rate in steady state conditions. The 
extraction of ICG across the liver remains constant for brief infusions. However, if 
ICG is infused for a longer time (> 4 h), the dye level in the plasma gradually 
increases, resulting in a slight overestimation (5-10%) of hepatic blood flow 
(Hendrick, 1986). 
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 Arterial and corresponding hepatic vein plasma samples were centrifuged 
at 3000 rpm for 30 min without the brake to pellet particulate matter. Optical 
density was then measured on a Spectronic spectrophotometer at 810 nm. The 
procedure was then repeated, and the values obtained for each sample were 
averaged. A standard curve was constructed by adding successive 5 µl aliquots 
of diluted dye (1:10 dilution) to 1 ml of plasma obtained from the animal before 
the dye infusion commenced. Hepatic plasma flow (HPF) was then calculated as 
follows: 
 
HPF= (IR x 10 x SCMD)/(dog weight (kg) x (0.005) x (A-H))  (14) 
 
where IR is the ICG infusion rate (ml/min), SCMD is the standard curve mean 
difference per 5 µl increments and A-H is the difference in absorbance between 
the arterial and the hepatic venous sample. The value of 10 was used to correct 
for the dilution of ICG used in the standard curve, and 0.005 was the volume in 
ml used as increments in the standard curve. Hepatic blood flow (HBF) was 
derived from HPF: 
 
HBF = HPF/(1-hematocrit)       (15) 
 
Because this technique measured total hepatic blood flow only, the distribution of 
blood flow in the vessels supplying the liver was assumed. The normal 
distribution of flow was assumed to be 20% artery and 80% portal vein at 
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baseline. However, flow distribution was altered during somatostatin infusion, 
since the latter decreases portal flow modestly. Flow distribution was therefore 
assumed to be 28% artery and 72% portal in the presence of somatostatin 
(Greenway et al., 1971).  
 
Glucose Mixing in the Portal Vein 
 When glucose is infused in the slow, laminar flow of the portal vein, mixing 
of the glucose in the blood can be problematic. The paraaminohippuric acid 
(PAH) method was used when necessary to assess whether good mixing of 
glucose had occurred in the portal vein during intraportal glucose infusion. 
 The liver PAH method is based on the principle that this substance, not 
being extracted by the liver or erythrocytes, should be quantitively recovered in 
the portal and hepatic veins if good mixing occurs. PAH is mixed with the glucose 
that is infused in the portal vein, so that the PAH infusion rate is 0.4 mg/kg/min. 
The concentration of PAH is then measured on whole blood samples from 
arterial, portal venous, and hepatic venous blood (Brun, 1951). The assay 
involves a 1:5 dilution of the blood sample in a reagent solution (10 g p-
dimethyamino-benzaldeyhyde, 600 ml 95% ethanol, 40 ml 2N HCl, deionized 
H2O up to 1000 ml). Light absorbance of the diluted samples is then measured 
on a spectrophotometer at 465 nm, and compared with a standard curve built 
with increasing PAH concentrations in blood drawn from the animal before the 
start of the PAH infusion. The ratio between the recovery of PAH in portal and 
hepatic veins, and the actual intraportal PAH infusion rate is then used as an 
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index of mixing of the intraportal infusate with the blood entering and exiting the 
liver. A ratio of 1.0 would represent perfect mixing. 
 Because of the magnitude of the CV for assessing mixing, samples were 
considered unmixed if the hepatic vein PAH recovery was >140% or <60% of the 
actual amount of PAH infused. Animals were excluded from the study if poor 
mixing, as defined above, occurred in more than 40% of the sample time points 
during intraportal glucose infusion period.  
 
Blood Pressure and Heart Rate 
 For specific aims I, III and IV, systolic and diastolic blood pressure and 
heart rate were determined throughout the experiments at each sampling time 
using a Digi-Med Blood Pressure Analyzer (Micro-Med, Inc., Louisville, KY). 
 
Calculations 
 
Net Hepatic Substrate Balance 
 Both ICG and ultrasonic flow probes were used to estimate total hepatic 
blood flow in these studies via the arterio-venous difference technique. The net 
hepatic balances and net hepatic fractional extraction of blood glucose, lactate, 
glycerol, and plasma NEFA were calculated using both ultrasonic-determined 
and ICG-determined flow. As previously mentioned, the data shown are those 
calculated using ultrasonic-determined flow as this flow does not require an 
assumption about the distribution of arterial versus portal flow.  
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 For both the indirect and direct method of calculation, the net balance of a 
substrate across an organ, otherwise known as the A-V difference technique, 
utilized the Fick Principle as described for ICG blood flow. In short, net hepatic 
substrate balance (NHSB) was calculated directly as the difference between the 
substrate load exiting the liver (Loadout) and the substrate load entering the liver 
(Loadin), as shown in the following equation: 
 
NHSB = Loadout - Loadin (D)       (16) 
 
The Loadout was calculated from the ultrasonic data according to the equation: 
 
Loadout = [S]H x HBF       (17) 
 
where [S]H is the substrate concentration in the hepatic vein and HBF is the total 
hepatic blood flow, as determined by adding the arterial flow to the portal vein 
flow. The hepatic artery supplies blood directly to the liver and the portal vein 
drains the digestive oranges and the spleen, and then supplies blood to the liver. 
Thus, Loadin (D) calculated from the ultrasonic data was the sum of the loads in 
the two vessels as calculated according to the following equation: 
 
Loadin (D) = ([S]A x ABF) + ([S]P x PBF)     (18) 
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where [S]A and [S]P are substrate concentrations at the hepatic artery and the 
portal vein, respectively, and ABF and PBF are blood flow in the hepatic artery 
and the portal vein, respectively. For all glucose balance calculations, glucose 
concentrations were converted from plasma to blood values by using previously 
determined correction factors (CF: the mean of the ratio of the blood value to the 
plasma concentration for each period and for each blood vessel). Mean CFs 
during basal and experimental period were 0.74 and 0.74 for the artery, 0.74 and 
0.73 for the portal vein and 0.73 and 0.73 for the hepatic vein, respectively. 
(Hsieh et al., 1998; Pagliassotti et al., 1996a). For NEFA calculations, plasma 
substrate concentrations and plasma flow were used rather than blood 
concentrations and blood flow. Plasma flow was determined by multiplying blood 
flow by (1-hematocrit). Positive numbers for net hepatic substrate balance 
indicate net production while negative numbers indicate net uptake. When the 
data were plotted as net hepatic uptake, positive values were used.  
 To circumvent any potential errors arising from incomplete mixing of 
glucose in the circulation during intraportal glucose infusion, a second, indirect 
method was also used for the calculation of the NHGU. This method differs from 
the direct calculation described above in that Loadin is determined using the 
equation: 
 
Loadin (I) = (GA X HBF) + GIRPO – GUG     (19) 
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where GA is the arterial blood glucose concentration, GIRPO is the portal glucose 
infusion rate, and GUG is the uptake of glucose by the gastrointestinal tract. 
GUG is measured in each animal in the absence of intraportal glucose infusion, 
and this value is then corrected for differences in glucose load reaching the gut 
during intraportal infusion. The glucose balance data presented in the results 
sections was determined using the indirect method because it is less subject to 
mixing problems. Nevertheless, there was no statistical difference between data 
determined using the indirect method versus the direct method. 
 Net hepatic fractional extraction (FE) was also calculated using ultrasonic-
determined blood flow according to the following equation: 
 
FE = NHSU / Loadin        (20) 
 
where NHSU is net hepatic substrate uptake and could represent NHGU when 
glucose is the substrate. 
 Net hepatic substrate balances and net hepatic fractional extractions were 
also calculated using the ICG blood flow data. These calculations were 
performed to verify the ultrasonic results, and to ensure that conclusions drawn 
from either method were similar, as explained earlier. The only difference in the 
ICG method is that Loadin and Loadout were calculated difference as shown 
below: 
 
Loadout = [S]H x HBF        (21) 
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Loadin = (0.28 x [S]A + 0.72 x [S]P) x HBF     (22) 
 
where HBF is total hepatic blood flow calculated using the ICG method, and 0.28 
and 0.72 are estimates of the normal distribution of flow in the artery and portal 
vein during somatostatin infusion (Greenway et al., 1971) as explained earlier. 
 
Net Hepatic Carbon Retention 
Net hepatic carbon retention was calculated as the sum of the balances of 
glucose and lactate, once the latter was converted to glucose equivalents. The 
calculation of net hepatic carbon retention is an established approach to estimate 
hepatic glycogen accretion and has been described and validated previously (An 
et al., 2008). It has the advantage of not being dependent upon an estimate of 
the prestudy glycogen content, which must be obtained from a separate set of 
42-h-fasted dogs. The calculation omits the contribution of gluconeogenic 
substrates other than lactate and fails to account for the glucose oxidized by the 
liver. However, these two rates are relatively small, quantitatively similar, and 
offsetting (Satake et al., 2002). 
 
Nonhepatic Glucose Uptake and Clearance 
 The average nonhepatic glucose uptake (nonHGU) between two time 
points (T1 and T2) was calculated by the following overall equation: 
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NonHGU = average total glucose infusion rate between T1 and T2 – (NHGU
T1 
+ 
NHGU
T2
)/2 –glucose mass change in the pool between T1 and T2    (23) 
   
where T1 and T2 represent the two measurement time points. Note that the 
((NHGU
T1 
+ NHGU
T2
)/2) term will be negative when the liver is taking up glucose. 
The glucose mass change in the pool is calculated using the following equation: 
 
Glucose mass change in the pool = = ((([GA]T2 - [GA]T1) / 100) * 
     ((0.22 * body wt in kg * 1000 *0.65) / body wt in kg)) / (T2-T1)  (24) 
 
where [GA] is the blood glucose concentration, T1 and T2 are the two end time 
points of the interval, 0.22 represents the volume of extracellular fluid (the 
volume of distribution) or 22% of the dog’s weight (Altszuler et al., 1956), and 
0.65 represents the pool fraction (Cowan et al., 1971). 
 Nonhepatic glucose clearance was calculated using the following 
equation: 
 
Nonhepatic glucose clearance = NonHGU / (([GA]T1 + [GA]T2) /2 / 100) (25) 
 
where [GA] is the blood glucose concentration and T1 and T2 are the two end 
time points of the interval. 
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Sinusoidal Hormone Concentrations 
 Because the liver is supplied by blood flow from both the hepatic artery 
and the portal vein, neither represents the true inflowing hepatic blood flow 
supply. For this reason, hepatic sinusoidal hormone levels (of insulin and 
glucagon) were calculated as follows: 
 
Hepatic Sinusoidal Hormone Level = [H]A x  (APF/TPF) +  [H]P x (PPF/TPF) (26) 
 
where A and P are arterial and portal vein plasma substrate concentration; APF 
and PPF are the arterial and portal vein plasma flow measured by the ultrasonic 
flow probes; TPF (total hepatic plasma flow) = APF + PPF.  Note this calculation 
represent the average inflowing hepatic sinusoidal hormone level, rather than the 
average sinusoidal level. 
 
Statistical Analysis  
 All data are presented as means ± S.E.M.. Time course data were 
analyzed with Two Way Repeated Measures ANOVA, and One Way ANOVA 
was used for any comparisons of other mean data. Post-hoc analysis was carried 
out using the Student-Newman-Keuls method. Statistical significance was 
accepted at P<0.05. The specific statistical tests used in the studies are 
described in the experimental design sections of chapters III-VI. 
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CHAPTER III 
 
THE EFFECT OF AN INTRAPORTAL NITRIC OXIDE (NO) DONOR (SIN-1) ON 
NET HEPATIC GLUCOSE METABOLISM IN THE PRESENCE OF THE 
PORTAL GLUCOSE SIGNAL 
 
Aim 
The purposes of specific aim 1 were two-fold. The first was to increase the 
power of the SIN-1 study initiated by DiCostanzo et al. The second was to 
determine whether the effect of SIN-1 on NHGU in the liver was secondary to 
hypotension induced by SIN-1 infusion or a direct effect of NO on the liver. 
 
Experimental design 
Each experiment consisted of a 90-min equilibration period (-120 to –30 
min), a 30-min basal period (-30 to 0 min), and a 240-min experimental period (0 
to 240 min), which was divided into a 90 minute period (P1) followed by a 150 
minute period (P2). In all experiments a constant infusion of indocyanine green 
dye (0.076 mg/min; Sigma Immunochemicals, St. Louis, MO) was initiated at -
120 min via the left cephalic vein and p-aminohippuric acid (PAH; 0.4 mg/kg/min; 
Sigma) was infused via the left saphenous vein from -120 to 0 min. At 0 min, a 
constant infusion of somatostatin (0.8 µg/kg/min; Bachem, Torrance, CA) was 
begun via the left saphenous vein to suppress endogenous insulin and glucagon 
secretion. At the same time, basal glucagon (0.57 ng/kg/min; Glucagen, Novo 
Nordisk, Bagsvaerd, Denmark) and 4-fold basal insulin (1.2 mU/kg/min; Eli Lilly & 
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Co., Indianapolis, IN) infusions were started through the splenic and jejunal 
catheters. Glucose (20% dextrose) was delivered intraportally at 4mg/kg/min, 
and PAH was mixed with it at a concentration allowing a delivery rate of 0.4 
mg/kg/min. In addition, a primed continuous infusion of 50% dextrose was begun 
via the right cephalic vein at time 0, so that the blood glucose could quickly be 
clamped at the desired hyperglycemic level (170-175 mg/dL). In P2, saline (SAL, 
n=8) was infused intraportally, or 3-morpholinosydnonimine (SIN-1; 4 µg/kg/min; 
Cayman Chemical, Ann Arbor, MI) was delivered intraportally (PoSIN-1, n=12) or 
peripherally via the right saphenous vein (PeSIN-1, n=10). The peripheral 
glucose infusion rate was adjusted in P2 to maintain a similar hepatic glucose 
load (HGL) to that seen in P1.  
 
Results 
 
Hemodynamic response 
Systolic blood pressure did not change significantly over the course of the 
experiment in response to saline infusion. The systolic blood pressure in the 
PeSIN-1 and PoSIN-1 groups were similar to those seen in SAL in the basal 
period and P1 but dropped significantly during P2 (Table 3.1). Diastolic blood 
pressure also fell significantly during P2 in the PeSIN-1 and PoSIN-1 groups 
(Table 3.1). The average heart rate did not change over time in SAL, but it 
increased (P<0.05) during P2 in both the PeSIN-1 and PoSIN-1 groups (Table 
3.1). 
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Hormone concentrations 
 The arterial and hepatic sinusoidal insulin levels increased three to four-
fold and remained stable during P1 and P2 in all groups (Table 3.2). Arterial and 
hepatic sinusoidal plasma glucagon concentrations remained basal in all groups 
(Table 3.2).  
 
Hepatic blood flow, blood glucose concentrations, and hepatic glucose load  
Portal vein blood flow decreased ~20% during P1 in all groups in response 
to somatostatin infusion (Table 3.3). There was a concomitant small increase in 
hepatic arterial flow, and as a consequence, total hepatic blood flow did not 
change significantly during the first experimental period. There were small 
increases in portal vein and hepatic arterial blood flow in all groups during P2, 
such that total flow was completely restored to baseline values in each group, 
and there were no significant differences among groups.  
Arterial blood glucose levels increased in all groups from a basal value of 
82±1 to 174±3 mg/dL during P1 and P2 (Fig. 3.2). The hepatic glucose loads 
increased proportionally and did not differ significantly among groups at any time 
(Fig. 3.2).  
 
Net hepatic glucose balance and change of net hepatic fractional extraction of 
glucose from baseline 
 
All groups exhibited a similar rate of net hepatic glucose output during the 
basal period. Coincident with the start of the experimental period (4X basal 
insulin, basal glucagon and hyperglycemia), all groups switched from net 
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production to net uptake of glucose, with the rates (4.8±0.4, 4.8±0.4 and 5.1±0.4 
mg/kg/min in SAL, PoSIN-1 and PeSIN-1, respectively) not being significantly 
different among groups during the last 30 minutes of P1 (Fig. 3.3). Subsequently, 
the rate of NHGU remained relatively stable in SAL and PeSIN-1 (5.5±0.4 and 
5.4±0.4 mg/kg/min), whereas in PoSIN-1 it was reduced to 4.2±0.3 mg/kg/min 
during P2 (P<0.05 vs. SAL and PeSIN-1). The change of hepatic fractional 
extraction of glucose from baseline followed a similar pattern, falling significantly 
in response to intraportal SIN-1 infusion (Fig. 3.3). 
 
Glucose infusion rates, nonhepatic glucose uptake 
The glucose infusion rate in all three groups increased over time. There 
was a tendency for the total glucose infusion rate to be lower in PoSIN-1, in line 
with the reduction in NHGU seen in response to portal SIN-1 infusion (Fig. 3.4). 
Nonhepatic glucose uptake increased modestly over time in all groups, but did 
not differ among groups (Fig. 3.4). 
 
Lactate metabolism and net hepatic carbon retention  
The arterial blood lactate concentrations rose in all groups during P1 and 
P2 relative to the basal period. After the experimental period began, net hepatic 
lactate balance changed from uptake to output, and output remained evident in 
all groups during P2 (Table 3.4). Net hepatic carbon retention did not differ 
between PeSIN-1 and SAL at any time but was reduced in PoSIN-1 during P2 
(3.8±0.2 in PoSIN-1 vs. 4.9±0.3 in SAL and 4.7±0.2 mg glucose 
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equivalents/kg/min in PeSIN-1, respectively, P<0.05).  
 
Glycerol and nonesterified fatty acid metabolism  
Arterial blood glycerol concentrations and net hepatic glycerol uptake were 
reduced 65–75% by hyperglycemia and hyperinsulinemia and remained 
suppressed in all groups throughout P1 and P2. The suppression of glycerol was, 
however, partially reversed during P2 in the PeSIN-1 and PoSIN-1 but not the 
SAL group (29±5, 48±5 and 45±5 mg/kg/min in SAL, PoSIN-1 and PeSIN-1, 
respectively) (Table 3.4). Arterial nonesterified fatty acid (NEFA) concentrations 
and net hepatic NEFA uptake changed in a pattern similar to glycerol, decreasing 
80–90% during P1 in all groups. There was, however, no rebound during P2 in 
the PeSIN-1 or PoSIN-1 groups (Table 3.4). 
 
Discussion 
The rate of hepatic glucose uptake in vivo depends on a complex set of 
variables, including neural, hormonal and substrate signals (Pagliassotti et al., 
1992a).  In the present study, we took great care to control these inputs so as to 
allow precise assessment of the effect of SIN-1 delivery on NHGU. To our 
knowledge, this study is the first in vivo investigation to explore the effects of the 
NO donor SIN-1 on net hepatic glucose uptake in the presence of portal glucose 
delivery, as well as elevated plasma insulin and glucose levels. Under these 
conditions, portal infusion of the NO donor SIN-1 caused a ~24% decrease in net 
hepatic glucose uptake and hepatic glycogen accumulation. We were unable to 
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detect any effect of portal SIN-1 on glucose uptake by nonhepatic tissues or 
whole body glucose utilization. Peripheral SIN-1 infusion was without effect on 
either hepatic or nonhepatic glucose utilization.  
 Although there are several NO donors available (e.g., SNAP, V-
PYRRO/NO, DEA/NO), we specifically chose to use SIN-1 in light of its metabolic 
fate. In vivo, SIN-1 decomposes non-enzymatically in a two step reaction with the 
second step yielding NO and superoxide (O2.-), which can readily form 
peroxynitrite (ONOO-) (Padmaja et al., 1993). NO or peroxynitrite can then 
nitrosylate glutathione to generate S-nitroso-glutathione (GSNO)  (Ji et al., 1999). 
According to Lautt’s HISS hypothesis, GSNO can act as an endogenous NO 
reservoir and serve as an intermediate between NO synthesis and guanylate 
cyclase activation in the HISS pathway (Guarino et al., 2004). In addition, we 
found SIN-1, in contrast to the other NO donors, has little effect on total hepatic 
blood flow, so that total hepatic blood flow did not differ among groups in the 
current study.  
In contrast to the liver, where blood flow was minimally altered, there was 
a marked overall hemodynamic response to SIN-1 infusion whether it was given 
into a peripheral vein or the hepatic portal vein. This was undoubtedly due to the 
well known vasodilatory effects of NO. Systolic and diastolic blood pressure both 
decreased significantly when the NO donor was infused, regardless of the route 
of infusion, while the heart rate rose secondary to hypotension. The drop in blood 
pressure and the rise in heart rate tended to be modestly greater when SIN-1 
was given peripherally. Although markers of NO levels were not measured in the 
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present study, this drop may have been associated with higher levels of SIN-1 in 
peripheral blood when the compound was infused through a peripheral vein as 
opposed to the hepatic portal vein.  
There are several possible ways that SIN-1 could affect the liver. First, it 
may act directly on hepatocytes to reduce NHGU. In vivo, hepatocytes are 
exposed to autogenously derived NO as well as NO derived from non-
parenchymal cells (Taylor et al., 1998). Both iNOS and eNOS are expressed in 
hepatocytes; additionally, iNOS has been found in hepatic Kupffer and Ito cells in 
various species, while nNOS has been localized in some nerve fibers in the rat 
liver (Alexander, 1998; Feelisch et al., 1999; Wei et al., 2002). Horton et al. 
(Horton et al., 1994) demonstrated that the NO donors S-nitroso-N-
acetylpenicillamine (SNAP) and SIN-1 inhibit gluconeogenesis from isolated rat 
hepatocytes in a time- and dose-dependent manner. They suggested that the 
mechanism by which this occurs involves a decrease in amount of 
phosphoenolpyruvate carboxykinase (PEPCK) protein. On the other hand, 
Sprangers et al. (Sprangers et al., 1998) showed that glycogen synthesis from 
glucose in rat hepatocytes was inhibited by the NO donor SNAP due to 
decreased glycogen synthase activity (less conversion of glycogen synthase b 
into a by synthase phosphatase). They also found that glycogen synthesis is 
more sensitive to inhibition by NO than is gluconeogenesis (Sprangers et al., 
1998). Borgs et al. (Borgs et al., 1996) observed that NO infusion (34 µmol/L) 
increased the rate of glucose output in the perfused rat liver ~3 fold due to a 
stimulation of glycogenolysis which occurred as a result of activation of glycogen 
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phosphorylase. Similarly, an in vivo study carried out by Ming et al. (Ming et al., 
2000) showed that portal SIN-1 infusion potentiates norepinephrine-induced 
glucose output from the liver in cats, and this potentiation is blocked by inhibition 
of guanylate cyclase, a key signaling molecule downstream of NO. Although the 
underlying mechanisms still remain to be elucidated, it appears that the 
regulation of hepatic metabolism by NO may involve downstream signals such as 
protein nitrosylation and/or multiple cGMP-dependent pathways.  
It is also possible, however, that SIN-1 reduces NHGU through an indirect 
effect on the liver. Such an indirect effect could have come about as a result of 
an increase in sympathetic drive to the liver secondary to the hypotension 
resulting from intraportal SIN-1 infusion. The fact that an increase in sympathetic 
drive occurred during SIN-1 infusion is supported by our finding that the heart 
rate increased in response to the drug and by our observation that lipolysis 
increased in response to SIN-1, as indicated by the increase in the arterial blood 
glycerol level. Increased sympathetic input to the liver would have been expected 
to reduce NHGU (Dicostanzo et al., 2006). In our earlier study, eliminating 
sympathetic input to the liver by selective sympathetic denervation augmented 
the NHGU seen in response to elevated glucose and insulin levels (Dicostanzo et 
al., 2006). The PeSIN-1 group was therefore included to assess the possibility 
that SIN-1 could have an indirect effect on the liver. In the PeSIN-1 group, SIN-1 
was given via a leg vein in order to bring about a similar or greater hemodynamic 
response to that seen with portal vein SIN-1 infusion. In this way, sympathetic 
input to the liver was increased by an amount equal to or greater than when SIN-
 86 
1 was given intraportally. In the PeSIN-1 group, NHGU averaged ~5.5 mg/kg/min 
during P1 and P2 and did not differ from the rate evident during saline infusion, 
indicating that increased sympathetic input to the liver, if it occurred, did not 
reduce NHGU. This then indicates that the decrease in NHGU seen when SIN-1 
was infused portally was not secondary to hypotension. The increases in heart 
rate and lipolysis seen in P2 in response to SIN-1 infusion actually tended to be 
slightly greater when SIN-1 was given into a peripheral vein than when it was 
given into the portal vein. Despite this, there was no decrease in NHGU or 
hepatic glycogen synthesis, suggesting that NO regulates hepatic glucose 
metabolism through a direct action on the liver. Further studies need to be 
performed to determine the mechanism by which this regulation comes about. 
Major extrahepatic glucose consumers include skeletal muscle, adipose 
tissue, brain, etc. In our previous studies in which insulin and glucose were 
elevated in conscious dogs, we found that muscle glucose uptake (measured 
using a hindlimb balance technique) accounted for a significant portion of the 
increase in nonhepatic glucose uptake (Galassetti et al., 1998). In the present 
experiments, nonhepatic glucose uptake in response to intraportal SIN-1 infusion 
was not greater than when saline was given or SIN-1 was infused via a leg vein.  
In 1997, Lautt (Lautt, 2005) proposed that the liver produces HISS and 
that the latter enhances muscle glucose uptake and muscle insulin sensitivity. 
HISS generation is reported to involve the hepatic parasympathetic nervous 
system, the production of NO and the interaction of NO with glutathione in the 
liver (Guarino et al., 2003; Guarino et al., 2004). In a study carried out by Sadri et 
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al. (Sadri et al., 1997), intraportal, but not intravenous, administration of L-NAME, 
a nonselective  nitric oxide synthase antagonist, significantly reduced whole body 
insulin sensitivity as measured under euglycemic conditions using the rapid 
insulin sensitivity test (RIST) in rats. This suggests that NOS inhibition in the liver 
resulted in a drop in hepatic NO, which resulted in peripheral insulin resistance. 
This insulin resistance was reversed by SIN-1 infusion into the portal vein, but 
not into a peripheral vein (Sadri et al., 1999). Thus, the insulin resistance that 
was induced by the inhibition of NOS in the liver was reversed by providing NO 
directly to the liver. However, our present data do not support the concept that 
hepatic NO action promotes glucose uptake in peripheral tissues under 
hyperglycemic conditions. There are several possible explanations as to why this 
was the case.  First, HISS was thought to be active only in the fed state in 
rodents (Seredycz et al., 2006). Thus, failure to observe an effect of portal SIN-1 
infusion on nonhepatic glucose uptake in 42-h fasted dogs could be due to the 
fast duration or a species difference. In addition, most HISS experiments that 
have been conducted under euglycemic conditions (Guarino et al., 2003; Guarino 
et al., 2004; Lautt, 2005; Moore et al., 2002; Sadri et al., 1999; Sadri et al., 1997), 
while in the present study, a hyperinsulinemic hyperglycemic clamp was used, 
and as a result, muscle glucose uptake may have reached a rate that would 
make a response to a hepatic NO signal hard to detect. The current study sheds 
no light on the mechanism by which HISS works or the nature of the putative 
signaling substance “HISS”.  
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 In line with our current finding, that intraportal infusion of the NO donor 
SIN-1 reduced NHGU in the presence of hyperinsulinemia and hyperglycemia, 
normal dogs that received an intraportal infusion of the NOS inhibitor L-NAME (L-
NG-nitroarginine methyl ester) exhibited enhanced NHGU under 
hyperinsulinemic and hyperglycemic conditions (Moore et al., 2005a). 
In conclusion, we demonstrate for the first time that intraportal infusion of 
an NO donor, SIN-1, reduced NHGU and net hepatic carbon retention under 
hyperglycemic and hyperinsulinemic conditions in conscious 42-h-fasted dogs. 
The lack of changes in NHGU and glycogen storage when the same 
hemodynamic response was seen in response to peripheral SIN-1 administration 
suggests that the effects of portal SIN-1 probably came about as a result of a 
direct effect of NO on hepatocytes. The molecular mechanism by which NO 
brings about its hepatic effect needs to be elucidated. The effects on nonhepatic 
glucose uptake in response to intraportal infusion of SIN-1 were not detected, so 
that total body glucose disposal tended to be reduced by hepatic NO elevation. 
These findings indicate that hepatic NO may play a role in directing the 
disposition of glucose reaching the liver via the portal vein, and, by extension, an 
oral glucose load, into liver.  
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Table 3.1: Heart rate, systolic and diastolic blood pressure during the basal and experimental periods 
in conscious 42-h-fasted dogs given saline or SIN-1 infused into the portal vein or into a peripheral vein
Experimental Period
Group Basal Period Period 1 Period 2
Systolic Blood Pressure, mmHg
 SAL 178±5 173±5 163±8
 PoSIN-1 164±3 167±4 117±5*†
 PeSIN-1 175±6 178±6 120±5*†
Diastolic Blood Pressure, mmHg
 SAL 96±4 94±4 95±5
 PoSIN-1 87±2 89±3 78±3*†
 PeSIN-1 95±2 93±2 80±2*†
Heart Rate, beats/min
 SAL 94±5 100±4 101±7
 PoSIN-1 88±6 86±4 107±5*
 PeSIN-1 96±5 88±5 120±10*
Data are means±S.E.M.; n=7 in the saline (SAL) group, n=12 in the group that received 3-morpholinosydnonimine 
(SIN-1) in the portal vein (PoSIN-1), and n=10 in the group that received SIN-1 in the peripheral vein (PeSIN-1) 
*= Significant statistical difference (P<0.05) from basal period within the group
†= Significant statistical difference (P<0.05) from SAL group
 
 90 
Table 3.2: Hormone concentrations during the basal and experimental periods in conscious 
42-h-fasted dogs given saline or SIN-1 infused into the portal vein or into a peripheral vein
Experimental Period
Group Basal Period Period 1 Period 2
Arterial Plasma Insulin, µU/ml
 SAL 9±2 26±3* 26±2*
 PoSIN-1 7±1 21±2* 22±2*
 PeSIN-1 7±1 21±3* 25±3*
Hepatic Sinusoidal Insulin, µU/ml
 SAL 19±3 74±6* 81±4*
 PoSIN-1 19±3 89±6* 78±6*
 PeSIN-1 21±5 94±9*  95±12*
Arterial Plasma Glucagon, pg/ml
 SAL 45±7 51±4 44±6
 PoSIN-1 36±4 42±3 37±3
 PeSIN-1 37±3 43±5 39±5
Hepatic Sinusoidal Glucagon, pg/ml
 SAL 59±7 69±6 61±6
 PoSIN-1 45±4 59±4* 51±4
 PeSIN-1 42±3 64±6*  61±4*
Data are means±S.E.M; n=8 in SAL goup, n=12 in PoSIN-1 group and n=10 in PeSIN-1 group  
*= Significant statistical difference (P<0.05) from basal period within the group
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Table 3.3: Average hepatic arterial, portal, and total hepatic blood flow during the basal and experimental
periods in conscious 42-h-fasted dogs given saline or SIN-1 infused into the portal vein or into a peripheral vein
Experimental Period
Group Basal Period Period 1 Period 2
Average Hepatic Arterial Blood Flow, ml/kg/min
 SAL 6.0±0.5 9.4±0.8* 10.1±1.1*
 PoSIN-1 4.8±0.4 5.8±0.5† 6.9±0.5*†
 PeSIN-1 5.8±0.6 7.0±0.8† 7.4±0.7†
Average Hepatic Portal Blood Flow, ml/kg/min
 SAL 22.2±2.0 18.2±1.5* 19.3±1.6
 PoSIN-1 22.2±1.3 17.5±1.2* 20.0±1.2
 PeSIN-1 22.2±1.8 17.3±1.3* 18.5±1.2
Average Total Hepatic Blood Flow, ml/kg/min
 SAL 28.2±2.5 27.6±2.3 29.4±2.7
 PoSIN-1 27.0±1.7 23.3±1.7 26.9±1.7
 PeSIN-1 28.0±2.4 24.3±2.1 25.9±1.9
Data are means±S.E.M.; n=8 in SAL goup, n=12 in PoSIN-1 group and n=10 in PeSIN-1 group   
* = Significant statistical difference (P<0.05) from basal period within the group
† = Significant statistical difference (P<0.05) from SAL group
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Table 3.4: Average lactate, glycerol and NEFA concentration and net hepatic 
balance during the basal and experimental periods in conscious 42-h-fasted 
dogs given saline or SIN-1 infused into the portal vein or into a peripheral vein
Experimental Period
Group Basal Period Period 1 Period 2
Arterial Blood Lactate, µmol/L
 SAL 412±50 1390±134 1174±116
 PoSIN-1 327±17 1049±45* 966±45*
 PeSIN-1 467±41 1033±91 1010±73
Net Hepatic Lactate Balance, µmol/kg/min
 SAL -6.1±0.9 10.0±2.1 7.8±1.8
 PoSIN-1 -5.3±0.3 6.8±1.0 4.5±0.9*
 PeSIN-1 -4.5±0.7 11.7±2.3 7.6±2.0
Arterial Blood Glycerol, µmol/L
 SAL 99±14 35±6 29±5
 PoSIN-1 88±6 36±4 48±5*
 PeSIN-1 101±5 38±3 45±5*
Net Hepatic Glycerol Uptake, µmol/kg/min
 SAL 1.9±0.3 0.7±0.1 0.6±0.1
 PoSIN-1 1.7±0.2 0.6±0.1 1.0±0.1*
 PeSIN-1 2.0±0.2 0.7±0.1 0.9±0.2
Arterial Plasma NEFA, µmol/L
 SAL 1034±81 183±23 140±16
 PoSIN-1 976±41 136±18 143±20
 PeSIN-1 853±53 129±20 110±19
Net Hepatic NEFA Uptake, µmol/kg/min
 SAL 3.8±1.2 0.2±0.1 0.3±0.1
 PoSIN-1 3.4±0.3 0.3±0.1 0.4±0.1
 PeSIN-1 1.9±0.6 0.2±0.1 0.2±0.1
Data are means±S.E.M.; n=8 in SAL goup, n=12 in PoSIN-1 group and n=10 in PeSIN-1 group  
All values in each group during the experimental period are significantly different (P<0.05)
from the basal period. * = Significant statistical difference (P<0.05) from SAL group
Negative values for balance data indicate net hepatic uptake
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   Figure 3.1: Schematic representation of the study. The protocol comprises the basal 
(-30-0 min) and experimental periods (period 1, 0-90 min; period 2, 90-240 min). 
Somatostatin was infused peripherally and insulin (4-fold basal) and glucagon (basal) 
were given intraportally, whereas glucose was delivered intraportally (4 mg/kg/min) 
and peripherally at a variable rate to increase the hepatic glucose load 2-fold basal 
during period 1 and period 2. The saline (SAL) group (n = 8) received intraportal 
saline during period 2; PoSIN-1 group (n = 12), received intraportal 3-
morpholinosydnonimine (SIN-1, 4 µg/kg/min) during period 2. PeSIN-1 group (n = 10) 
received peripheral SIN-1 (4 µg/kg/min) during period 2. 
-Performed in 42 h fasted
-SIN-1 (3-Morpholinylsydnoneiminechloride): NO Donor
or
PeSin-1 (n=10)
PoSin-1 (n=12) Portal SIN-1 (4 ug/kg/min)
SAL (n=8)
Peripheral SIN-1 (4 ug/kg/min)
Peripheral glucose to 2X blood glucose level
Portal Saline
or
-120 240 min
Portal glucose (4 mg/kg/min)
0-30
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90
Somatostatin+ Portal Ins (4XBasal) and Portal GGN (Basal)
conscious dogs
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Figure 3.2: Arterial blood glucose and hepatic glucose loads in 42-h-fasted 
conscious dogs during the basal and experimental periods. See Fig. 3.1 for 
description of study conditions.  Data are means±S.E.M. 
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Figure 3.3: Net hepatic glucose uptake and change of net hepatic fractional 
extraction of glucose from baseline in 42-h-fasted conscious dogs during the 
basal and experimental periods. See Fig. 3.1 for description of study conditions. 
Data are means±S.E.M. *P<0.05 compared with SAL group. †P<0.05 compared 
with the PeSIN-1 group. 
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Figure 3.4: Glucose infusion rate and nonhepatic glucose uptake in 42-h-fasted 
conscious dogs during the basal and experimental periods. See Fig. 3.1 for 
description of study conditions. Data are means±S.E.M. 
 97 
CHAPTER IV 
 
EFFECTS OF INTRAPORTAL INFUSION OF THE SSRI ESCITALOPRAM 
(LEXAPRO) ON NET HEPATIC GLUCOSE UPTAKE  
 
Aim 
To examine whether escitalopram enhances net hepatic glucose uptake in 
conscious dogs under fixed hyperinsulinemic and hyperglycemic conditions, 
when the role of the liver in glucose disposition is very important to glucose 
homeostasis. 
Experimental Design 
Animals were divided into three experimental groups in a randomized 
study setting. Each experiment consisted of a 90-min equilibration period (-120 to 
-30 min), a 30-min basal period (-30 to 0 min), and a 270-min experimental 
period (0 to 270 min), which was divided into a 90 minute period (P1) followed by 
a 180 minute period (P2). In all experiments a constant infusion of indocyanine 
green dye (0.076 mg/min; Sigma Immunochemicals, St. Louis, MO) was initiated 
at –120 min via the left cephalic vein. At 0 min, a constant infusion of 
somatostatin (0.8 µg/kg/min; Bachem, Torrance, CA) was begun via the left 
saphenous vein to suppress endogenous insulin and glucagon secretion. Basal 
glucagon (0.57 ng/kg/min; Glucagen, Novo Nordisk, Bagsvaerd, Denmark) and 
4-fold basal insulin (1.2 mU/kg/min; Eli Lilly & Co., Indianapolis, IN) infusions 
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were then started through the splenic and jejunal catheters and maintained for 
the duration of the study. In addition, at time 0, a primed continuous infusion of 
50% dextrose was started via the right cephalic vein, so that the blood glucose 
could be quickly be clamped at the desired hyperglycemic level (~165 mg/dL). In 
P2, saline was infused intraportally in the control group (SAL, n=11), while 
escitalopram oxalate (Forest Research Institute, Jersey City, NJ) was infused 
intraportally at 2 µg/kg/min (L-ESC, n=6) or 8 µg/kg/min (H-ESC, n=7). Intraportal 
infusion of the drug facilitated liver targeting and reflected the route of the drug 
entry seen clinically. The peripheral glucose infusion rate was adjusted in P2 to 
maintain a similar hepatic glucose load (HGL) to that seen in P1.  
 
Results 
 
5-HT levels  
The 5-HT levels in the liver were significantly increased in response to 
intraportal escitalopram infusion at 8 µg/kg/min (H-ESC vs. SAL, P<0.05) (Table 
4.1). Arterial, portal and hepatic vein blood 5-HT concentrations did not change 
significantly in any group throughout the study (Table 4.1). There was a 
consistent (with the exception of L-ESC group during P2) albeit small net hepatic 
production of serotonin in each group (Table 4.1). 
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 Hormone concentrations 
The arterial and hepatic sinusoidal insulin concentrations increased three- 
to fourfold and remained stable during P1 and P2 in all groups (Table 4.2). 
Arterial and hepatic sinusoidal plasma glucagon concentrations, on the other 
hand, remained near basal (Table 4.2). The mean plasma cortisol concentrations 
also remained statistically unchanged from basal in each group (Table 4.2). 
 
Hepatic blood flow, blood glucose concentrations, and hepatic glucose load  
Portal vein blood flow decreased ~20% in all groups during P1 in response 
to somatostatin infusion (Table 4.3). There tended to be a concomitant and 
somewhat offsetting increase in hepatic arterial flow. Nevertheless, total hepatic 
blood flow tended to be slightly reduced during P1 and P2 in all groups. 
Arterial blood glucose concentrations increased in all groups from a basal 
value of 82±2  to 164±3 mg/dL during P1 and P2 (Fig. 4.2). The hepatic glucose 
loads increased proportionally and did not differ significantly among groups at 
any time (Fig. 4.2).  
 
Net hepatic glucose balance and net hepatic fractional glucose extraction  
All groups exhibited a similar rate of net hepatic glucose output during the 
basal period. Coincident with the start of the experimental period (4X basal 
insulin, basal glucagon and hyperglycemia), all groups switched from net output 
to net uptake of glucose, with the rates not being significantly different among 
groups during P1 (Fig. 4.3). Subsequently, the rate of net hepatic glucose uptake 
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remained relatively stable in SAL and L-ESC (2.4±0.3 and 2.4±0.2 mg/kg/min), 
whereas it increased in H-ESC and averaged 4.1±0.6 mg/kg/min during the last 
hour of P2 (P<0.05 vs. SAL). The net hepatic fractional glucose extraction 
followed a similar pattern, increasing significantly in response to intraportal 
escitalopram infusion at 8 µg/kg/min (Fig. 4.3). 
 
Glucose infusion rates, nonhepatic glucose uptake 
The glucose infusion and nonhepatic glucose uptake rates increased over 
time in all groups (Fig. 4.4). In response to intraportal escitalopram infusion at 8 
µg/kg/min, the area under the curve (AUC) for the change from baseline in 
glucose infusion rate was significantly greater than in the other two groups 
(128±27 in H-ESC vs. 49±10 in SAL and 66±15 mg/kg/min X180 min in L-ESC 
group, P<0.05) during P2 (90–270 min). Nonhepatic glucose uptake did not differ 
significantly among groups at any time. 
 
Lactate metabolism, net hepatic carbon retention and hepatic glycogen content  
The arterial blood lactate concentrations rose in all groups during P1 and 
P2. After the experimental period began, net hepatic lactate balance changed 
from uptake to output, and the output rates remained elevated in all groups 
during P2 (Table 4.4). Net hepatic carbon retention (mg glucose 
equivalents/kg/min) did not differ between SAL, L-ESC and H-ESC at any time 
during P1 but it increased in H-ESC relative to the other two groups during P2 
(3.8±0.5 in H-ESC vs. 2.8±0.2 in SAL and 2.7±0.1 L-ESC group, respectively, 
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P<0.05). In agreement with this, the hepatic glycogen content at the end of study 
was greater in H-ESC than in L-ESC and SAL (5.6 ± 0.4 vs. 3.3± 0.2 and 4.0 ± 
0.4 g /100 g liver, respectively, P<0.05).   
 
Glycerol and nonesterified fatty acid metabolism  
Arterial blood glycerol concentrations and net hepatic glycerol uptakes 
were reduced by 40–65% in response to hyperglycemia and hyperinsulinemia 
and remained suppressed in all groups throughout P1 and P2 (Table 4.4). 
Arterial plasma nonesterified fatty acid concentrations and net hepatic 
nonesterified fatty acid uptakes changed in a pattern similar to glycerol, 
decreasing 85–95% during P1 and P2 in all groups (Table 4.4). 
 
Discussion 
To our knowledge, this study is the first in vivo investigation to explore the 
effects of the SSRI escitalopram on the ability of the liver to take up and store 
glucose. In the presence of fourfold basal insulin and basal glucagon, 
hyperglycemia caused net hepatic glucose uptake of ~2.0 mg/kg/min during P1 in 
all three groups. Portal infusion of the SSRI escitalopram at 2 µg/kg/min (L-ESC) 
did not significantly enhance net hepatic glucose uptake during P2 compared 
with the control group (SAL). However, when the infusion rate was increased to 8 
µg/kg/min (H-ESC), net hepatic glucose uptake was ~60% greater than the 
corresponding rate in SAL. Similar to net hepatic glucose uptake, net hepatic 
carbon retention did not differ among groups during P1. The enhancement of net 
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hepatic glucose uptake during P2 in H-ESC was accompanied by a ~60% 
increase in net hepatic carbon retention, and the hepatic glycogen content at the 
end of the study was greater in H-ESC than in SAL and L-ESC. At the same time, 
glucose uptake by nonhepatic tissues was not significantly altered by 
escitalopram infusion. There was a tendency (not statistically significant) for 
arterial and sinusoidal insulin levels to be higher in the L-ESC and H-ESC groups 
than in SAL group in period 2 when escitalopram was given.  Since somatostatin 
inhibited insulin secretion, as confirmed by reduced arterial c-peptide levels (data 
not shown), this could have resulted from a drug induced decrease in insulin 
clearance or more than likely a random difference in insulin clearance in the L-
ESC and H-ESC groups. In an earlier study, it was demonstrated that SSRI 
Sertraline increases plasma insulin levels in rats without changing peripheral 
insulin sensitivity (Gomez et al., 2001). Nevertheless, it seems unlikely that the 
tendency of insulin to be higher in the H-ESC group was responsible for the 
enhancement of net hepatic glucose uptake seen in that group since it was a 
small change and the same tendency for insulin to be higher in the L-ESC group 
did not result in increased net hepatic glucose uptake.  
Evidence shows that serotonin has a range of biological functions 
including acting as a neurotransmitter and as a regulator of vascular tone and 
glucose metabolism. Treatment with serotonin or its precursor tryptophan 
induces hypoglycemia in rodents (Smith et al., 1977; Yamada et al., 1989), 
whereas 5-HT receptor antagonists cause hyperglycemia (Wozniak et al., 1991). 
In addition, SSRIs improve glucose tolerance and insulin sensitivity in obese and 
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diabetic rats (Gomez et al., 2001; Picarel-Blanchot et al., 1994) and humans 
(Breum et al., 1995; Maheux et al., 1997; Potter van Loon et al., 1992). However, 
the mechanisms that account for hypoglycemia or improved glucose tolerance in 
individuals with diabetes after treatment with SSRIs are not fully understood. 
In our previous study, infusion of the SSRI fluvoxamine into the liver 
through the hepatic portal vein increased net hepatic glucose uptake and hepatic 
carbon storage under hyperglycemic hyperinsulinemic conditions in  conscious 
dogs (Moore et al., 2004a). Fluvoxamine inhibits reuptake of serotonin into the 
presynaptic nerve terminals, but whether this is the mechanism by which it brings 
about an increase in net hepatic glucose uptake remains unknown. In the present 
study, escitalopram was chosen because it is the most selective SSRI available, 
having a very low affinity for serotonergic (5-HT1-7), alpha- and beta-adrenergic, 
dopamine (D1-5), histamine (H1-3), muscarinic (M1-5), and benzodiazepine 
receptors (Waugh et al., 2003). Since some of these receptors could influence 
glucose metabolism, using escitalopram allows us to more definitively study the 
effect of serotonin on hepatic glucose metabolism. The patterns of enhancement 
in net hepatic glucose uptake and net hepatic carbon retention in response to 
intraportal escitalopram infusion at 8 µg/kg/min were similar to those seen during 
intraportal infusion of fluvoxamine, confirming the role of hepatic serotonin in the 
regulation of hepatic glucose uptake. Fluvoxamine may also have inhibited 
peripheral glucose uptake since it was shown to significantly reduced nonhepatic 
glucose uptake albeit at a single time point at the end of our earlier study (Moore 
et al., 2004a). There was no such effect of escitolapram on nonhepatic glucose 
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metabolism in the present study. It should be noted, however, that there was a 
tendency for an elevation in the plasma epinephrine level to occur when 
fluvoxamine was infused but not when escitolapram was given (data not shown), 
thereby potentially explaining the reduction in nonhepatic glucose uptake.  
5-HT receptor subtypes have been grouped into seven families, 5-HT 
receptors 1 to 7, based on the second messenger system they employ as well as 
their sequence homologies. Each family comprises several variant subtypes. 
With the exception of the 5-HT3 receptor, 5-HT receptors are G-protein-coupled 
receptors. 5-HT1, 5-HT2 and 5-HT4 receptors are found in relative abundance in 
the liver (genecards.org). 5-HT4 receptor is coupled to Gs, which activates 
adenylyl cyclase (AC), and increases synthesis of cAMP. cAMP in turn activates 
protein kinase A (PKA), and PKA phosphorylates downstream protein kinases. 
PKA also causes activation of glycogen phosphorylase in hepatocytes thereby 
triggering the degradation of hepatic glycogen. 5-HT2 receptor is coupled to Gq, 
which activates phospholipase C (PLC), yielding diacylglycerol (DAG). DAG 
activates protein kinase C (PKC), which then activates downstream protein 
kinases. By contrast, 5-HT1 receptor is coupled to Gi, which inhibits AC and PKA. 
It is possible that the activation of hepatic 5-HT1 receptor will cause inactivation 
of PKA, and in turn result in an increase in net hepatic glucose uptake and 
hepatic glycogen deposition in response to escitalopram. The latter possibility is 
supported by a recent study which showed that a 5-HT1 receptor agonist could 
enhance glycogen synthesis in cultured hepatocytes (Hampson et al., 2007). 
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Twenty mg escitalopram by mouth OQD is commonly prescribed to treat 
depression. It has been shown in human subjects that i.v. infusion of 
escitalopram at a rate of 10 mg/h (~2 µg/kg/min) brings about a similar 
pharmacokinetic profile to 20 mg of the drug p.o. (Sogaard et al., 2005). In the 
present study, when escitalopram was infused intraportally at 2 µg/kg/min, a 
dose which was believed to mimic the pharmacokinetic profile in humans taking 
20 mg escitalopram daily, no change of net hepatic glucose uptake was 
observed. However, net hepatic glucose uptake was significantly enhanced in 
response to the portal infusion of escitalopram at 8 µg/kg/min. Little is known 
about how the pharmacokinetics of escitalopram in dogs and humans compare, 
but an early citalopram (escitalopram racemate) study showed that its half life is 
much shorter and its systemic plasma clearance rate is much higher in dogs than 
in humans (Fredricson Overo, 1982). This suggests that in order to mimic the 
pharmacokinetic profile in humans, higher doses of escitalopram are needed in 
the dog model. Therefore, the enhancement of net hepatic glucose uptake seen 
in the present study with a high dose of escitalopram may reflect that seen in 
humans with a typical oral dose of the drug. The enhancement of net hepatic 
glucose uptake was accompanied by an increase in net hepatic carbon retention, 
which reflects hepatic glycogen deposition. In a net sense, ~85% of the glucose 
taken up by the liver in response to the drug was deposited in liver glycogen, 
while most of the remaining glucose left the liver as lactate. It appears that portal 
escitalopram infusion had no effects on nonhepatic glucose uptake, although it is 
hard to conclusively rule out such a possibility because of the variability 
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associated with the measurement of this parameter. This means that the 
increase in whole body glucose disposal seen in response to intraportal 
escitalopram infusion at 8 µg/kg/min was most likely the result of augmented net 
hepatic glucose uptake. 
As noted above, the augmentation of net hepatic glucose uptake and 
hepatic glucose storage could have resulted from a direct interaction of 
endogenous serotonin with its receptor on hepatocytes. Recently, it was reported 
that physiological concentrations of serotonin or a 5-HT1 receptor agonist have 
direct stimulatory effects on glycogen synthesis in primary cultures of rat 
hepatocytes (Hampson et al., 2007). It is also possible, however, that the 
increase in net hepatic glucose uptake seen in the present study could have 
been brought about by a neural signal initiated in the liver. A rise in hepatic 
serotonin levels resulting from intraportal serotonin injection can decrease the 
afferent firing rate in the hepatic branch of the vagus nerve, similar to the effect 
seen in response to intraportal glucose injection (Niijima, 1981) (Niijima, 1996). 
The vagus nerve communicates with the hypothalamus via the hypothalamic 
projections to the medulla oblongata and the liver could receive autonomic input 
as a result of hypothalamic nuclei receiving serotonergic input (Buijs et al., 2003; 
Hosoya, 1985). Furthermore, stimulation of hypothalamic autonomic efferent can 
enhance hepatic glycogen synthase activity (Shimazu, 1967). These 
investigations suggest a mechanism by which a change of serotonin levels in the 
liver could elicit a neural signal which may be coordinated by the hypothalamus 
to enhance net hepatic glucose uptake. In line with this theory, we observed an 
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increase in 5-HT levels in the liver in response to intraportal escitalopram infusion 
at 8 µg/kg/min. Consistent with our previous observations with fluvoxamine, 
however, we did not detect a significant increase in 5-HT levels in the blood. 
Such measurements may not be very sensitive readouts for alterations in 
neurotransmitter levels in the synapse (Ahren et al., 1988),  given the variance of 
the analytical method and the limited power to detect a change of 5-HT levels 
(the power calculation was set based on detecting differences in net hepatic 
glucose balance).  We also cannot rule out the involvement of central 
serotonergic sensing since the infused SSRI escitalopram can penetrate the 
blood-brain barrier and may thus activate the brain serotonergic system directly. 
The central serotonergic system has recently been shown to regulate peripheral 
glucose metabolism without changing energy expenditure, locomotor activity or 
body weight (Zhou et al., 2007). These authors showed that 5-HT2C receptor 
agonists significantly improved glucose tolerance and reduced the plasma insulin 
level in mouse models of obesity and type 2 diabetes. Furthermore, they showed 
that the mechanism required downstream activation of melanocortin-4 receptors 
in the CNS. The precise workings of the serotonin receptors/pathways regulating 
hepatic glucose metabolism require further elucidation. Highly selective receptor 
agonists/antagonists will undoubtedly provide valuable mechanistic insights into 
the role of serotonin receptors in modulating glucose homeostasis.  
In conclusion, our data indicate that intraportal infusion of a SSRI, 
escitalopram, enhanced net hepatic glucose uptake and hepatic glycogen 
deposition under hyperglycemic and hyperinsulinemic conditions in conscious 
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42-h-fasted dogs. These findings raise the possibility that serotonin may play a 
role in directing the disposition of an oral glucose load. Hepatic-targeted SSRIs 
might therefore help to control postprandial hyperglycemia in individuals with 
diabetes. 
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Table 4.1: Serotonin levels and net hepatic balance in conscious 42-h-fasted dogs
given saline, or a low or high dose escitalopram infusion into the hepatic portal vein
   Experimental Period
Group Basal Period Period 1 Period 2
5-HT Levels in Liver, ng/mg protein
 SAL N/A N/A 543±141
 L-ESC N/A N/A 799±208
 H-ESC N/A N/A 908±72*
Arterial Blood 5-HT, µg/L
 SAL 1140±283 1054±238 968±250
 L-ESC 835±176 835±165 702±126
 H-ESC 805±203 766±217 728±172
Portal Blood 5-HT, µg/L
 SAL 1235±322 1139±243 933±200
 L-ESC 873±149 780±126 733±123
 H-ESC 901±240 834±202 730±173
Hepatic Blood 5-HT, µg/L
 SAL 1268±299 1150±220 1041±226
 L-ESC 889±131 861±138 694±113
 H-ESC 945±230 861±175 769±197
Net Hepatic 5-HT Balance, µg/kg/min
 SAL 1.5±2.0 1.0±0.6 2.6±1.5
 L-ESC 0.7±1.8 1.8±1.1 -0.7±1.4
 H-ESC 2.0±1.8 0.7±1.3 0.9±1.3
N/A=liver sample is not available due to the fact that biopsy was only taken after completion of experiments
Data are means ±S.E.M.. n=6 dogs in each group
SAL=the group that received saline; L-ESC=the group that received escitalopram in the portal
 vein at 2 µg/kg/min; H-ESC=the group that received escitalopram in the portal vein at 8 µg/kg/min
Negative values for balance data indicate net hepatic uptake
* = Significant statistical difference (P<0.05) from the saline group
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Table 4.2: Hormone concentrations during the basal and experimental periods in conscious 42-h-fasted 
dogs given saline, or a low or high dose escitalopram infusion into the hepatic portal vein
Experimental Period
Group Basal Period Period 1 Period 2
Arterial Plasma Insulin, µU/ml
 SAL 8±1 19±1* 22±2*
 L-ESC 8±1 22±2* 26±2*
 H-ESC 8±1 23±2* 26±3*
Hepatic Sinusoidal Insulin, µU/ml
 SAL 22±3 81±13* 78±10*
 L-ESC 24±8 94±8* 98±6*
 H-ESC 25±4 95±7* 98±8*
Arterial Plasma Glucagon, pg/ml
 SAL 43±4 41±3 40±3
 L-ESC 40±6 45±9 44±8
 H-ESC 35±4 43±3 37±3
Hepatic Sinusoidal Glucagon, pg/ml
 SAL 50±4 56±4 53±4
 L-ESC 47±5 61±7 57±8
 H-ESC 40±4 63±4* 51±3
Arterial Cortisol, µg/dL
 SAL 4±1 5±1 3±1
 L-ESC 3±1 3±1 3±1
 H-ESC 4±1 5±1 3±1
Data are means±S.E.M.; n=11 dogs in the saline group (SAL), n=6 in the group that received escitalopram
 at 2 µg/kg/min (L-ESC) and n=7 in the group that received escitalopram at 8 µg/kg/min (H-ESC) 
*= Significant statistical difference (P<0.05) from basal period within the group
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Table 4.3: Average hepatic arterial, portal, and total hepatic blood flow during the basal and experimental periods in 
conscious 42-h-fasted dogs given saline, or a low or high dose escitalopram infusion into the hepatic portal vein
Experimental Period
Group Basal Period Period 1 Period 2
Average Hepatic Arterial Blood Flow, ml/kg/min
 SAL 5.1±0.4 5.9±0.5 6.8±0.9
 L-ESC 5.2±0.4 5.9±0.8 6.9±1.1
 H-ESC 5.0±0.2 5.5±0.3 6.0±0.6
Average Hepatic Portal Blood Flow, ml/kg/min
 SAL 22.6±1.4 17.9±1.2* 17.9±1.2*
 L-ESC 25.6±0.7 18.3±0.8* 17.3±0.6*
 H-ESC 21.4±1.7 16.3±1.2* 17.4±1.1
Average Total Hepatic Blood Flow, ml/kg/min
 SAL 27.7±1.4 23.8±1.4 24.7±1.4
 L-ESC 30.8±0.9 24.2±1.4* 24.8±1.5
 H-ESC 26.4±1.7 21.8±1.4 23.5±1.2
Data are means±S.E.M.; n=11 dogs in the saline group (SAL), n=6 in the group that received escitalopram
 at 2 µg/kg/min (L-ESC) and n=7 in the group that received escitalopram at 8 µg/kg/min (H-ESC) 
*= Significant statistical difference (P<0.05) from basal period within the group
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Table 4.4: Average lactate, glycerol and NEFA concentrations and net hepatic
balances during the basal and experimental periods in conscious 42-h-fasted dogs 
given saline, or a low or high dose escitalopram infusion into the hepatic portal vein
Experimental Period
Group Basal Period Period 1 Period 2
Arterial Blood Lactate, µmol/L
 SAL 327±58 673±84 783±81
 L-ESC 395±32 934±98 855±73
 H-ESC 551±90 1025±192 986±103
Net Hepatic Lactate Balance, µmol/kg/min
 SAL -7.3±1.1 3.5±4.3 3.0±2.8
 L-ESC -6.6±0.9 6.8±1.6 3.6±1.4
 H-ESC -5.2±1.5 4.1±1.5 3.5±1.8
Arterial Blood Glycerol, µmol/L
 SAL 82±14 43±11 34±15
 L-ESC 97±9 34±5 24±4
 H-ESC 98±7 46±10 31±7
Net Hepatic Glycerol Uptake, µmol/kg/min
 SAL 1.8±0.4 1.0±0.4 0.6±0.3
 L-ESC 2.1±0.3 0.5±0.1 0.5±0.1
 H-ESC 1.4±0.2 0.7±0.1 0.6±0.2
Arterial Plasma NEFA, µmol/L
 SAL 803±114 108±11 90±18
 L-ESC 909±75 133±17 96±14
 H-ESC 1027±57 138±20 100±14
Net Hepatic NEFA Uptake, µmol/kg/min
 SAL 4.4±1.5 0.2±0.1 0.1±0.1
 L-ESC 3.2±0.4 0.4±0.1 0.2±0.1
 H-ESC 3.0±0.5 0.4±0.1 0.2±0.1
Data are means±S.E.M.; n=11 dogs in the saline group (SAL), n=6 in the group that received escitalopram
 at 2 µg/kg/min (L-ESC) and n=7 in the group that received escitalopram at 8 µg/kg/min (H-ESC) 
All values in each group during the experimental period were significantly different (P<0.05)
from the basal period. Negative values for balance data indicate net hepatic uptake
 
 
 
 
 
 
 
 
 113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-120 270 min
Peripheral glucose to double hepatic glucose load
0-30
Basal Period 1 Period 2
90
+
or
Somatostatin+Portal Ins (4XBasal) and Portal GGN (Basal)
Portal escitalopram (2 ug/kg/min)
Saline
Performed in 42 h fasted conscious dogs 
Escitalopram: an SSRI
SAL (n=10)
L-ESC (n=6)
Portal escitalopram (8 ug/kg/min)
or
H-ESC (n=6)
   Figure 4.1: Schematic representation of the study. The protocol comprises the basal 
(-30-0 min) and experimental periods (period 1, 0-90 min; period 2, 90-270 min). 
Somatostatin was infused peripherally and insulin (4-fold basal) and glucagon (basal) 
were given intraportally, while glucose was delivered peripherally at a variable rate to 
increase the hepatic glucose load 2-fold basal during period 1 and period 2. The 
saline (SAL) group (n=11) received intraportal saline during period 2. L-ESC group 
(n=6), received intraportal escitalopram (2 µg/kg/min) during period 2. H-ESC group 
(n=7), received intraportal escitalopram (8 µg/kg/min) during period 2 
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   Figure 4.2: Arterial blood glucose and hepatic glucose loads in 42-h-fasted conscious 
dogs during the basal and experimental periods. See Fig. 4.1 for description of study 
conditions. Data are means ± S.E.M. 
 
 115 
Time (min)
-30 0 30 90 150 210 270
N
et
 
H
ep
at
ic
 
Fr
ac
tio
n
al
Ex
tr
ac
tio
n
 
o
f G
lu
co
se
0.00
0.04
0.08
0.12
0.16
*
*
*
*
*
N
et
 
He
pa
tic
 
G
lu
co
se
 
Ba
la
n
ce
(m
g/
kg
/m
in
)
-8
-6
-4
-2
0
2
4
*
Output
Uptake
Period 1 Period 2
Saline or portal escitalopram
Hyperinsulinemic and hyperglycemic clamp
SAL
H-ESC
L-ESC
* *
*
*
† † † †
†
†
†
†
*
†
† †
†
†
†
 
 
 
 
 
 
 
 
 
 
   Figure 4.3: Net hepatic glucose uptake and net hepatic fractional extraction of 
glucose in 42-h-fasted conscious dogs during the basal and experimental periods. 
See Fig. 4.1 for description of study conditions. Data are means±S.E.M; *P<0.05 
compared with SAL group. †P<0.05 compared with L-ESC group. 
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   Figure 4.4: Glucose infusion rate and nonhepatic glucose uptake in 42-h-fasted 
conscious dogs during the basal and experimental periods. See Fig. 4.1 for 
description of study conditions. Data are means±S.E.M; *P<0.05 compared with SAL 
group. †P<0.05 compared with L-ESC group. 
 
 117 
CHAPTER V 
 
THE ROLE OF sGC/cGMP PATHWAY IN THE REGULATION OF NET 
HEPATIC GLUCOSE UPTAKE  
 
Aim 
We previously showed in the conscious dog that increased hepatic NO 
resulting from portal SIN-1 infusion inhibits NHGU. Because NO can activate 
soluble guanylate cyclase (sGC), the aim of the present study was to determine 
whether a sGC/cGMP dependent mechanism is responsible for the regulation of 
NHGU by hepatic NO. 
 
Experimental Design 
As described in Fig. 5.1, each experiment consisted of a 90-min 
equilibration period (-120 to -30 min), a 30-min basal period (-30 to 0 min), and a 
270-min experimental period (0 to 270 min), which was divided into a 90 minute 
period (P1) followed by a 180 minute period (P2). In all experiments a constant 
infusion of indocyanine green dye (0.076 mg/min; Sigma Immunochemicals, St. 
Louis, MO) was initiated at –120 min via the left cephalic vein. At 0 min, a 
constant infusion of somatostatin (0.8 µg/kg/min; Bachem, Torrance, CA) was 
begun via the left saphenous vein to suppress endogenous insulin and glucagon 
secretion. At the same time, basal glucagon (0.57 ng/kg/min; Glucagen, Novo 
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Nordisk, Bagsvaerd, Denmark) and 4-fold basal insulin (1.2 mU/kg/min; Eli Lilly & 
Co., Indianapolis, IN) infusions were started through the splenic and jejunal 
catheters and maintained for the duration of the study. In addition, at time 0, a 
primed continuous infusion of 50% dextrose was started via the right cephalic 
vein so that the blood glucose could be quickly be clamped at the desired 
hyperglycemic level (~160 mg/dL). In P2, saline was infused intraportally in the 
control group (SAL, n=10), and ODQ (Cayman Chemical Company, Ann Arbor, 
MI) was infused intraportally at 0.8 µg/kg/min in the ODQ (n=10) and ODSN (n=6) 
groups, while SIN-1 (Cayman Chemical Company, Ann Arbor, MI) was infused 
intraportally at 4 µg/kg/min in the ODSN group for the last 90 min of P2. The 
peripheral glucose infusion rate was adjusted as needed to maintain a similar 
hepatic glucose load (HGL) to that seen in P1.  
 
Results 
 
Hormone concentrations 
 The arterial and hepatic sinusoidal insulin levels increased three to four-
fold and remained stable during P1 and P2 in all groups (Table 5.1). Arterial and 
hepatic sinusoidal plasma glucagon concentrations, on the other hand, remained 
basal throughout the study in all groups (Table 5.1). The mean plasma cortisol 
concentrations also remained basal and unchanged in each group (Table 5.1). 
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Hepatic blood flow, blood glucose concentrations, and hepatic glucose load  
Portal vein blood flow decreased ~20% in all groups during P1 in response 
to somatostatin infusion (Table 5.2). There was a concomitant and offsetting 
(~20%) increase in hepatic arterial flow. Consequently, total hepatic blood flow 
tended to be slightly reduced during both P1 and P2 in all groups. 
Arterial blood glucose levels increased in the all groups from a basal value 
of 80±2 to 159±2 mg/dL during P1 and P2 (Fig. 5.2). The hepatic glucose loads 
increased proportionally in all groups and did not differ significantly among 
groups at any time (Fig. 5.2).  
 
Net hepatic glucose balance and net hepatic fractional glucose extraction  
All groups exhibited a similar rate of net hepatic glucose output during the 
basal period. Coincident with the start of the experimental period (4X basal 
insulin, basal glucagon and hyperglycemia), all groups switched from net output 
to net uptake of glucose, with the rates (2.2±0.3, 2.2±0.3, and 2.6±0.4 mg/kg/min 
in SAL, ODQ and ODSN groups, respectively) not being significantly different 
among groups (Fig. 5.3). Subsequently, the rate rose to 3.1±0.3 mg/kg/min in 
SAL, whereas it increased to 4.7±0.5 and 4.5±0.6 mg/kg/min in the ODQ and 
ODSN groups, respectively, during the last hour of the experiment (P<0.05 vs. 
SAL). The net hepatic fractional extraction of glucose followed a similar pattern, 
increasing significantly and similarly in response to intraportal ODQ infusion in 
the absence or presence of SIN-1 (Fig. 5.3). 
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Glucose infusion rates, nonhepatic glucose uptake 
The glucose infusion and nonhepatic glucose uptake rates increased over 
time in all groups (Fig. 5.4). In the ODQ and ODSN groups, the glucose infusion 
rate was significantly increased over that required in the saline group. 
Nonhepatic glucose uptake did not differ significantly between groups at any time, 
although there was a tendency for it to be increased in the presence of ODQ. 
 
Lactate metabolism, net hepatic carbon retention and hepatic glycogen content  
The arterial blood lactate concentrations rose in all groups during P1 and 
remained elevated in P2. After the experimental period began, net hepatic lactate 
balance changed from uptake to output, and the output rates remained increased 
in all groups during P2 (Table 5.3). Net hepatic carbon retention (mg glucose 
equivalents/kg/min) did not differ among groups at any time during P1 but was 
increased relative to the control group during P2 in response to ODQ, regardless 
of the presence or absence of SIN-1, (3.8±0.2 in ODQ and  3.8±0.4 in ODSN vs. 
2.4±0.2 in the SAL group, P<0.05).   
 
AMP-activated protein kinase signaling in the liver 
Compared with the saline group (n=4), intraportal infusion of ODQ (n=5) 
and intraportal infusion of ODQ and SIN-1 (n=5) were associated with a decrease 
of ~30% in the phosphorylation of Thr-172 in AMP-activated protein kinase 
(AMPK) as well as a decrease in the phosphorylation of Ser-79 in acetyl-CoA 
carboxylase (ACC) in the liver (Fig. 5.5). 
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Glycerol and nonesterified fatty acid metabolism  
Arterial blood glycerol concentrations and net hepatic glycerol uptake were 
reduced by 55–70 % in response to hyperglycemia and hyperinsulinemia and 
remained suppressed in all groups throughout P1 and P2 (Table 5.3). Arterial 
plasma nonesterified fatty acid (NEFA) concentrations and net hepatic NEFA 
uptake changed in a pattern similar to glycerol, decreasing ~85% during P1 and 
remaining suppressed in P2 in all groups (Table 5.3). 
 
Discussion 
To our knowledge, this report is the first in vivo work to explore effects of 
the sGC dependent pathway on net hepatic glucose uptake under hyperglycemic 
hyperinsulinemic conditions. Under these conditions, portal infusion of the sGC 
inhibitor ODQ caused a ~45% increase in net hepatic glucose uptake and a 
~55% increase in hepatic glycogen accumulation. Hepatic cGMP levels were 
reduced by ~25% (P<0.05, data not shown) in response to ODQ, confirming the 
inhibition of sGC in the liver by ODQ. Intraportal infusion of SIN-1 did not 
attenuate the enhancement of NHGU induced by ODQ. At the same time, the 
rate of glucose uptake by nonhepatic tissues tended to increase, although we 
were unable to detect any significance due the variability of the signal. As a result, 
whole body glucose utilization increased ~30% in response to intraportal ODQ 
infusion.  
 Our previous study showed that portal but not peripheral infusion of the 
nitric oxide donor SIN-1 inhibited NHGU, suggesting that the effect of NO was 
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the result of a direct effect within the liver (An et al., 2008). This concept is 
supported by the expression of all three isoforms of NOS in the liver. Both iNOS 
and eNOS are expressed in hepatocytes; additionally, iNOS has been found in 
hepatic Kupffer and Ito cells in various species, while nNOS has been identified 
in some nerve fibers in the rat liver (Alexander, 1998; Feelisch et al., 1999; Wei 
et al., 2002). There are also other experiments supporting the concept that NO 
regulates hepatic glucose metabolism. Borgs et al. (Borgs et al., 1996) observed 
that NO infusion (~0.15 µmol/g liver/min) increased the rate of glucose output in 
the perfused rat liver as a result of activation of glycogen phosphorylase. Horton 
et al. (Horton et al., 1994) demonstrated that the NO donors S-nitroso-N-
acetylpenicillamine (SNAP) and SIN-1 inhibited gluconeogenesis in isolated rat 
hepatocytes and they suggested that this may be associated with a decrease in 
phosphoenolpyruvate carboxykinase (PEPCK) activity. Sprangers et al. 
(Sprangers et al., 1998) showed that glycogen synthesis from glucose in rat 
hepatocytes was inhibited by the NO donor SNAP due to decreased glycogen 
synthase activity (less conversion of glycogen synthase b into a).  
Activation of sGC and production of cGMP is one of the main signaling 
pathways associated with the biological action of NO. It has been shown that 
glucose transport in cardiomyocytes was inhibited by different membrane-
permeant cGMP analogues whereas inhibition of endogenous cGMP production 
with ODQ increased glucose transport (Bergemann et al., 2001). To date, 
however, no one has shown whether this downstream target is responsible for 
the changes in glucose metabolism seen in response to NO/NO donor treatment. 
 123 
ODQ is a potent and specific inhibitor of sGC, and as a result is an important 
pharmacological tool used in differentiating cGMP dependent and -independent 
effects (Hwang et al., 1995). By infusing this drug intraportally to inhibit sGC in 
the liver of the conscious dog, the present study was clearly able to show that 
inhibition of sGC augmented net hepatic glucose uptake under conditions of 
elevated insulin and glucose. Furthermore, intraportal infusion of SIN-1 
concomitantly with SIN-1 did not attenuate this effect. These findings suggest the 
sGC/cGMP dependent pathway has the ability to regulate net hepatic glucose 
uptake in the whole animal. Further, it appears that the sGC/cGMP pathway is 
responsible for the inhibition of NHGU resulting from SIN-1 infusion seen in our 
previous experiments (An et al., 2008). Major extrahepatic glucose consumers 
include skeletal muscle, adipose tissue, brain, etc. In the present experiments, 
nonhepatic glucose uptake tended to increase when ODQ was infused. This 
finding is not consistent with previous observations by others that inhibition of 
hepatic guanylyl cyclase in response to the intraportal administration of the GC 
inhibitors Methylene Blue or ODQ significantly reduced glucose uptake at 
peripheral tissues in rats (Guarino et al., 2004). This inconsistency could be 
related to the use of different experimental designs, different duration of fast, the 
use of different species or that fact that our data regarding nonhepatic glucose 
uptake do not indicate a real difference.  
There are several possible ways that NO/sGC/cGMP could affect NHGU. 
Many biological effects of NO and cGMP in the cell are mediated by PKG 
(Vaandrager et al., 1996),  so it is possible that the PKG-dependent pathway is 
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the downstream signal responsible for the regulation of NHGU by NO. Evidence 
supports a role for PKG in glucose metabolism. PKG was found to phosphorylate 
GSK-3β, a key regulator of glycogen synthase, on Ser 9, thereby inhibiting its 
enzyme activity both in vitro and in vivo (Zhao et al., 2005). Young et al. showed 
that activation of PKG by cGMP-stimulated glucose oxidation in skeletal muscle, 
likely through the phosphorylation and activation of UCP-3 (Young et al., 1998). 
On the other hand, MacKenzie et al. showed that cGMP can modulate glucose 
transport in cultured vascular smooth muscle cells, but effects of cGMP are 
unlikely to be mediated through the action of PKG since the PKG inhibitor KT-
5823, at doses up to 1µM, did not block the stimulation of glucose transport by an 
cGMP analog, 8-bromo-cGMP (MacKenzie et al., 2001). In addition, the 
expression of PKG levels are low in the liver (MacKenzie et al., 2001; Walter, 
1981), and very few metabolic enzymes in the liver have been identified as 
physiological targets regulated by PKG. Further studies will be necessary to 
explore the role of PKG relative to the sGC/cGMP pathway in the regulation of 
hepatic glucose uptake. It has been well established that cAMP leads to 
activation of cAMP-dependent protein kinase (PKA), which in turn 
phosphorylates many intracellular enzymes involved in the regulation of glycogen 
metabolism, gluconeogenesis, and glycolysis (Exton, 1987). Since cGMP-inhibits 
the cAMP-specific phosphodiesterase (PDE3), which could hydrolyze  cAMP, it is 
possible that ODQ could lower hepatic cGMP thereby removing the inhibition on 
PDE3, which could, in turn, reduce hepatic cAMP levels and potentially alter 
glucose metabolism. However, the hepatic PDE3 activity (pmol/min/mg dry 
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weight) in the present study was not different between groups (3.6x10-3±0.3x10-3 
in ODQ vs. 3.2x10-3±0.3x10-3 in SAL group). This indicates that PDE3 does not 
appear to be the mechanism responsible for the metabolic response seen in the 
present study. 
Last, it is possible that NO/sGC/cGMP may regulate NHGU through an 
AMPK dependent pathway. It has recently been reported that NO can activate 
AMPK in endothelium and muscle via a sGC/cGMP-dependent pathway (Lira et 
al., 2007; Zhang et al., 2008). In line with this concept, we demonstrated that 
intraportal infusion of ODQ was associated with a decrease (~30%) in the 
phosphorylation of Thr-172 in AMPK without changing it protein level. This 
observation is confirmed by a decrease (~45%) in the phosphorylation of Ser-79 
in ACC, a marker of AMPK activity, in the liver. It remains unclear whether the 
AMPK pathway is required for the metabolic response seen in the present study.  
AMPK has been proposed to act as a ‘metabolic master switch’ mediating 
the adaptation to systemic and cellular energy status. In the past few years, 
AMPK has been implicated in the control of hepatic glucose homeostasis (Viollet 
et al., 2006), although data are still controversial. Bergeron et al. (Bergeron et al., 
2001) showed that systemic infusion of AICAR (5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside), an AMPK activator, suppressed hepatic 
glucose output in overnight-fasted normal and obese rats. This finding was 
supported by an in vitro experiment which showed that treatment with an  
adenovirus expressing a constitutively active form of AMPK alpha2 reduced 
glucose output in cultured hepatocytes (Foretz et al., 2005), and an in vivo 
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observation that liver-specific AMPK alpha2 KO mice had increased fasting 
hepatic glucose production (Andreelli et al., 2006). These studies were in 
contrast to those of Iglesias et al., who demonstrated that a intraperitoneal 
injection of AICAR caused a marked increment in net hepatic glycogen 
breakdown in 5-h-fasted rats (Iglesias et al., 2002). In agreement with Iglesias et 
al, Pencek and colleagues showed that intraportal AICAR infusion in 18-h-fasted 
conscious dogs led to an increase in hepatic glucose output in the presence of 
basal intraportal glucagon, high physiological insulin, and hyperglycemia, 
euglycemia, or hypoglycemia (Camacho et al., 2005b; Pencek et al., 2005). They 
were also able to show that the increase in hepatic glucose output in response to 
AICAR infusion was due to a stimulation of net hepatic glycogenolysis. The latter 
observation is supported by the finding that AMPK can inactivate glycogen 
synthase and activate phosphorylase (Polekhina et al., 2003). The differences 
between these studies and the results by Bergeron et al. can be attributed to 
differences in hepatic glycogen content. Consistent with differences in hepatic 
glycogen levels being responsible for these differences is the observation that 
the stimulation of NHGO in response to an intraportal AICAR infusion was lost 
when given to a 42-h-fasted dog in which liver glycogen was markedly reduced 
(Pencek et al., unpublished data). Camacho et al. (Camacho et al., 2005a) 
speculated that the stimulation of hepatic glucose output by AICAR in 18-h-fasted 
dogs was due to an off-target drug effect since the increase in glucose output 
induced by AICAR remained even in the presence of high physiological insulin 
levels (~15 fold), when AMPK activation was presumably inhibited, as evidenced 
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by ACC (Ser79) phosphorylation not being different between AICAR treated and 
saline treated animals.  It needs to be noted that the AMPK activity in that study 
was not measured, and ACC, the index of AMPK activity could be regulated by 
insulin via an AMPK independent mechanism and that may compromise the 
conclusion that AMPK was inhibited by elevated insulin (Brownsey et al., 2006). 
Nevertheless, AMPK plays an important role in the regulation of hepatic glucose 
production, glucose homeostasis, and development of AMPK activators could 
become a therapy for the metabolic abnormalities associated with type 2 
diabetes (Viollet et al., 2006; Zhang et al., 2009). The current study showed that 
a reduction in AMPK phosphorylation was associated with an enhancement of 
NHGU induced by intraportal infusion of ODQ during conditions that mimic the 
postprandial state. The speculation that inactivation of AMPK in the liver could 
promote NHGU is supported by a recent study relating to downstream effect of 
AMPK activation by Mukhtar et al. (Mukhtar et al., 2008). They found that AMPK 
activation by AICAR inhibited glucose phosphorylation and glucokinase 
translocation in hepatocytes, which could potentially inhibit glucose uptake. The 
inhibition of glucose-induced GK translocation by AICAR was associated with 
phosphorylation of both GKRP and the cytoplasmic glucokinase binding protein, 
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2) (Mukhtar et al., 
2008). Whether the inactivation of AMPK is involved in the regulation of NHGU 
by hepatic NO is at present unclear and needs to be further investigated. 
We previously indicated that portal infusion of the NO donor SIN-1 
reduced NHGU in the presence of the portal glucose delivery, hyperglycemia and 
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hyperinsulinemia in conscious dog (An et al., 2008). This result is consistent with 
the observation that intraportal infusion of NOS inhibitor L-NAME enhanced 
NHGU under hyperinsulinemic and hyperglycemic conditions, and the 
augmentation was partially reversed by giving SIN-1 intraportally (Nishizawa et 
al., 2008). The present results combined with these earlier findings raise the 
possibility that the hepatic NO/sGC/cGMP action may be responsible for the 
effect of oral/ portal glucose delivery on NHGU. One may postulate that a 
pathway involved in the alteration of the NO action in the liver may comprise part 
of the feeding signal that triggers an increase in hepatic glucose uptake, although 
the pattern of hepatic NO changes in response to feeding and fasting remain to 
be established.  
In conclusion, we demonstrate for the first time that intraportal infusion of 
ODQ to inhibit sGC in the liver, increased NHGU and net hepatic carbon 
retention under hyperglycemic and hyperinsulinemic conditions in conscious 42-
h-fasted dogs. It appears that AMPK pathway is involved, although the exact 
molecular mechanism by which NO/sGC/cGMP brings about its hepatic effect 
needs to be elucidated. These findings indicate that hepatic NO/sGC/cGMP may 
play a role in directing the partition of glucose entry the body via the portal vein, 
and, by extension, an oral glucose load, between the liver and muscle. 
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Table 5.1: Hormone concentrations during the basal and experimental periods in 
conscious 42-h-fasted dogs given saline, ODQ or ODQ+SIN-1 infused into the portal vein
Experimental Period
Group Basal Period Period 1 Period 2
Arterial Plasma Insulin, µU/ml
 SAL 8±1 20±2* 23±2*
 ODQ 7±1 20±2* 22±2*
 ODSN 6±1 18±2* 21±1*
Hepatic Sinusoidal Insulin, µU/ml
 SAL 23±3 85±12* 83±8*
 ODQ 24±5 80±8* 85±10*
 ODSN 19±3 89±8* 83±6*
Arterial Plasma Glucagon, pg/ml
 SAL 39±4 39±3 36±4
 ODQ 41±4 40±4 38±3
 ODSN 33±4 35±4 35±3
Hepatic Sinusoidal Glucagon, pg/ml
 SAL 44±6 52±4 49±5
 ODQ 47±7 53±6 54±5
 ODSN 40±6 50±3 47±3
Arterial Cortisol, µg/dL
 SAL 4±1 4±1 3±1
 ODQ 4±1 4±1 2±1
 ODSN 4±1 3±1 3±1
Data are means±S.E.M.; n=10 in SAL and ODQ groups. N=6 in ODSN group.  
*= Significant statistical difference (P<0.05) from basal period within the group
Basal period:-30-0 min and experimental period 1: 0-90 min; period 2: 90-270 min 
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Table 5.2: Average hepatic arterial, portal, and total hepatic blood flow during the basal and
experimental periods in conscious 42-h-fasted dogs given saline, ODQ or ODQ+SIN-1 into the portal vein
Experimental Period
Group Basal Period Period 1 Period 2
Average Hepatic Arterial Blood Flow, ml/kg/min
 SAL 5.4±0.4 6.4±0.5 7.3±0.8*
 ODQ 6.1±0.8 7.8±1.1 8.6±1.0*
 ODSN 5.0±0.4 5.0±0.4* 5.7±0.4
Average Hepatic Portal Blood Flow, ml/kg/min
 SAL 24.1±2.0 19.4±1.9* 18.4±1.8*
 ODQ 26.4±2.4 20.0±2.2* 20.1±2.0*
 ODSN 23.3±3.2 18.3±2.2 19.5±2.3
Average Total Hepatic Blood Flow, ml/kg/min
 SAL 29.5±2.1 25.8±2.1 25.7±2.1
 ODQ 32.5±2.8 27.7±3.0 28.7±2.6
 ODSN 28.3±3.5 23.3±2.4 25.2±2.5
Data are means±S.E.M.; n=10 in SAL and ODQ groups. N=6 in ODSN group.  
* = Significant statistical difference (P<0.05) from basal period within the group
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Table 5.3: Average lactate, glycerol and NEFA concentration and net 
hepatic balance during the basal and experimental periods in conscious 
 42-h-fasted dogs given saline, ODQ or ODQ+SIN-1 into the portal vein
Experimental Period
Group Basal Period Period 1 Period 2
Arterial Blood Lactate, µmol/L
 SAL 506±119 966±72 852±62
 ODQ 461±52 1033±144 909±99
 ODSN 438±61 848±122 866±124
Net Hepatic Lactate Balance, µmol/kg/min
 SAL -6.0±1.1 4.8±1.0 3.5±1.1
 ODQ -5.4±1.4 5.3±1.8 3.0±1.2
 ODSN -4.9±0.9 8.0±2.6 6.3±1.9
Arterial Blood Glycerol, µmol/L
 SAL 84±8 38±7 35±6
 ODQ 88±9 37±7 29±6
 ODSN 74±14 29±7 31±8
Net Hepatic Glycerol Uptake, µmol/kg/min
 SAL 1.2±0.2 0.4±0.1 0.5±0.1
 ODQ 1.8±0.2 0.5±0.2 0.6±0.2
 ODSN 1.4±0.2 0.5±0.1 0.6±0.2
Arterial Plasma NEFA, µmol/L
 SAL 949±106 154±36 127±29
 ODQ 955±96 140±27 146±39
 ODSN 883±161 101±21 121±33
Net Hepatic NEFA Uptake, µmol/kg/min
 SAL 2.1±0.4 0.3±0.1 0.3±0.2
 ODQ 2.7±0.4 0.3±0.1 0.4±0.2
 ODSN 2.1±0.4 0.3±0.1 0.4±0.2
Data are means±S.E.M.; n=10 in SAL and ODQ groups. N=6 in ODSN group.  
All values in each group during the experimental period are significantly different (P<0.05)
from the basal period. Negative values for balance data indicate net hepatic uptake
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   Figure 5.1: Schematic representation of the study. The protocol comprises the 
basal (-30-0 min) and experimental periods (period 1, 0-90 min; period 2, 90-270 
min). Somatostatin was infused peripherally and insulin (4-fold basal) and glucagon 
(basal) were given intraportally, while glucose was delivered peripherally at a 
variable rate to increase the hepatic glucose load 2-fold basal during period 1 and 
period 2. The saline (SAL) group (n=10) received intraportal saline during period 2. 
ODQ group (n=10), received intraportal ODQ. ODSN group (n=6), received 
intraportal ODQ during period 2 and SIN-1 in the last 90 min of period 2.  
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   Figure 5.2: Arterial blood glucose and hepatic glucose loads in 42-h-fasted 
conscious dogs during the basal and experimental periods. See Fig. 5.1 for 
description of study conditions. Data are means ± S.E.M. 
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   Figure 5.3: Net hepatic glucose uptake and net hepatic fractional extraction of 
glucose in 42-h-fasted conscious dogs during the basal and experimental 
periods. See Fig. 5.1 for description of study conditions. Net hepatic fractional 
extraction of glucose data represent the averaged values for the last hour in 
each group. Data are means±S.E.M.; *P<0.05 compared with the ODQ group. 
†P<0.05 compared with the ODSN group. 
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   Figure 5.4: Glucose infusion rate and nonhepatic glucose uptake in 42-h-
fasted conscious dogs during the basal and experimental periods. See Fig. 5.1 
for description of study conditions. Data are means±S.E.M. *P<0.05 compared 
with the ODQ group. †P<0.05 compared with the ODSN group. 
 
*† 
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   Figure 5.5: ODQ decreases phosphorylation of AMPK at Thr172 and ACC at 
Ser79 in the liver (biophy taken at the end of the experiments). See Fig. 5.1 for 
description of study conditions. Data are means±S.E.M.; *P<0.05 compared with 
SAL group. The blots shown are representative of at least four blots obtained from 
independent assays. 
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CHAPTER VI 
 
THE EFFECT OF AN INTRAPORTAL INFUSION OF A CGMP ANALOG 8-
BROMO-CGMP ON NET HEPATIC GLUCOSE METABOLISM 
 
Aim 
We previously showed that increased hepatic NO resulting from portal 
SIN-1 infusion inhibits NHGU, and the inhibition of hepatic sGC/cGMP resulting 
from portal ODQ infusion enhances NHGU. Thus, the aim of the present study 
was to determine whether increased hepatic cGMP would inhibit NHGU. 
 
Experimental Design 
As shown in Fig. 6.1, each experiment consisted of a 90-min equilibration 
period (-120 to -30 min), a 30-min basal period (-30 to 0 min), and a 270-min 
experimental period (period 1, 0-90 min; period 2, 90-180 min; period 3, 180-270 
min). In all experiments a constant infusion of indocyanine green dye (0.076 
mg/min; Sigma Immunochemicals, St. Louis, MO) was initiated at –120 min via 
the left cephalic vein. At 0 min, a constant infusion of somatostatin (0.8 µg/kg/min; 
Bachem, Torrance, CA) was begun via the left saphenous vein to suppress 
endogenous insulin and glucagon secretion. At the same time, basal glucagon 
(0.57 ng/kg/min; Glucagen, Novo Nordisk, Bagsvaerd, Denmark) and 4-fold basal 
insulin (1.2 mU/kg/min; Eli Lilly & Co., Indianapolis, IN) infusions were started 
through the splenic and jejunal catheters and maintained for the duration of the 
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study. Glucose (20% dextrose) was delivered intraportally at 4mg/kg/min, and 
PAH was mixed with it to allow a delivery rate of 0.4 mg/kg/min. In addition, a 
primed continuous infusion of 50% dextrose was begun via the right cephalic 
vein at time 0 so that the blood glucose could quickly be clamped at the desired 
hyperglycemic level (~170 mg/dL). In P2, saline was infused intraportally in the 
control group (SAL, n=10), and a membrane permeable cGMP analog, 8-Bromo-
cGMP (Tocris Bioscience, Ellisville, MO) was infused intraportally at 50 µg/kg/min 
in the CGMP (n=6) groups. In P3, in three dogs from the cGMP group, the 
peripheral glucose infusion rate was adjusted to maintain a similar arterial 
glucose to that seen in P1, and in the other three dogs, arterial blood glucose 
was lowered to compensate for the increase in hepatic blood flow thus allowing 
the hepatic glucose load (2X basal) to remain matched to that in P1.  
 
Results 
 
Hemodynamic response 
Blood pressure did not change significantly over the course of the 
experiment in response to saline infusion (Table 6.1). The systolic blood pressure 
in the CGMP/L and CGMP/H groups were similar to those seen in SAL in the 
basal period and P1 but tended to decrease in P2, and dropped significantly 
during P3 (Table 6.1). Diastolic blood pressure also fell significantly during P3 in 
response to intraportal 8-Br-cGMP infusion (Table 6.1). The average heart rate 
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did not change over time in SAL but it tended to increase during P2 and P3 in the 
CGMP/L and CGMP/H groups (Table 6.1). 
 
Hepatic blood flow, blood glucose concentrations, and hepatic glucose load  
Portal vein blood flow decreased by ~20% in all groups during P1 in 
response to somatostatin infusion (Table 6.2). There was a concomitant and 
offsetting (~20%) increase in hepatic arterial flow. As a result, total hepatic blood 
flow tended to be slightly reduced during P1 in all groups. Hepatic portal blood 
flow increased by ~30% in response to 8-Br-cGMP during P2 and P3. 
Consequently, total hepatic blood flow remained near basal during P2 and P3 in 
the SAL group, while it increased by 27% and 16% in CGMP/L, and by 32% and 
31% in CGMP/H during P2 and P3, respectively. 
The arterial blood glucose level increased in the all groups from a basal 
value of 85±2 to 172±2 mg/dL during P1 and P2. It was sustained at that level 
during P3 in the SAL and CGMP/H groups, while it was allowed to drop to 127±2 
mg/dL during P3 in the CGMP/L group (Fig. 6.2). The hepatic glucose loads 
increased to 2X basal during P1, P2 and P3 in the SAL group, and during P1 in 
CGMP/L and CGMP/H groups. It increased by ~30% in the CGMP/L group and 
~25% in the CGMP/H group, respectively, during P2 because of the increase in 
portal vein blood flow. The hepatic glucose loads remained elevated during P3 in 
the CGMP/H group, but returned to the 2X basal in the CGMP/L group during P3 
(Fig. 6.2).  
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Hormone concentrations 
 The arterial and hepatic sinusoidal insulin levels increased three- to 
fourfold during P1 and P2 in all groups (Table 6.3). Compared with P1, the 
elevated sinusoidal insulin levels declined by ~25% in response to 8-Br-cGMP in 
P2 and P3 (Table 6.2). Arterial plasma glucagon concentrations remained near 
basal throughout the study, but hepatic sinusoidal glucagon concentrations fell by 
~20% in response to 8-Br-cGMP (Table 6.2). The mean plasma cortisol 
concentrations also remained statistically unchanged from basal in each group 
(Table 6.2). Norepinephrine (nmol/L) rose to 238±48 and 203±47 (p<0.05 v.s. 
84±8 in P1, and epinephrine (nmol/L) rose to 161±47 and 216±100 (NS v.s. 
136±34 in P1) in response to the hypotention induced by 8-Br-cGMP during P2 
and P3, respectively. 
 
Net hepatic glucose balance and net hepatic fractional glucose extraction  
All groups exhibited a similar rate of net hepatic glucose output during the 
basal period (Fig. 6.3). Coincident with the start of the experimental period (4X 
basal insulin, basal glucagon and hyperglycemia), all groups switched from net 
output to net uptake of glucose, with the rates (4.8±0.4, 4.3±0.9 and 4.9±0.5 
mg/kg/min in SAL, CGMP/L and CGMP/H groups during P1, and 5.4±0.5, 
4.7±0.9 and 5.4±0.7 mg/kg/min in SAL, CGMP/L and CGMP/H groups during P2, 
respectively) not being significantly different between groups (Fig. 6.3). 
Subsequently, NHGU rose to 5.8±0.5 mg/kg/min in SAL during P3, whereas it 
decreased to 2.6±1.0 mg/kg/min (P<0.05 vs. SAL) in the CGMP/L group, and to 
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4.7±0.4 mg/kg/min in the CGMP/H group. In response to 8-Br-cGMP during P3, 
the average rate of NHGU was reduced by ~35% (P<0.05 vs. SAL) (Fig. 6.3). 
The net hepatic fractional extraction of glucose was 0.09±0.01, 0.10±0.01 and 
0.11±0.01 in the SAL group. In response to 8-Br-cGMP, it deceased from 
0.08±0.03 to 0.06±0.02 in P2, and 0.05±0.02 in P3 in the CGMP/L group, and 
from 0.10±0.02 to 0.09±0.01 in P2, and 0.08±0.02 in P3 in the CGMP/H group, 
respectively (Fig. 6.3). During P3, the change of net hepatic fractional extraction 
of glucose from baseline was ~0.01 in the SAL group, but was~ -0.03 (P<0.05 v.s. 
SAL) in response to intraportal 8-Br-cGMP infusion (Fig. 6.3). 
 
Glucose infusion rates, nonhepatic glucose uptake 
The glucose infusion rate increased over time in the SAL group but it 
changed less in the CGMP/H group (Fig. 6.4). In the CGMP/L group, the glucose 
infusion rate increased over time during P1 and P2, but was significantly 
decreased over that required in the saline group during period 3. Nevertheless, 
nonhepatic glucose uptake did not differ significantly among groups at any time 
(Fig. 6.4). 
 
Lactate metabolism, net hepatic carbon retention and hepatic glycogen content  
The arterial blood lactate concentrations rose in all groups during P1 and 
remained elevated in P2. After the experimental period began, net hepatic lactate 
balance changed from uptake to output, and the output rates remained elevated 
in all groups during P2 and P3 (Table 6.4). Net hepatic carbon retention (mg 
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glucose equivalents/kg/min) did not differ among groups at any time during P1 
but decreased in response to 8-Br-cGMP relative to the control group during P3 
(2.1±0.8 in CGMP/L [P<0.05 vs. SAL], 4.0±0.2 in CGMP/H, and 5.2±0.3 in SAL 
group).   
 
Glycogen synthase and phosphorylase in the liver 
Compared with the saline group (n=4), intraportal infusion of 8-Br-cGMP 
(n=6) was associated with a decrease in glycogen synthase activity (GS ratio L/H 
Glc6P 0.03±0.03 in CGMP v.s.0.11±0.12 in SAL, P<0.05), and no change of 
glycogen phosphorylase activity (GPh ratio -/+ AMP 0.13±0.15 in CGMP v.s. 
0.11±0.14  in SAL) in the liver was detected. 
 
Glycerol and nonesterified fatty acid metabolism  
Arterial blood glycerol concentrations and net hepatic glycerol uptake were 
reduced by 30–70% in response to hyperglycemia and hyperinsulinemia and 
remained suppressed in all groups throughout P1 and P2 (Table 6.4). The 
suppression of glycerol was, however, partially reversed during P2 and P3 in 
response to 8-Br-cGMP but not saline (28±5, 31±6 in SAL and 54±10, 60±13 
µmol in response to 8-Br-cGMP [average value of CGMP/L and CGMP/H groups] 
during P2 and P3, respectively). Arterial plasma nonesterified fatty acid (NEFA) 
concentrations and net hepatic NEFA uptake changed in a pattern similar to 
glycerol, decreasing 60-90% during P1 and remaining suppressed in P2 and P3 
in all groups (Table 6.4). There was, however, no apparent rebound during P2 
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and P3 in response to 8-Br-cGMP (Table 6.4). 
 
Discussion 
Our earlier experiments showed that an increase in hepatic NO resulting 
from intraportal infusion of the NO donor SIN-1 inhibited NHGU (An et al., 2008). 
In addition, the inhibition of hepatic cGMP production by intraportal infusion of the 
sGC inhibitor ODQ enhanced NHGU and hepatic glycogen accumulation. In the 
present study, we showed that intraportal infusion of a cGMP analog, 8-Br-cGMP 
reduced NHGU in the presence of hyperinsulinemia, hyperglycemia, basal 
glucagon and portal glucose delivery in 42-h-fasted dogs. This finding confirmed 
our previous data that the cGMP pathway in the liver has the ability to regulate 
NHGU. Furthermore, this finding and the observation that NHGU was inhibited 
when SIN-1 was infused intraportally suggest that cGMP dependent pathway is 
the likely mechanism by which NO regulates NHGU. 
In the present study, intraportal infusion of cGMP analog, 8-Br-cGMP, 
reduced the ability of the liver to take up glucose. Systolic and diastolic blood 
pressure both decreased ~25% when the 8-Br-cGMP was infused, and this was 
undoubtedly due to the vasodilatory effects of the compound. The fact that there 
was an increase in sympathetic drive during 8-Br-cGMP infusion is supported by 
our findings that the heart rate rose secondary to hypotension, norepinephrine 
and epinephrine levels increased, and by our observation that lipolysis increased 
in response to the drug, as indicated by the increase in the arterial blood glycerol 
level. Increased sympathetic input to the liver would have been expected to 
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reduce NHGU (Dicostanzo et al., 2006). However, in our previous experiments 
(An et al., 2008), when SIN-1 was given via a leg vein to bring about a similar 
hemodynamic response to that seen in the present study, and sympathetic input 
to the liver was increased by a similar amount, there was no decrease in NHGU 
or hepatic glycogen synthesis , suggesting that increased sympathetic input to 
the liver in the present study was not the mechanism responsible for the 
reduction of NHGU. 
At the same time, 8-Br-cGMP significantly increased hepatic portal blood 
flow by ~30% during P2, while the hepatic arterial flow was not significantly 
altered. As the liver is a low-resistance organ, hepatic arterial flow is mainly 
determined by the blood pressure and the resistance at the hepatic artery, 
whereas hepatic portal flow is mainly determined by resistance at gastrointestinal 
vessels. The fact that hepatic arterial blood flow remained unchanged in the 
present study was probably due to the offsetting effects of the decrease in blood 
pressure and the decrease in hepatic arterial resistance in response to 8-Br-
cGMP infusion. Portal blood flow, on the other hand, increased by ~30% 
probably because the effects of the reduction of the resistance of the 
gastrointestinal vessels were greater than the drop of the blood pressure. As a 
result of these vascular effects, the total hepatic blood flow increased by ~25%, 
the total hepatic glucose load increased, and the hepatic sinusoidal insulin and 
glucagon levels declined in accord with the change in blood flow, while NHGU 
was not significantly different among groups during P2. It remains unknown how 
much difference there is between the effects of increasing the hepatic glucose 
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load by increasing hepatic blood flow with the glucose level constant and the 
effects of increasing the glucose level with hepatic blood flow constant (Shiota et 
al., 2000). In order to minimize the potential metabolic effect of the increase in 
hepatic glucose load associated with the change of blood flow, in the CGMP/L 
group, we lowered the arterial glucose levels from ~170 to ~125 mg/dL during P3 
to match the level of hepatic glucose load in P1. As a result, the total hepatic 
glucose load returned to 2X basal, while NHGU was significantly reduced by 55% 
(P<0.05) in the CGMP/L group infusion during P3. NHGU tended to decrease by 
~20% in CGMP/H group during P3, when the arterial glucose levels remained at 
~170 mg/dL, and the hepatic glucose load was increased due to the change of 
the blood flow. When the data from two CGMP groups were analyzed together, 
we found that the NHGU was reduced by 35% (P<0.05) in response to 8-Br-
cGMP during P3 versus the SAL group, when the total hepatic glucose load was 
virtually the same. It should be noticed that in period 3, there was a ~25% and 
~20% reduction of insulin and glucagon levels in the liver, respectively, in 
response to 8-Br-cGMP. One may postulate that this reduction of sinusoidal 
insulin could be partially responsible for the reduction of NHGU. However, the 
changes in the sinusoidal hormone concentrations were small and the 
consequences of the decreases in the glucagon and insulin would have been 
offsetting. It seems unlikely, therefore, that changes in insulin and glucagon 
mediated the decrease in NHGU caused by 8-Br-cGMP. Thus despite the 
imperfect of the study, the data support the concept that cGMP decreases NHGU 
in vivo. 
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It has been shown that there is crosstalk between cAMP and cGMP 
signaling pathways (Algara-Suarez et al., 2004). Thus, it is conceivable that 8-Br-
cGMP infusion in the present study also activated PKA in the liver, which could 
have been responsible for the change of NHGU. However, the assay of hepatic 
glycogen phosphorylase, one of the markers of PKA, was not changed in 
response to 8-Br-cGMP, suggesting that was not the case. 
It has been demonstrated that NO can activate AMPK in endothelium and 
muscle via a sGC/cGMP dependent pathway (Lira et al., 2007; Zhang et al., 
2008), a process that may involve CaM kinase (Zhang et al., 2008). We recently 
showed that lowering of hepatic cGMP in dogs was associated with a reduction 
in the AMPK and ACC phosphorylation in the liver. These results suggest that 
elevated hepatic NO or cGMP may limit NHGU through the activation of AMPK in 
the liver. This hypothesis is supported by the finding that AMPK can inactivate 
glycogen synthase and activate phosphorylase (Polekhina et al., 2003), and a 
recent study which showed that AMPK activation by AICAR inhibits glucokinase 
translocation and glucose phosphorylation in hepatocytes, as a result of 
phosphorylation of both GKRP and PFK2 (Mukhtar et al., 2008). These data fit 
into our current observation that the activity of hepatic glycogen synthase was 
significantly reduced in response to 8-Br-cGMP. 
Evidence has suggested that AMPK plays a role in hepatic glucose 
metabolism, and could be a therapeutic target for people with type 2 diabetes 
(Viollet et al., 2006; Zhang et al., 2009). This notion has been supported by a 
number of studies. Bergeron et al. (Bergeron et al., 2001) showed that systemic 
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infusion of AICAR, an AMPK activator, suppressed hepatic glucose output in 
overnight-fasted rats. This finding was supported by an in vitro experiment which 
showed that treatment with an adenovirus expressing a constitutively active form 
of AMPK alpha2 reduced glucose output in cultured hepatocytes (Foretz et al., 
2005), and an in vivo observation that liver-specific AMPK alpha2 KO mice had 
increased fasting hepatic glucose production (Andreelli et al., 2006). It has been 
shown that activation of AMPK in mouse liver can inhibit hepatic 
gluconeogenesis and decrease glycogen content (Foretz et al., 2005). It should 
be noted that the reduction of hepatic glucose output induced by activation of 
AMPK in above studies was mainly due to the suppression of gluconeogenesis, 
since the glycogen content of the livers was virtually zero (Bergeron et al., 2001; 
Foretz et al., 2005; Viollet et al., 2006). On the other hand, when there was 
glycogen in the liver, Iglesias et al. demonstrated that an intraperitoneal injection 
of AICAR resulted in a marked increment in net hepatic glycogen breakdown in 
rats (Iglesias et al., 2002), likewise Pencek et al. showed that intraportal AICAR 
infusion in 18-h-fasted conscious dogs caused an increase in glycogenolysis and 
hepatic glucose output (Camacho et al., 2005b; Pencek et al., 2005). Thus, it 
appears that the different outcomes regarding hepatic glucose output seen in 
response to the activation of hepatic AMPK in the aforementioned studies can be 
explained by differences in hepatic glycogen levels, in particular, the balance 
between the increase in glycogenolysis, if any, and the suppression of hepatic 
gluconeogenesis. Therefore, it is not surprising to find an association between 
inactivation of AMPK and increased hepatic glucose uptake and storage in the 
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present work. 
In conclusion, we demonstrated that intraportal infusion of 8-Br-cGMP 
decreased NHGU under hyperglycemic and hyperinsulinemic conditions in 
conscious 42-h-fasted dogs. The exact molecular mechanism by which 
NO/sGC/cGMP brings about its hepatic effect remains to be established. 
Whether this pathway is involved in the metabolic response to feeding also 
needs to be determined.  
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Table 6.1: Heart rate, systolic and diastolic blood pressure during the basal (-30-0 min) and 
experimental periods (period 1, 0-90 min; period 2, 90-180 min; period 3, 180-240 min) in
conscious 42-h-fasted dogs given saline, or 8-Br-cGMP infused into the portal vein
Experimental Period
Group Basal Period Period 1 Period 2 Period 3
Systolic Blood Pressure, mmHg
 SAL 178±5 173±5 168±8 163±10
 CGMP/L 175±8 183±10 164±1 127±14*†
 CGMP/H 180±1 173±11 170±7 150±10*
Diastolic Blood Pressure, mmHg
 SAL 96±4 94±4 95±6 102±10
 CGMP/L 79±3 83±6 73±12 54±5*†
 CGMP/H 90±2 84±8 80±7 67±12*†
Heart Rate, beats/min
 SAL 94±5 100±4 94±10 106±9
 CGMP/L 91±25 85±23 109±22 115±21
 CGMP/H 100±15 86±14 125±17 136±31
Data are means±S.E.M.; n=8 in the saline (SAL) group, n=3 in the group that received 8-Br-cGMP
 in the portal vein and and arterial glucose was maintained at ~125 mg/dL in period 3(CGMP/L), and n=3 in the group 
that received 8-Br-cGMP in the portal vein and and arterial glucose was maintained at ~170 mg/dL in period 3 (CGMP/H)
*= Significant statistical difference (P<0.05) from basal period within the group
†= Significant statistical difference (P<0.05) from SAL group
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Table 6.2: Average hepatic arterial, portal, and total hepatic blood flow during the basal and  
experimental periods in conscious 42-h-fasted dogs given saline, or 8-Br-cGMP infused into the portal vein
Experimental Period
Group Basal Period Period 1 Period 2 Period 3
Average Hepatic Arterial Blood Flow, ml/kg/min
 SAL 6.2±0.6 9.5±0.9* 10.1±1.1* 10.8±1.4*
 CGMP/L 4.3±0.2 5.2±0.9† 5.4±0.6† 5.7±0.6
 CGMP/H 5.2±1.2 6.4±1.3 5.7±1.2 5.7±1.0
Average Hepatic Portal Blood Flow, ml/kg/min
 SAL 22.2±2.0 18.4±1.5 19.0±1.6 19.2±1.8
 CGMP/L 29.7±3.1 22.5±3.2 37.8±4.6† 33.7±5.4†
 CGMP/H 21.6±4.5 16.9±4.2 29.7±6.6† 29.4±8.5
Average Total Hepatic Blood Flow, ml/kg/min
 SAL 28.3±2.2 27.9±2.1 29.1±2.4 30.0±2.7
 CGMP/L 34.1±4.1 27.7±3.4 43.3±4.9† 39.5±6.0
 CGMP/H 26.8±4.7 23.3±4.6 35.4±6.5 35.1±8.4
Data are means±S.E.M.; n=10 in the saline (SAL) group, n=3 in the group that received 
8-Br-cGMP in the portal vein and and arterial glucose was maintained at ~125 mg/dL  
in period 3(CGMP/L), and n=3 in the group that received 8-Br-cGMP in the portal vein
and arterial glucose was maintained at ~170 mg/dL in period 3 (CGMP/H)
* = Significant statistical difference (P<0.05) from basal period within the group
†= Significant statistical difference (P<0.05) from SAL group
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Table 6.3: Hormone concentrations during the basal and experimental periods  
in conscious 42-h-fasted dogs given saline, or 8-Br-cGMP infused into the portal vein
Experimental Period
Group Basal Period Period 1 Period 2 Period 3
Arterial Plasma Insulin, µU/ml
 SAL 8±1 25±3* 25±2* 25±2*
 CGMP/L 9±1 22±2* 25±3* 24±4*
 CGMP/H 8±2 19±2* 25±2* 25±3*
Hepatic Sinusoidal Insulin, µU/ml
 SAL 21±4 79±8* 85±10* 80±8*
 CGMP/L 18±5 89±9* 78±4* 77±4*
 CGMP/H 20±7 91±18* 60±11* 60±10*
Arterial Plasma Glucagon, pg/ml
 SAL 45±7 50±4 46±6 46±6
 CGMP/L 35±8 37±4 36±4 35±3
 CGMP/H 33±5 38±5 39±4 33±5
Hepatic Sinusoidal Glucagon, pg/ml
 SAL 58±7 69±6 65±6 62±7
 CGMP/L 43±11 53±7 44±7 39±6
 CGMP/H 44±4 55±5 47±5 43±4
Arterial Cortisol, µg/dL
 SAL 3±1 5±1 3±1 4±1
 CGMP/L 3±1 3±1 5±1 5±2
 CGMP/H 2±1 3±1 4±1 4±1
Data are means±S.E.M.; n=10 in the saline (SAL) group, n=3 in the group that received 
8-Br-cGMP in the portal vein and and arterial glucose was maintained at ~125 mg/dL  
in period 3(CGMP/L), and n=3 in the group that received 8-Br-cGMP in the portal vein
and arterial glucose was maintained at ~170 mg/dL in period 3 (CGMP/H)
*= Significant statistical difference (P<0.05) from basal period within the group
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Table 6.4: Average lactate, glycerol and NEFA concentration and net 
hepatic balance during the basal and experimental periods in conscious 
 42-h-fasted dogs given saline, or 8-Br-cGMP infused into the portal vein
Experimental Period
Group Basal Period Period 1 Period 2 Period 3
Arterial Blood Lactate, µmol/L
 SAL 412±50 1390±134* 1202±122* 1155±141*
 CGMP/L 425±159 1065±183* 1027±175* 1036±184*
 CGMP/H 535±179 1135±157* 1030±163* 1151±71*
Net Hepatic Lactate Balance, µmol/kg/min
 SAL -6.1±0.9 10.0±2.1* 8.4±2.1* 6.6±1.7*
 CGMP/L -5.8±0.3 10.5±3.4* 7.6±2.4* 4.7±1.5*
 CGMP/H -3.2±2.8 10.6±3.8* 6.5±1.4* 8.5±2.1*
Arterial Blood Glycerol, µmol/L
 SAL 99±14 35±5* 28±5* 31±6*
 CGMP/L 111±8 41±14* 50±19* 48±15*
 CGMP/H 81±12 40±3* 58±2* 73±13
Net Hepatic Glycerol Uptake, µmol/kg/min
 SAL 1.9±0.3 0.7±0.1* 0.6±0.1* 0.7±0.1*
 CGMP/L 2.3±0.3 0.7±0.3* 1.5±0.5 1.5±0.5
 CGMP/H 1.4±0.2 0.7±0.2* 1.7±0.4 2.0±0.7
Arterial Plasma NEFA, µmol/L
 SAL 1006±78 221±23* 146±17* 131±16*
 CGMP/L 1185±65 237±26* 171±42* 145±27*
 CGMP/H 950±173 289±74* 324±81* 299±92*
Net Hepatic NEFA Uptake, µmol/kg/min
 SAL 3.8±1.3 0.3±0.1* 0.3±0.1* 0.4±0.1*
 CGMP/L 3.6±0.2 0.4±0.1* 0.3±0.3* 0.4±0.4*
 CGMP/H 2.7±0.7 0.8±0.4* 1.1±0.3* 0.5±0.9*
Data are means±S.E.M.; n=10 in the saline (SAL) group, n=3 in the group that received 
8-Br-cGMP in the portal vein and and arterial glucose was maintained at ~125 mg/dL  
in period 3(CGMP/L), and n=3 in the group that received 8-Br-cGMP in the portal vein
and arterial glucose was maintained at ~170 mg/dL in period 3 (CGMP/H)
* = Significant statistical difference (P<0.05) from basal period within the group
Negative values for balance data indicate net hepatic uptake
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   Figure 6.1: Schematic representation of the study. The protocol comprises the 
basal (-30-0 min) and experimental periods (period 1, 0-90 min; period 2, 90-180 
min; period 3, 180-240 min). Somatostatin was infused peripherally and insulin (4-
fold basal) and glucagon (basal) were given intraportally, whereas glucose was 
delivered intraportally (4 mg/kg/min) and peripherally at a variable rate to increase 
the hepatic glucose load 2-fold basal or arterial blood glucose 2-fold basal during 
period 1, 2 and 3. The saline (SAL) group (n=10) received intraportal saline during 
period 2 and 3. Out of six subjects received intraportal 8-Bromo-cGMP at 50 
µg/kg/min during period 2 and 3, three had lowered arterial glucose to match the 
hepatic glucose load to the in period 1(CGMP/L, n=3), and three of them had 
arterial glucose maintained to that in period 1 (CGMP/H, n=3).  
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   Figure 6.2: Arterial blood glucose and hepatic glucose loads in 42-h-fasted 
conscious dogs during the basal and experimental periods. See Fig. 6.1 for 
description of study conditions. Data are means ± S.E.M. 
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   Figure 6.3: Net hepatic glucose uptake and net hepatic fractional extraction 
of glucose in 42-h-fasted conscious dogs during the basal and experimental 
periods. See Fig. 6.1 for description of study conditions. Averaged values 
during period 3 in the saline group (n=10) and the 8-Br-cGMP treated group 
(n=6) are expressed as histograms. Data are means±S.E.M.; *P<0.05 
compared with SAL group. †P<0.05 compared with CGMP/H group 
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   Figure 6.4: Glucose infusion rate and nonhepatic glucose uptake in 42-h-fasted 
conscious dogs during the basal and experimental periods. See Fig. 6.1 for 
description of study conditions. Data are means±S.E.M.; *P<0.05 compared with 
CGMP/L group. †P<0.05 compared with CGMP/H group 
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CHAPTER VII 
 
SUMMARY AND CONCLUSIONS 
 
The liver plays a critical role in the uptake and storage of glucose after a 
carbohydrate meal. It has been shown in conscious dogs, that during a 
continuous intraduodenal glucose infusion, in a net sense, ~53% of the absorbed 
glucose is taken up by the liver, with the majority being stored as glycogen 
(Moore et al., 1991). A time course study in humans showed that in response to 
mixed meal ingestion (three meals during the day, 5 h apart), hepatic glycogen 
concentration increased continuously throughout the day without any detectable 
decrease after breakfast or lunch, and peaked at ~4 h after dinner (Hwang et al., 
1995). Thus, the postprandial uptake of glucose by the liver, which occurs over 
14-16 h of the day, plays an important part in the body's ability to maintain 
glucose homeostasis. 
It has been suggested that hepatic glucose uptake is impaired in 
individuals with type 2 diabetes (Basu et al., 2000). Likewise, postprandial 
hepatic glycogen storage is defective in individuals with type 1 (Hwang et al., 
1995) and type 2 diabetes (Krssak et al., 2004). Impairments in net hepatic 
glucose uptake and hepatic glycogen synthesis exacerbate postprandial 
hyperglycemia, which in turn contributes to kidney and nerve damage, as well as 
increased risk for the development of cardiovascular disease (Hays et al., 2008). 
Given the substantial increase in the prevalence of diabetes in recent years 
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(Spanakis et al., 2009), it is critical to understand how hepatic glucose uptake is 
normally regulated as well as the cause of dysregulation in this process in insulin 
resistant individuals. 
It is well established that hepatic insulin/glucagon levels, the hepatic 
glucose concentration/load, and the route of glucose delivery are three major 
determinants of NHGU (Cherrington, 1999). The role of the latter in the mediation 
of NHGU has been an area of research for two decades, but the mechanism by 
which it exerts its effects is still not completely understood.  
Our attention turned towards biological mediators, such as NO, and 5-HT, 
since in vitro data suggested that these factors may play a role in the regulation 
of NHGU and, further, could be involved in the portal glucose signal (Lautt, 2004; 
Moore et al., 2004b). Although a link between hepatic NO production and the 
portal glucose signal is still not established, it has been shown that the 
expression of iNOS in the liver is markedly increased  in diabetic rats (~70%) 
(Madar et al., 2005) and in diabetic mice (~150%) (Fujimoto et al., 2005). These 
data, along with the observation that the response of the liver to the portal 
glucose signal is impaired in insulin resistant animals (Coate et al., unpublished 
data), suggest that increased hepatic NO may be involved in the impaired 
response to the portal glucose signal in diabetes.  
In the first part of my dissertation, intraportal infusion of an NO donor, SIN-
1, was shown to reduce NHGU and net hepatic carbon retention under 
hyperglycemic and hyperinsulinemic conditions in conscious 42-h-fasted dogs. 
Further, the lack of changes in NHGU and glycogen storage when the same 
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hemodynamic response was seen in response to peripheral SIN-1 administration 
suggested that the effects of portal SIN-1 came about as a result of a direct effect 
of NO on hepatocytes. These findings raise the possibility that hepatic NO plays 
a physiologic role in the regulation of NHGU.  
Our conclusions from specific aim I led us to further investigate the effect 
of hepatic NO in regulating NHGU. cGMP-independent NO reactions include 
interaction of NO with superoxide anion to generate peroxynitrite, nitrosylation of 
cysteine thiol residues and nitration of tyrosine on target proteins. It is well 
known, however, that NO can activate sGC and thereby increase the production 
of cGMP. Thus, in the second part of the dissertation, the role of sGC/cGMP in 
the mediation of NHGU was determined. Intraportal infusion of ODQ to inhibit 
sGC and the production of cGMP in the liver, resulted in increased NHGU and 
net hepatic carbon retention under hyperglycemic and hyperinsulinemic 
conditions in conscious 42-h-fasted dogs. Further, we showed that intraportal 
infusion of SIN-1 did not attenuate the enhancement of NHGU. At a mechanistic 
level, we showed that the increase in NHGU was associated with a reduction in 
phosphorylation of AMPK and ACC. We next showed that intraportal infusion of 
8-Br-cGMP, a cGMP analog, decreased NHGU and net hepatic carbon retention 
under hyperglycemic and hyperinsulinemic conditions in conscious 42-h-fasted 
dogs. These data suggest that NO can regulate NHGU as a result of the 
alteration of the sGC/cGMP pathway in the liver.  
The findings from the fourth part of the dissertation showed that that 
intraportal infusion of a SSRI, escitalopram, enhanced net hepatic glucose 
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uptake and hepatic glycogen deposition under hyperglycemic and 
hyperinsulinemic conditions in conscious 42-h-fasted dogs. These data suggest 
that serotonin may play a role in the regulation of NHGU and the portal glucose 
signal, and raised the possibility that hepatic-targeted SSRIs might help to control 
postprandial hyperglycemia in individuals with diabetes.  
The work presented in this dissertation demonstrates that NHGU can be 
suppressed by the increase in hepatic NO or cGMP, which resulted from the 
intraportal infusion of an NO donor SIN-1 or a cGMP analog 8-Br-cGMP, 
respectively. Conversely, NHGU was enhanced by the decrease in hepatic 
cGMP resulting from the intraportal infusion of a sGC inhibitor ODQ. It is now 
established that the expression of nNOS, eNOS and iNOS can be regulated at 
the transcriptional level under various conditions (Kroncke et al., 2000). For 
instance, high glucose was shown to decrease iNOS expression and nitric oxide 
production in cultured smooth muscle cells (Nishio et al., 1996). It has also been 
shown that NOS activity can be regulated within one minute through 
phosphorylation under various physiological and pathological conditions such as 
stimulation of cytokines, hormones, etc. (Schulz et al., 2005). Thus, it is 
conceivable that under basal condition, there is an inhibitory tone of hepatic 
NO/cGMP that restrains NHGU, and that this inhibitory signal is rapidly removed 
in response to portal glucose delivery thereby enhancing NHGU. In addition, we 
showed that NHGU was enhanced by an increase in hepatic 5-HT which resulted 
from the intraportal infusion of the SSRI escitalopram. Taken together, these 
above data give rise to the possibility that portal glucose delivery results in 
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removal of an inhibitory signal (NO) and the simultaneous augmentation of a 
stimulatory signal (5-HT), thereby leading to an increase in NHGU. This 
hypothesis needs to be further investigated. Thus, future experiments are 
required to determine whether the level of hepatic NO/cGMP changes in 
response to portal glucose delivery. If so, which isoforms of NOS in the liver are 
involved should be determined. On the mechanistic level, one direction is to 
determine the role of PKG in the mediation of NHGU by using introportal delivery 
of the inhibitor of PKG (cGMP-dependent protein kinase) delivered intraportally. 
Another direction is to investigate whether there is a cGMP independent pathway 
that contributes to the metabolic effects caused by hepatic NO. Studies are 
currently underway to examine the effect of PKG in the regulation of NHGU.  
The studies described in this dissertation have a number of important 
implications. First, the fact that NO/cGMP and 5-HT are natural constituents of 
hepatocytes, along with the data from this work, suggest that they may comprise 
part of an endogenous pathway involved in regulation of hepatic glucose uptake 
in vivo. Thus, these data suggest a possible mechanism by which the portal 
glucose signal may work. Second, since hepatic NOS is upregulated, and portal 
glucose signal/hepatic glucose uptake is impaired in insulin resistance, 
understanding the regulation of NHGU by NO may provide insight into 
mechanisms underlying this disease in the liver. Third, mechanisms that 
decrease hepatic NO/cGMP may be effective in countering impaired hepatic 
glucose uptake, and a compound with similar hepatic actions might therefore 
help to correct postprandial hyperglycemia in individuals with diabetes. 
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